Image For Activity Cover
2022 World Conference on Lung Cancer (ePosters)
Conference | 2022
What's Included
EP01.01-002. Challenges in the Use of NLST Image Data for Quantitative Algorithm Development
Faculty:
- Artit Jirapatnakul, United States

EP01.01-003. DELFI-L101: Development of a Blood Based Assay That Evaluates Cell-Free DNA Fragmentation Patterns to Detect Lung Cancer
Faculty:
- Peter Bach, United States

EP01.01-004. The Correlation Between Exhaled Volatile Organic Compounds Using Breath Analyzer and Interleukin-23 (IL-23) in Lung Cancer
Faculty:
- Raden Dicky Listiandoko, Indonesia

EP01.01-005. Increased Levels of mRNAs and miRNAs Associated with Imminent and Advanced Lung Cancer
Faculty:
- Ilona Urbarova, Norway

EP01.01-006. Sensitive Detection of Lung Cancer Using a Multiomic Plasma Cell-Free DNA Sequencing Assay
Faculty:
- Jing Shan Lim, United States

EP01.01-007. Incorporating cfDNA Detection to CT Scan Assessment in Post-Surgical Lung Cancer Patients
Faculty:
- Joana Espiga De Macedo, Portugal

EP01.01-008. Expression of PD-L1 mRNA and Its Epigenetic Regulators: MicroRNA-17, -93 and -142 in Early Stages NSCLC Patients’ Plasma
Faculty:
- Natalia Krzyzanowska, Poland

EP01.01-009. Common MicroRNAs in Pre-diagnostic Serum Associated with Lung Cancer in Two Cohorts up to Eight Years Before Diagnosis: A HUNT Study
Faculty:
- Oluf Røe, Norway

EP01.01-010. Graphene Based Activity Sensors Detect All Stages of Lung Cancer Using an Evolutionary Machine Learning Algorithm Approach
Faculty:
- Paul Dempsey, United States

EP01.01-011. Utility of Arm-level cfDNA Fragment Size Distribution in the Early Detection of Lung Cancer and Pan Cancer
Faculty:
- Lifeng Wang, China

EP01.01-002. Clinical and Molecular Features of Chinese Early-stage Multiple Primary Lung Cancer Patients
Faculty:
- Yongjie Wang, China

EP01.02-001. Citizens’ Perspective on Combination Screening for Lung Cancer, COPD and CVD
Faculty:
- Carina Behr, Netherlands

EP01.02-002. Awareness of Palestinians about Lung Cancer Symptoms: A National Cross-sectional Study
Faculty:
- Hanan Abukmail, Palestine

EP01.02-003. Lung Cancer Screening: A Systematic Review of Knowledge Translation Interventions
Faculty:
- Paul Dawkins, New Zealand

EP01.02-004. Education Messages and Strategies About Lung Cancer Screening: A Systematic Review
Faculty:
- Rachael Dodd, Australia

EP01.02-005. Exploring Individuals’ Views on Invitation to Lung Cancer Screening: Developing a Tailored Approach
Faculty:
- Rachael Murray, United Kingdom

EP01.02-006. Excuse Me? Patient Perceptions of Lung Cancer Screening Results
Faculty:
- Rayan Ihle

EP01.02-007. It's Not How You Start, It's How You Finish: Patient Motivators to Follow Low-Dose Screening Recommendations
Faculty:
- Rayan Ihle

EP01.02-008. Pocket Nodules, An Innovative Patient Education Tool to Explain Lung Nodules
Faculty:
- Theresa Roelke

EP01.03-001. Māori Perspectives on a Potential Lung Cancer Screening Programme Aotearoa NZ: An Indigenous People’s Perspective.
Faculty:
- Anne Fraser

EP01.03-002. Implementation of the International Lung Screen Trial (ILST) in Catalonia: A Cost Analysis study
Faculty:
- Antoni Rosell

EP01.03-003. AI Detection of Emphysema in an Ultra-Low Dose CT Lung Cancer Screening Program
Faculty:
- Chellan Kumarasamy

EP01.03-004. Should We Screen for Lung Cancer? A 10-Country Analysis Identifying Key Decision-Making Factors
Faculty:
- Charlotte Poon

EP01.03-005. Current status of High-risk Smokers Participating in Population-based National Lung Cancer Screening Program in Korea
Faculty:
- EunKyo Kang

EP01.03-006. Potential Drivers of Lung Cancer Screening Participation in Australia: A Qualitative Study to Inform Future Implementation
Faculty:
- Emily Stone

EP01.03-007. Lung Cancer Screening Use Among Screening-Eligible Adults With Disability in the United States: Evidence From Population-Based Data
Faculty:
- Hermine Poghosyan

EP01.03-008. Lung Cancer Screening Patients Experiences and Satisfaction: Quantitative and Qualitative Findings From a Survey Study
Faculty:
- Jaileene Perez-Morales

EP01.03-009. Cost-effectiveness of Lung Cancer Screening in New Zealand Varies by Ethnicity
Faculty:
- Peter Sandiford

EP01.03-010. China Lung Cancer Screening Study (CLUS) Version 2.0: Study Design and Baseline Screening Results
Faculty:
- Fangfei Qian

EP01.03-011. Clinical Features and Surgical Outcomes of Young Patients with Ground Glass Opacity Featured Lung Adenocarcinoma
Faculty:
- Rirong Qu

EP01.03-012. Acceptability and Feasibility of Lung Cancer Screening in Australia: The View of Key Stakeholders
Faculty:
- Rachael Helen Dodd

EP01.03-013. A Pilot Study of Lung Cancer Screening with Low Dose CT in Georgia (One Centre Experience and Preliminary Data).
Faculty:
- Salome Kukava

EP01.04-001. A Programmatic Approach to Improve Efficiency in Lung Cancer Screening
Faculty:
- Brendon Stiles

EP01.04-002. The Impact of Enforcing a Structure in Lung Cancer Screening Strategy on the Effectiveness and Efficiency of the Screening Program
Faculty:
- Iakovos Toumazis

EP01.04-003. Effectiveness of Cloud-based Computer Aided Quality Control System in Korean National Lung Cancer Screening
Faculty:
- Ji-Youn Song

EP01.04-004. Overcoming the Barriers to Lung Cancer Screening using a Systemwide Approach
Faculty:
- Michael Gieske

EP01.04-005. Quantitative Characteristics in Global CT Lung Cancer Screening Populations Using the ELIC Distributed Database and Computation Environment
Faculty:
- Stephen Lam

EP01.04-006. Clinical Scores, Biomarkers and It Tools in Lung Cancer Screening - Can an Integrated Approach Overcome Current Challenges?
Faculty:
- Wieland Voigt

EP01.05-001. Radiomics to Increase the Effectiveness of Lung Cancer Screening Programs. Radiolung Preliminary Results
Faculty:
- Antoni Rosell

EP01.05-002. Role of the Lung Cancer Screening MDT in the Manchester Lung Health Check Programme
Faculty:
- Avik Ghoshal

EP01.05-003. Changes of Repeated Lung Cancer Screening Results and Affected Factors; Analysis of Korean National Lung Cancer Screening Program
Faculty:
- EunKyo Kang

EP01.05-004. Trial in Progress: An Observational Study for Management of Lung Nodules across Latin America (DOuBLED Study)
Faculty:
- Felipe Marques da Costa

EP01.05-005. The Accuracy of Baseline Low-dose CT Lung Cancer Screening: A Systematic Review and Meta-analysis
Faculty:
- Lanwei Guo

EP01.05-006. Influenza Season Influence on Incidence and Outcome of Nodules in the NELSON Trial
Faculty:
- Harriet Louise Lancaster

EP01.05-007. Radiomics Based Machine Learning Model for Sub-cm Lung Nodule Malignancy Diagnosis in the PanCan Screening Study
Faculty:
- Ian Janzen

EP01.05-008. Pre-Trial Validation of a Risk Prediction Model for Pulmonary Nodules Trained on a Nested Case-Control Study with No External Cohort
Faculty:
- Michael Nolan Kammer

EP01.05-009. Simulation-Based Sample Size Estimation for an Early Detection of Lung Cancer Clinical Utility Trial in Indeterminate Pulmonary Nodules
Faculty:
- Michael Nolan Kammer

EP01.05-010. Using a Pattern Submodel Approach to Predict Lung Cancer in High-Risk Lung Nodule Clinics
Faculty:
- Valerie F. Welty

EP01.05-011. Radiologic Features of Nodules Attached to the Mediastinal or Diaphragmatic Pleura
Faculty:
- Yeqing Zhu

EP01.06-001. Lung Cancer after First Primary Breast Cancer: Risk Factors and Results of Treatment
Faculty:
- Camilla Vanni

EP01.06-002. Impact of Immediate AI Enabled Patient Triage to Chest CT on the Lung Cancer Pathway: LungIMPACT
Faculty:
- David Baldwin

EP01.06-003. Female Asian Nonsmoker Screening Study (FANSS): Exploring Lung Cancer Screening in a High Risk Population
Faculty:
- Elaine Shum

EP01.06-004. Eliciting Quantitative Smoking History by the Use of Natural Language Processing
Faculty:
- John C. Ruckdeschel

EP01.06-005. Assessment of Cardiovascular Risk in the Non Screening Radically Treated Lung Cancer Cohort
Faculty:
- Marius Rohan Theiveehathasan

EP01.06-006. Impact of Low Dose CT Screening on Cause of Death in Different Socio-Economic Groups
Faculty:
- Michael Peter Alan Davies

EP01.06-007. The Impact of Modified Screening Eligibility Criteria on Race and Sex Disparities in Lung Cancer Screening
Faculty:
- Matthew Smeltzer

EP01.06-008. Low Dose CT Screening in Asian Female-Never-Smokers is as Efficacious as in Asian Male-Ever-Smokers. A Systemic Review and Meta-Analysis
Faculty:
- Natthaya Triphuridet

EP01.06-009. Frequency of Lung Adenocarcinoma in Patients With Growing Nonsolid and Part-Solid Nodules With Solid Component ≤5 mm
Faculty:
- Natthaya Triphuridet

EP01.07-001. Surveillance with FDG PET/CT after Completion of Therapy for NSCLC: A Status Update on Inclusion in the SUPE_R Trial
Faculty:
- Kasper Guldbrandsen

EP01.07-002. Objectives and Design of the ACR Lung Cancer Screening CT Incidental Findings - Quick Reference Guide
Faculty:
- Michael Gieske

EP01.07-003. Accuracy of Cytological Diagnosis for Malignant Nodule in Participants With Nonsolid Nodules and Part-Solid Nodules With Solid Component≤5 mm
Faculty:
- Natthaya Triphuridet

EP01.07-004. FDG-PET-CT for Staging Screen Detected Lung Cancer
Faculty:
- Renelle L Myers

EP01.07-005. Combined Diffusion-Weighted Imaging and Dynamic Contrast-Enhanced MRI for Diagnosing Indeterminate Pulmonary Nodules
Faculty:
- Fang Wu

EP01.07-006. Incidence and Resource Burden for the Management of CT Detected Ground Glass Opacities at a Tertiary Lung Cancer Service in the UK
Faculty:
- Muhammad Arsalan Ashraf

EP02.01-001. Plasma Cell-Free DNA as a Point-of-Care Wellbeing Biomarker for Early-Stage Non-Small Cell Lung Cancer Patients
Faculty:
- Anna L McGuire

EP02.01-002. Development of Circulating and Tissue Biomarkers Predicting Immune Phenotype and Response to Immunotherapy in NSCLC.
Faculty:
- Brian David Henderson

EP02.01-003. Predictive Role of Novel Grading System on Adjuvant Chemotherapy in Early Resected Lung Adenocarcinoma Based on EGFR Mutation Status
Faculty:
- Yiming He

EP02.01-004. Application of a Genomic Assay for Risk Stratification of Resected NSCLC in a Community Cancer Center Setting, a Pilot Study
Faculty:
- Hiroshi Yamagata

EP02.01-005. The Efficacy of Platinum-Based Chemotherapy as Adjuvant Therapy in EGFR Mutant Lung Adenocarcinoma
Faculty:
- Ken Onodera

EP02.01-006. Advances in the Treatment of Postoperative Recurrence of Non-Small Cell Lung Cancer and Their Real-World Impact on Survival
Faculty:
- Kohei Hashimoto

EP02.01-007. Clinicopathologic and Prognostic Features of Early Resected Lung Adenocarcinoma Characterized With Uncommon EGFR Mutation
Faculty:
- Shenghui Li

EP02.01-008. Clinicopathological Features of Rare but Targetable Mutations in Surgically Resected Lung Carcinomas
Faculty:
- Luka Brcic

EP02.01-009. PD-L1 Expression in Biopsies and Surgical Specimens of Lung Cancer: Impact of Biopsy Methods and Neoadjuvant Therapy
Faculty:
- Mir Alireza Hoda

EP02.01-010. Preoperative PET-SUVmax and Volume Based PET Metrics of the Tumor Fail to Predict Nodal Upstaging in Early-Stage Lung Cancer
Faculty:
- Oezlem Okumus

EP02.01-011. Immune-related Histologic Phenotype in Pretreatment Tumor Biopsy Predicts Efficacy of Neoadjuvant Anti-PD-1 Treatment in Squamous Lung Cancer
Faculty:
- Pei Yuan

EP02.01-012. PD-L1 Expression Predicts Prognosis in Completely Resected NSCLC Patients with an EGFR Mutation
Faculty:
- Yi-Fan Qi

EP02.01-013. Real World Treatment Patterns, Prevalence and Outcomes in Patients with KRAS Mutated Non Small Cell Lung Cancer in Southwestern Ontario
Faculty:
- Sara Kuruvilla

EP02.01-014. Prognostic Classification of Early-Stage Lung Cancer Using Preoperative Prealbumin and D-dimer Levels
Faculty:
- Takashi Yamamichi

EP02.01-015. Computer-Aided Volumetry by Multidetector Computed Tomography is Efficient for Prognostic Prediction of Early-Stage Solid Lung Cancers
Faculty:
- Taketo Kato

EP02.01-016. Molecular Alterations and Clinical Prognostic Factors in Resectable Non-Small Lung Cancer
Faculty:
- Thanaporn Thamrongjirapat

EP02.01-017. The Role of Adjuvant Chemotherapy for Stage II/III Lung Adenocarcinoma Based on Epidermal Growth Factor Receptor Mutation Status
Faculty:
- Yasuhiro Tsutani

EP02.01-018. EGFR Mutations Promote Lung Adenocarcinoma From Adenocarcinoma in Situ to Minimally Invasive Carcinoma to Invasive Adenocarcinoma
Faculty:
- Jianfei Zhu

EP02.02-001. Genome-wide Analysis and Dynamic Changes of Human Non-small Cell Lung Carcinoma Cells After Radiation
Faculty:
- Yajing Du Yajing

EP02.02-002. Increased Utilization of Stereotactic Body Radiotherapy Has Decreased Treatment Disparities for Early-Stage NSCLC
Faculty:
- Ashwin Ganesh

EP02.02-003. Mean Lung Dose Correlates with Volume of Radiation-Induced Lung Injury in Patients Treated with SABR for Lung Cancer
Faculty:
- Angus John Killean

EP02.02-004. Clinical Outcomes Following Photon-Based and Proton-Based Stereotactic Body Radiation Therapy for Early Stage Lung Cancer
Faculty:
- Bong Kyung Bae

EP02.02-005. Changes in PFT Parameters and Correlation with Symptomatic Pulmonary Toxicity Following SBRT For Early Stage Lung Cancer
Faculty:
- Bong Kyung Bae

EP02.02-006. Differing Doses: The Effects of Radiation Dose Calculation Algorithms on Local Control in Early-Stage Lung Cancer
Faculty:
- Bradley Ackerson

EP02.02-007. Correlation between Biological Equivalent Dose and Radiological Changes after Lung Stereotactic Ablative Radiation Therapy
Faculty:
- Carla Cases Copestake

EP02.02-008. Transbronchial Microwave Ablation of Lung Nodules - Good Safety Profile and Promising Mid-Term Results
Faculty:
- Wing Yan Joyce Chan

EP02.02-009. Stereotactic Body Radiotherapy for Primary and Metastatic Lung Cancer, Cyberknife-M6 Experience
Faculty:
- Sureyya Sarihan

EP02.02-010. Histology Impacts Time-to-Treatment on Lung SBRT Outcomes
Faculty:
- Gregory Videtic

EP02.03-001. The Role of Completion Lobectomy Following Sublobar Resection in Patients with T1 Non-Small Cell Lung Cancer
Faculty:
- Akif Turna

EP02.03-002. Impact of Society and National Guidelines on Patient Selection for Lung Cancer Surgery in the UK from 2008 to 2013
Faculty:
- Chiara Proli

EP02.03-003. Survival of Patients with Interstitial Lung Disease Who Undergoing Lung Cancer Surgery: A Propensity Score Matching Study
Faculty:
- Sang Hoon Lee

EP02.03-004. Association Between Sarcopenia and Outcomes of Lung Cancer Surgery in Old-Age Patients: Interim Analysis of Prospective Cohort Study
Faculty:
- Hyeok Sang Woo

EP02.03-005. Perioperative Factors That Predict or Are Associated With Prolonged Air Leaks After Robotic-Assisted Pulmonary Lobectomy
Faculty:
- Eric M Toloza

EP02.03-006. Oncological Outcome And Surgical Instruments in VATS Lobectomy For Early Stage Lung Cancer
Faculty:
- Federico Femia

EP02.03-007. Seeds of Gold. Triple Contrast Marking in Hybrid Operative Room for All-in One Diagnostic and Therapeutic Precision Surgery
Faculty:
- Francesco Guerrera

EP02.03-008. Combined Robotic Assisted Thoracic Surgery (CRATS)
Faculty:
- Eric Dolven Anderson

EP02.03-009. Real-world Disease-Free Survival as a Predictor of Overall Survival in Resected Early-Stage Non-Small Cell Lung Cancer
Faculty:
- Howard (Jack) West

EP02.03-010. Intrapulmonary and Hilar Lymph Node Dissection Performed by the Surgical Team: Impact on Pathological Stage of NSCLC
Faculty:
- Jefferson Luiz Gross

EP02.03-011. Timeliness of Surgery for Early-Stage Lung Cancer: Perspectives from Surgeons and Patients
Faculty:
- Jeffrey Zhu

EP02.03-012. Peri-operative and Oncologic Outcomes after Robotic-Assisted Segmentectomy at a NCI-designated Cancer Center
Faculty:
- Jobelle Joyce Anne Baldonado

EP02.03-013. Should Visceral Pleural Invasion Be Prognostic Factor in Early-Stage Lung Adenocarcinoma With Tumor Size 3cm or Less?
Faculty:
- Kisung Park

EP02.03-014. Pulmonary Segmentectomy via Minimally Invasive Open Surgery: An Analysis From a Japanese High-Volume Hospital
Faculty:
- Kazuo Nakagawa

EP02.03-015. Fully Robotic Arm Robot Assisted Lung Surgery Exploration
Faculty:
- taiyang liuru

EP02.03-016. Dynamics of Recurrence After Curative Resection of Non-small Cell Lung Cancer
Faculty:
- Masaya Yotsukura

EP02.03-017. Novel Intraoperative CT-Guided Marking Using O-Arm in Video-Assisted Thoracoscopic Surgery
Faculty:
- Yoshimitsu Hirai

EP02.03-019. T3 Non Small Cell Lung Cancer with Satellite Nodules: A Multicentric Analysis.
Faculty:
- Pietro Bertoglio

EP02.03-020. Patient Outcomes Following Salvage Lung Cancer Surgery Post Definitive Chemotherapy or Radiation
Faculty:
- Riley Bowker

EP02.03-021. Uncertain Resection for Localized cN0M0 Non Small Cell-Lung Cancer: The Crucial Prognosis of Suboptimal Lymph Node Assessment
Faculty:
- Romain Vergé

EP02.03-022. Evolution of Lung Cancer Resection Quality: A Prospective Staggered Implementation Quality Improvement Study
Faculty:
- Raymond U Osarogiagbon

EP02.03-023. Decreasing Time to Definitive Therapy with MIDAS: Minimally Invasive Diagnosis and Surgery
Faculty:
- Patrick Ross

EP02.03-024. Clinical and Prognostic Impact of Pleural Adhesions during Lung Cancer Surgery
Faculty:
- Satoshi Shiono

EP02.03-025. Long-Term Oncological Outcomes and Risk Factors of Recurrence After Segmentectomy for Primary Lung Cancer
Faculty:
- Shinsuke Uchida

EP02.03-026. Is Ratio of Surgical Margin to Nodule Size a Prognostic Factor in Stage 1 Adenocarcinoma?
Faculty:
- Tiffany Melissa ERGIN

EP02.03-027. After Surgery Factors Affecting Relapse in Early Stage Non Small Cell Lung Cancer
Faculty:
- Tiffany Melissa ERGIN

EP02.03-028. Pathologic Risk Factors for Recurrence in Early Stage Invasive Lung Adenocarcinoma with Tumor Spread through Air Spaces
Faculty:
- Eunjue Yi

EP02.03-029. Prognostic Factors in Curative Intent Stage I lung Adenocarcinoma: Hospital's Cancer Registry Based Analysis
Faculty:
- Vinícius Guimarães Silva

EP02.04-001. Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-Positive NSCLC: ALNEO Phase II Trial (GOIRC-01-2020)
Faculty:
- Alessandro Leonetti

EP02.04-002. Synergy of Local Treatment with Pulsed Electric Fields and Anti-PD1 Checkpoint Blockade
Faculty:
- Chiara Pastori

EP02.04-003. A Retrospective Comparison of Survival Outcomes in EGFR-mutated, NSCLC Patients on Osimertinib +/- Brain Metastases
Faculty:
- Ishjot Litt

EP02.04-004. Time to Surgery After Neoadjuvant Immunotherapy: Not a Day Too Soon
Faculty:
- Nathan Mynard

EP02.04-005. Phase II NAUTIKA1 Study of Targeted Therapies in Stage II-III NSCLC: Preliminary Data of Neoadjuvant Alectinib for ALK+ NSCLC
Faculty:
- Jay M Lee

EP02.04-006. Adjuvant Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Preoperative Chemotherapy
Faculty:
- Lei Deng

EP02.04-007. Phase 2 Trial of Neoadjuvant KRASG12C Directed Therapy with Adagrasib (MRTX849) With or Without Nivolumab in Resectable NSCLC (Neo-KAN)
Faculty:
- Patrick M Forde

EP02.04-008. Efficacy and Safety of Neoadjuvant Chemoimmunotherapy in Resectable Non-small Cell Lung Cancer (NSCLC): a systematic review and meta-analysis
Faculty:
- Sebawe Syaj

EP02.04-009. Real World Survival Outcome Analysis of Adjuvant Therapies in Non-EGFR, Non-ALK Early Stage Resected NSCLC
Faculty:
- Tedi Hoxha

EP02.04-010. Clinical Outcomes After Neoadjuvant Tislelizumab plus Chemotherapy in Resectable Stage IIIA-B NSCLC: A Retrospective Study
Faculty:
- Xiangyang Cheng, China

EP03.01-001. Is Airflow Limitation a CausalFactor for Lung Squamous Cell Carcinoma? Evidence from Mendelian Randomization Analysis
Faculty:
- Qing Zhang

EP03.01-002. Co-occurring Mutations, Smoking Status and Prognosis of Early-stage Resected NSCLCs with EGFR Mutations
Faculty:
- Alison Moore

EP03.01-003. Clinical Features and Molecular Profile of Advanced Non-small Cell Lung Cancer in Latin America: LATINO Lung (LACOG 0116)
Faculty:
- Clarissa Mathias

EP03.01-004. Impact of Covid-19 Pandemic in Lung Cancer Patients in Albania
Faculty:
- Daniela Xhemalaj

EP03.01-005. Clinicopathological Features of ROS1-rearranged Adenocarcinomas: A Single Institutional Experience Spanning Four Years From India
Faculty:
- Aruna Nambirajan

EP03.01-006. Familial Aggregation in Non-small Cell Lung Cancer - An Observational Study
Faculty:
- Sindhura Durga Chitikela

EP03.01-007. Comprehensive Genomic Profile of Advanced Lung Cancer in a Region With the Worst Human Development Index in Brazil
Faculty:
- Eldsamira Mascarenhas

EP03.01-008. Shift in Lung Cancer Stage at Diagnosis during the COVID-19 Pandemic in New York City
Faculty:
- Emanuela Taioli

EP03.01-009. BrainMets-Cross-Sectional Study To Identify The Presence Of Brain Metastasis At Diagnosis Of Advanced NSCLC EGFRm in Portuguese Patients
Faculty:
- Maria Encarnação Teixeira

EP03.01-010. Clinicopathological Characteristics of Non-Small Cell Lung Cancer patients in the United Arab Emirates and Correlation with Their Outcomes
Faculty:
- Fathi Azribi

EP03.01-011. Prevalence of KRASMutations in Treatment-naïve Non-small Cell Lung Cancer Patients in Hong Kong
Faculty:
- James C Ho

EP03.01-012. Characterization of Lung Cancer in Patients With High Familial Aggregation of Cancer: Preliminary Data From the SCAN Study
Faculty:
- Juan Carlos Laguna

EP03.01-013. Improving the Risk Estimation for Second Primary Lung Cancer after Lung Cancer by Taking Histologic Subtype into Account
Faculty:
- Marian Eberl

EP03.01-014. Results From the BEWELL Study: Black Raspberry Nectar for the Prevention of Lung Cancer (NCT04267874)
Faculty:
- Marisa BIttoni

EP03.01-015. Disease-Free Survival and Clinical Characteristics in Early-Stage NSCLC Patients From a Danish Cohort
Faculty:
- Peter Meldgaard

EP03.01-016. The Canadian Small Cell Lung Cancer Database (CASCADE): Results from a Multi-Institutional Real-World Evidence Collaboration
Faculty:
- Sara Mieko Moore

EP03.01-017. Epidemiology of Lung Cancer in Northern Serbia During the Past Ten Years
Faculty:
- Tomi Kovacevic

EP04.01-001. Prevalence And Outcomes of EGFR Exon 20 Insertion Mutation In NSCLC: Princess Margaret Cancer Center Experience
Faculty:
- Abhenil Mittal

EP04.01-002. Costs of Locoregional and Metastatic Recurrences in Patients with Resectable Stage II-III NSCLC in Spain
Faculty:
- Amelia Insa

EP04.01-003. Is It Time for a New Paradigm in Care of Young Cancer Patients? A Retrospective Study
Faculty:
- Andreina Vasconcelos

EP04.01-004. Interim Feedback on Pilot Public Facing Website for Cancer Clinical Trial Patient-Reported Symptom Data: Project Patient Voice
Faculty:
- Bellinda King-Kallimanis

EP04.01-005. Lung Cancer Diagnosis Following Emergency Admission: Diagnostic and Therapeutic Pathways and Outcomes Within an Italian Cancer Center
Faculty:
- Carlo Genova

EP04.01-006. A Systematic Review (SR) of Cost-effectiveness Analysis (CEA) of ALK Inhibitors (iALK) in Advance Non-small Cell Lung Cancer (NSCLC)
Faculty:
- Carolina Gabay

EP04.01-007. Impact of Precision Medicine Methods on First-Line Therapies in Metastatic Non-Small Cell Lung Cancer
Faculty:
- Chetan Vakkalagadda

EP04.01-008. Factors Impacting Time from Biopsy to Initiation of Treatment for Advanced NSCLC at an Academic Hospital and Affiliate Hospitals
Faculty:
- Chetan Vakkalagadda

EP04.01-009. Performance Indicators of Lung Cancer MDT at a Regional Center: Disagreements Between Trust and NLCA Data
Faculty:
- Qudratullah Qudratullah

EP04.01-010. Addressing Barriers to Lung Cancer Care for Diverse Populations through Patient Navigation: The University of Miami Experience
Faculty:
- Estelamari Rodriguez

EP04.01-011. Diagnostic Approach and Treatment of Lung Cancer Patients in Portugal: Portuguese Lung Cancer Study Group Survey
Faculty:
- Fernanda Estevinho

EP04.01-012. Sex and Age-Related Guideline-Adherence Disparities in Non-Small-Cell Lung Cancer Treatment Patterns: Real-World Data
Faculty:
- Heidi Andersén

EP04.01-013. Frailty Index Predicts Treatment Outcomes in Older Adults with Lung Cancer
Faculty:
- James Fletcher

EP04.01-014. Adherence to Treatment Recommendations From Multidisciplinary Tumor Boards
Faculty:
- Julia Roeper

EP04.01-015. Lung Cancer after Solid Organ Transplantation - A Claims Data Analysis
Faculty:
- Julia Walter

EP04.01-017. Cost-Effectiveness of Atezolizumab for Adjuvant Treatment of Patients with Stage II-IIIA PD-L1+ Non-small Cell Lung Cancer
Faculty:
- Millie Das

EP04.01-018. Medical Oncology and Radiation Oncology Consultation in Non-small Cell Lung Cancer (NSCLC). A Population-Based Study Using Administrative Data
Faculty:
- Michela Febbraro

EP04.01-019. Into the Wild: Assessing Acute Care for Lung Cancer Patients, A Cohort Study to Improve Cancer Care at Emergency Department
Faculty:
- Mariano Provencio

EP04.01-020. Impact of Next-Generation Sequencing on Treatment Choice Among Patients with Metastatic NSCLC from the CHUM University Center
Faculty:
- Myriam Nait Ajjou

EP04.01-021. Cancer Clinical Quality Registries: A Systematic Review of the Utilisation and Effectiveness of Knowledge Translation Interventions
Faculty:
- Paul Dawkins

EP04.01-022. Real-world Evidence of Durvalumab for Stage III NSCLC: Survival Outcomes and Patterns of Care Post-progression
Faculty:
- Pedro Aguiar Jr

EP04.01-023. Development of an Australia and New Zealand Lung Cancer Clinical Quality Registry (ANZLCR)
Faculty:
- Robert Stirling

EP04.01-024. Influence of Lung Diagnostic Assessment Program on Health Resource Utilization in Lung Cancer in Southeastern Ontario, Canada
Faculty:
- Shahad AlGhamdi

EP04.01-025. Implementation of Electronic Patient Reported Outcomes in Routine Cancer Care
Faculty:
- Shalini Vinod

EP04.01-026. Cone-Beam CT Guided Navigation Bronchoscopy: a Cost-Effective Modality for the Diagnosis of Pulmonary Nodules
Faculty:
- Stephan Elisius Kops

EP04.01-027. Pain and Interventions in Stage IV Non-Small Cell Lung Cancer: A Province-Wide Analysis
Faculty:
- Vivian S Tan

EP04.01-029. Reduction of ER Visits of Lung Cancer Patients Through Care Interventions in Day-To-Day Clinical Service: Experience of a Thoracic Unit in Mexico
Faculty:
- Saul Campos-Gomez

EP04.02-001. Sex as a Potential Independent Prognostic Factor in Non-Small Cell Lung Cancer Survival
Faculty:
- Chelsea Ann Ford-Sahibzada

EP04.02-003. Improving Supportive Care for Patients with Thoracic Cancer
Faculty:
- LaKedia Charman Banks

EP04.02-004. The Patient Impact of Liquid Biopsy - Health-Related Quality of Life in Patients Undergoing Liquid Biopsy for Advanced Non-Small Cell Lung Cancer
Faculty:
- Lucy Corke

EP04.02-005. First Comprehensive Lung Cancer Long-Term Survivorship Program - Late Toxicities and Overall Survival
Faculty:
- Martin Metzenmacher

EP04.02-006. Burn-Out Syndrome: Neglected Syndrome Among Health Care Professionals Managing Lung Cancer Patients
Faculty:
- Tomi Kovacevic

EP05.01-001. Hispanic Patients with Unresectable Stage III NSCLC under PACIFIC Protocol: Evidence of Interior Outcomes and Health Inequity
Faculty:
- Andres F Cardona

EP05.01-002. Real World Treatment Patterns and Outcomes among Unresectable Stage III Non-Small Cell Lung Cancer Patients Initiating Chemoradiotherapy
Faculty:
- Ashwini Arunachalam

EP05.01-003. First Real-World Data on Unresectable Stage III NSCLC Patients Treated with Durvalumab after Chemoradiotherapy in Asia Area
Faculty:
- ChihHsi Kuo

EP05.01-004. Induction Chemoimmunotherapy before Definitive Chemoradiotherapy for Large-Volume Unresectable Locally Advanced NSCLC
Faculty:
- Yu Wang

EP05.01-005. Impact of Antibiotic Use Before Definitive Concurrent Chemoradiation in Patients With Locally Advanced Non Small Cell Lung Cancer
Faculty:
- Youling Gong

EP05.01-006. Population Kinetic Assessment of Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Faculty:
- David J. Stewart

EP05.01-007. CONCORDE - A Phase Ib Platform Study of Novel Agents in COmbinatioN with COnventional RaDiothErapy in Non-small Cell Lung Cancer (NSCLC)
Faculty:
- Gerard M Walls

EP05.01-008. The Scottish Inflammatory Prognostic Score predicts survival in non-small cell lung cancer treated with chemoradiotherapy
Faculty:
- Grace Ball

EP05.01-009. A Clinical Outcome Comparison of IMRT and VMAT in Stage II and III NSCLC Irradiated with Radical Intent
Faculty:
- Jose Belderbos

EP05.01-010. External Validation of Two Prediction Models for Severe Radiation-induced Lymphopenia during Concurrent Chemoradiotherapy for Lung Cancer
Faculty:
- Jose Belderbos

EP05.01-011. Real World Outcomes of Durvalumab after Chemoradiotherapy in unresectable advanced Non-Small Cell Lung Cancer: The Mayo Clinic Experience
Faculty:
- Joel Rivera Concepcion

EP05.01-012. Avoiding Cardiac Toxicity in Lung Cancer Radiotherapy (ACcoLade) Trial - Initial Results
Faculty:
- Kathryn Banfill

EP05.01-013. Increased C-reactive Protein after Chemoradiotherapy and Immunotherapy in Locally Advanced Non-small Lung Cancer Indicates Worse Survival
Faculty:
- Karmen Stanic

EP05.01-014. Circulating Tumor DNA to Identify Genomic Biomarkers of Radiation Sensitivity in Locally Advanced Non-Small Cell Lung Cancer
Faculty:
- Emily Lebow

EP05.01-015. Validate Radiomics Features and XGBoost Model in Radiation Pneumonitis (RP) Prediction in Patients with Primary Lung Cancer: A MultiCenter Study
Faculty:
- Jiali Liu

EP05.01-016. Radiation Recall Pneumonitis (RRP) Induced by Immune Checkpoint Inhibitors (ICIs) after Thoracic Radiotherapy for Lung Cancer
Faculty:
- Xiaotong Lu

EP05.01-017. Exploring the Benefits of Adaptive Radiotherapy in NSCLC-patients
Faculty:
- Marie Tvilum

EP05.01-018. Chemoradiotherapy Followed by Durvalumab in Unresectable Locally Advanced NSCLC- A Single Institution Experience in Croatia
Faculty:
- Marko Jakopovic

EP05.01-019. 4D CT Ventilation Image-Guided Lung Functional Avoidance Radiotherapy: A Single-Arm Prospective Pilot Clinical Trial
Faculty:
- Megan Eileen Daly

EP05.01-020. Unanticipated Radiation Re-planning for Stage III Non-small Cell Lung Cancer
Faculty:
- Melinda Mushonga

EP05.01-021. Radiation Dose to Cardiac Substructures and the Incidence of Cardiac Events in Patients with Stage III NSCLC Receiving CCRT
Faculty:
- Meng Xu Welliver

EP05.01-022. Evaluation of the Management of Stage III NSCLC at Mohamed IV Center for Cancer Treatment Casablanca
Faculty:
- Maryam Zaouit

EP05.01-023. Feasibility of Functional Lung Avoidance using Ga-68 4D Ventilation Perfusion PET/CT: The HI-FIVE Trial
Faculty:
- Nicholas Wentworth Bucknell

EP05.01-024. Real-life Management of Stage III NSCLC Patients in Italy: The BE-PACIFIC Observational Study
Faculty:
- Paolo Bironzo

EP05.01-025. Planned Interim Analysis of a Phase II Trial of Concurrent Durvalumab and Radiation Therapy for Locally Advanced Lung Cancer
Faculty:
- Andreas Rimner

EP05.01-026. Carboplatin Dose Calculations for Patients with Lung Cancer: Significant Dose Differences Found Depending on Dosing Equation
Faculty:
- Seçkin Akgül

EP05.01-027. Uncertain Resection of pN2 NSCLC Patients-survival Analysis of Postoperative Radiotherapy and Driver Gene Mutations
Faculty:
- Qianyue Deng

EP05.01-028. Thoracic Radiotherapy of Baseline Severe Pulmonary Dysfunction NSCLC Patients and Predictive Analysis for Acute Radiation Pneumonitis
Faculty:
- Qianyue Deng

EP05.01-029. Association between DNA Repair Gene Pathway SNPs and Tumour Response in NSCLC Patients Receiving Radiotherapy: A Meta-Analysis
Faculty:
- Timothy Shun Man Chu

EP05.01-030. CRISP: First Real-World Evidence of NSCLC Stage I, II and III in Germany - AIO-TRK-0315
Faculty:
- Wilfried Ernst Erich Eberhardt

EP05.01-031. Lysimachia Capillipes Capilliposide C Enhances the Radiosensitivity of Lung Cancer by Promoting ERRFI1 via Inhibiting Phosphorylation of STAT3
Faculty:
- Kan Wu

EP05.01-032. The Incidence of Brain Metastasis and Radiation Pneumonitis With Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC
Faculty:
- YeonSil Kim

EP05.01-033. Stimulation CT-Based Radiomics Predict Radiation Pneumonitis after Chemoradiotherapy in Locally Advanced NSCLC
Faculty:
- Haihua Yang

EP05.01-036. Role of Nanoparticle Polymeric Micellar Paclitaxel in Reducing Toxicity and Enhancing Efficacy in Non-small Cell Lung Cancer
Faculty:
- Baohui Han

EP05.02-001. Early Treatment Failure Of Consolidation Durvalumab for Unresectable Stage III NSCLC: A Real-World Canadian Cohort
Faculty:
- Amanda Gibson

EP05.02-002. Who Benefits More of Durvalumab after Chemoradiotherapy (CRT) in Real-World Patients with Locally Advanced Non-Small-Cell Lung Cancer (NSCLC)?
Faculty:
- Blanca Távara

EP05.02-003. Durvalumab after Chemoradiotherapy (CRT) in Unresectable Stage III NSCLC. Comparative Study of Two Cohorts in the Real-World Setting
Faculty:
- Blanca Távara

EP05.02-004. Could Fifty Percent Tumor Viability Be a Good Prognostic Factor?
Faculty:
- Ezgi Cesur

EP05.02-005. Is Immunotherapy Safer Than Radiotherapy in Combination With Chemotherapy in Neoadjuvant Therapy?
Faculty:
- Ezgi Cesur

EP05.02-006. Neoadjuvant DS-8201 for Stage III Non-small Cell Lung Cancer with HER2 20ins
Faculty:
- Huizhao Hong

EP05.02-007. Impact Of Fibrinogen Levels and mGPS on Survival of Stage III/N2 NSCLC Patients Treated with Neoadjuvant Therapy and Radical Surgery
Faculty:
- Katharina Sinn

EP05.02-008. Phase II Trial of Neoadjuvant Icotinib Plus Chemotherapy for Stage II-IIIB EGFR-mutant Non-small-Cell Lung Cancer
Faculty:
- Fang-Liang Lu

EP05.02-009. Aumolertinib Versus Erlotinib/Chemotherapy for Neoadjuvant Treatment of Stage IIIA EGFR-mutant NSCLC (ANSWER)
Faculty:
- Wenhua Liang

EP05.02-010. Robotic-Assisted Thoracic Surgery Following Neoadjuvant Chemoimmunotherapy in Patients with Stage III Non-small Cell Lung Cancer
Faculty:
- Min Li

EP05.02-011. Phase II Trial of Neoadjuvant Tislelizumab with Chemotherapy for Resectable Stage IIB-III Non-small Cell Lung Cancer
Faculty:
- Yao-Bin Lin

EP05.02-012. Chemoradiotherapy versus Chemotherapy in Neoadjuvant Settings for Stage III-N2M0 Non-Small Cell Lung Cancer (NSCLC) Patients
Faculty:
- Marah Akhdar

EP05.02-013. Immune-Related Adverse Effects and Durvalumab Treatment Patterns in VHA Patients with Unresectable Stage III NSCLC
Faculty:
- Amanda M Moore

EP05.02-014. Neoadjuvant Toripalimab Combination in Patients with Stage IIB-IIIB NSCLC: A Single-Arm, Phase 2 Trial (Renaissance Study)
Faculty:
- Shi Yan

EP05.02-015. Neoadjuvant Prehabilitation Therapy for Locally Advanced Non-small-Cell Lung Cancer: Optimizing Outcomes throughout the Trajectory of Care
Faculty:
- Severin Schmid

EP05.02-016. Aumolertinib after Adjuvant Chemotherapy/Radiotherapy in Stage pIIIA-N2 Non-Small-Cell Lung Cancer with EGFR Mutation
Faculty:
- Yu Zhang

EP05.02-017. Prognostic Factors Following Induction Therapy for N2 Lung Cancer
Faculty:
- Takashi Inoue

EP05.02-019. Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: Surgical Outcomes in a Regionalized Pulmonary Oncology Network
Faculty:
- Yohann Pilon

EP05.02-020. IL-9Stimulates Anti-tumor Immune Response and Facilitates Checkpoint Blockade in Lung Cancer
Faculty:
- Yuqian Feng

EP05.02-021. An Updated Analysis of Toripalimab and Platinum-Doublet Chemotherapy as Neoadjuvant Therapy for Potentially Resectable NSCLC
Faculty:
- Yongchang Zhang

EP05.02-022. Thoracic Radiotherapy May Increase the Risk of Treatment-induced Pneumonitis after Immune Checkpoint Inhibitors: A Meta-Analysis
Faculty:
- Feng-Ming Spring Kong

EP05.03-001. Impact of Neoadjuvant Chemo/radiotherapy Followed by Surgical Resection on T4N0-1 Non-Small Cell Lung Cancer
Faculty:
- Akif Turna

EP05.03-002. Pulmonary Artery Reconstruction for Lung Cancer With N1 Vessel Infiltration: Is It Justified?
Faculty:
- Camilla Vanni

EP05.03-003. Superior Sulcus (Pancoast) Tumors: A 11-Year Single-Centre Experience
Faculty:
- Catarina Pereira Moita

EP05.03-004. Risk Prediction of Multiple-station N2 Metastasis in Patients with Clinical Single-station N2 Non-small Cell Lung Cancer
Faculty:
- Joon Young Kim

EP05.03-005. Clinical Impact of Histologic Type in Patients with Surgically Resected Stage II and III Non-small Cell Lung Cancer
Faculty:
- Hyeong Ryul Kim

EP05.03-006. Real-World Treatment Pathways In Stage III Non-Small Cell Lung Cancer in Portugal (PICTuRE): An Interim Analysis Of Surgical Patients
Faculty:
- Maria Encarnação Teixeira

EP05.03-007. Comparison of Surgical Methods in Patients Receiving Neoadjuvant Treatment; Thoracoscopy vs. thoracotomy
Faculty:
- Ezgi Cesur

EP05.03-008. Surgery after First-Line Alectinib for (Locally) Advanced ALK-rearranged NSCLC: Pathological Response and Peri-Operative Results
Faculty:
- Filippo Lococo

EP05.03-009. Prognostic Impact of Tumor Volume Doubling Time for Resected Squamous Cell Carcinoma of the Lung
Faculty:
- Kenta Nakahashi

EP05.03-010. Extended Resection of Non-small Cell Lung Cancer with Superior Vena Cava Involvement: A Systematic Review and Meta-analysis
Faculty:
- Shadi Hamouri

EP05.03-011. Bilateral Orthotopic Lung Transplantation for a Patient with Advanced Invasive Mucinous Adenocarcinoma
Faculty:
- Young Kwang Chae

EP05.03-012. Deep Learning-based Classifier to Predict Intensified Locoregional Approach Need in Stage III Non-Small Cell Lung Cancer
Faculty:
- Chenchen Zhang

EP06.01-001. The Longitudinal Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer at a Canadian Academic Centre: A Retrospective Chart Review
Faculty:
- Angelo Rizzolo

EP06.01-002. Cancer Care in a Time of COVID: Lung Cancer Patient's Experience of Telehealth and Connectedness
Faculty:
- Anne Fraser

EP06.01-003. Impact of COVID-19 on Lung Cancer Patients; The Patients' Perspective
Faculty:
- Desiree Hao

EP06.01-004. Lung Cancer Resection During the Covid-19 Pandemic: A Single Centre Study
Faculty:
- Tunde Nureini Oyebanji

EP06.01-005. COVID-19 and Post-COVID Outcomes in Lung Cancer Patients: Experience from an Indian Cancer Center
Faculty:
- Debapriya Mondal

EP06.01-006. Multidisciplinary Team during the COVID-19 Pandemic: The BE-PACIFIC Italian Observational Study Analysis
Faculty:
- Enrica Capelletto

EP06.01-007. Fate of Pneumonectomy Patients During Covid-19 Pandemic
Faculty:
- Gökberk Güler

EP06.01-008. COVID-Protected Pathways for Image Guided Lunc Cancer Intervention During the COVID-19 Pandemic: A Cohort Study
Faculty:
- Alexander Sheeka

EP06.01-009. Maintaining Thoracic Services During COVID-19 - A Single Centre Experience
Faculty:
- Hasanali David Walji

EP06.01-010. Clinical Outcomes after Hypo Fractionated Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer During The Covid-19 Pandemic In Morocco
Faculty:
- Meriem cherkaoui

EP06.01-011. COVID-19 Impact in Thoracic Surgery: a Comparison Between Public and Private Care in a Single-Center Facility
Faculty:
- Maria Teresa Ruiz Tsukazan

EP06.01-012. Impact of COVID-19 on the Stage of Lung Cancer Diagnosis at the Mohamed VI Center for Cancer Treatment in Morocco
Faculty:
- Souleymane Panandtigri

EP06.01-013. Differences of Oncology Treatment for Lung Cancer Patients in Pandemic COVID-19 Year: Our Clinical Experience
Faculty:
- Simonida Crvenkova

EP06.01-014. Lung Resections After COVID: Short-term Outcomes
Faculty:
- Srinivas Kodaganur Gopinath

EP06.01-015. Will Virtual Care Stand the Test of Time; One Site's Perspective on the Continuity of Virtual Care Post-Pandemic
Faculty:
- Suheon Lee

EP06.01-016. Nationwide Activity of Lung Cancer Surgery Before and During the COVID-19 Pandemic
Faculty:
- Tanel Laisaar

EP06.01-017. Clinical Impact of SARS-CoV2 Pandemic in the Diagnosis of Early-Stage Thoracic Tumours
Faculty:
- Yago Garitaonaindía Díaz

EP07.01-001. Molecular Profiling Predicts Outcomes in Patients With Resected Malignant Pleural Mesothelioma
Faculty:
- Christian Diego Rolfo

EP07.01-002. Surgery in Stage I-III Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER)- Medicare Analysis 1995-2015
Faculty:
- Qian Wang

EP07.01-003. Metadata-Oriented Data Engineering Approach for Integration of Medical Data: A Pilot Study
Faculty:
- Yusuf Kahya

EP07.01-004. Long Survivor Epithelioid Pleural Mesotheliomas Are Characterized by Tertiary Lymphoid Structures: An Update to the MATCH Study
Faculty:
- Federica Grosso

EP07.01-005. Second Primary Cancers in a Population-Based Mesothelioma Registry
Faculty:
- Giovanni Luca Ceresoli

EP07.01-006. Clinicopathologic Determinants of Survival in Thoracic NUT Carcinoma (TNUT): Analysis of a Pooled Database
Faculty:
- Philip A Haddad

EP07.01-007. Is Extended Resection for Tracheo Bronchial Adenoid Cystic Carcinoma Warranted?
Faculty:
- Jérôme Estephan

EP07.01-008. Perturbation of Warburg Effect by Dichloroacetate and Niclosamide in Malignant Pleural Mesothelioma in Vitro and in Vivo
Faculty:
- James C Ho

EP07.01-009. Solitary Fibrous Tumors of the Pleura, Clinical and Surgical Dilemma. Single-Center Experience
Faculty:
- Krzysztof Kurowski

EP07.01-010. Results of Multimodal Treatment in Patients with Malignant Pleural Mesothelioma Undergoing Pleurectomy/Decortication
Faculty:
- Kubra Alphan Kavak

EP07.01-011. Integrating PD-L1 Expression to the CALGB Prognostic Scoring System in Malignant Pleural Mesothelioma
Faculty:
- Luis Antonio Cabrera

EP07.01-012. Ipilimumab and Nivolumab in Pretreated Patients with Malignant Pleural Mesothelioma
Faculty:
- Marko Jakopovic

EP07.01-013. Physical Function, Symptom Burden, and Quality of Life in Patients with Malignant Pleural Mesothelioma
Faculty:
- Meng Wu

EP07.01-014. Mesothelioma-Associated Fibroblasts Enhance Mesothelioma Aggressiveness and Modulate Drug Response
Faculty:
- Michael Grusch

EP07.01-015. Multimodality Imaging for Characterization, Classification, and Staging of Malignant Pleural Mesothelioma, Focusing on MR Imaging
Faculty:
- Mi young Kim

EP07.01-016. Role of Neoadjuvant Chemotherapy in Thymic Tumors
Faculty:
- Riad Abdeljalil

EP07.01-017. Malignant Fibrous Solitary Tumour of the Pleura Is Not All the Same: Evaluation of Risk Stratification Models in a Large Single Centre Series
Faculty:
- Sara Ricciardi

EP07.01-018. Phase III Randomized Trial on Surgery, Chemo and Pleural Radiation (IMPRINT) for Resectable Pleural Mesothelioma (NRG LU-006)
Faculty:
- Andreas Rimner

EP07.01-019. Multiinstitutional Patterns of Use and Compliance with Tumor Treating Fields for Patients with Unresectable Malignant Pleural Mesothelioma
Faculty:
- Rupesh Kotecha

EP07.01-020. Pulmonary MALT Lymphoma: Detailed CT Findings
Faculty:
- Kyongmin Sarah Beck

EP07.01-021. Clinical and Biochemical Profiling of Pleural Mesothelioma Patients Treated With Immunotherapy
Faculty:
- Sara Manglaviti

EP07.01-022. Analysis of Second Surgery for Recurrence in Malignant Pleural Mesothelioma (MPM) Patients (P)
Faculty:
- Susana Cedres

EP07.01-023. Family History of Cancer in a Series of Malignant Pleural Mesothelioma (MPM) Patients (P)
Faculty:
- Susana Cedres

EP07.01-024. Preclinical Investigation of Immune Checkpoint Blockade and Anti-Angiogenic Therapy in Malignant Pleural Mesothelioma
Faculty:
- Sophie Rovers

EP07.01-025. Survival Advantage of Pulmonary Metastasectomy in Advanced Melanoma Patients: A Population-Based Study
Faculty:
- Sebawe Syaj

EP07.01-026. Primary Pulmonary Ewing'S Sarcoma: Post Hoc Analysis From Two International Multicenter Prospective Randomized Trials
Faculty:
- Theresa Stork

EP07.02-001. Evaluation of FGF18 as a Contributing Factor in Malignant Pleural Mesothelioma Growth and Its Role as a Potential Biomarker
Faculty:
- Berta Mosleh

EP07.02-002. Investigating the Role of MicroRNAs in Cell Growth and Cisplatin-Sensitivity of Malignant Pleural Mesothelioma
Faculty:
- Michaela B Kirschner

EP07.02-003. Characterization of the Extracellular Vesicle-Derived Transcriptome in Malignant Pleural Mesothelioma
Faculty:
- Michaela B Kirschner

EP07.02-004. Endogenous Retrovirus Expression and Type I Interferon Signaling in Human Mesothelioma
Faculty:
- Suna Sun

EP07.03-001. Comparison of Treatment Outcomes in Neoadjuvant Chemotherapy and Chemo-radiotherapy for Thymoma and Thymic Carcinoma
Faculty:
- Hyeon Seok Choi

EP07.03-002. Combined Classifications for Thymoma and Thymic Carcinoma From a 10 years CHUM University Hospital Real-world Experience
Faculty:
- Camille Gauvin

EP07.03-003. First Line Combination of Toripalimab and Chemotherapy in Advanced Thymic Carcinoma: A Single-Center, Prospective, Single-Arm, Phase II Trial
Faculty:
- Xingsheng Hu

EP07.03-004. Efficacy of Thoracic Radiotherapy for Local Progression in Advanced Thymic Carcinoma
Faculty:
- Mao Uematsu

EP07.03-005. MesoGraph: Graph Neural Networks for Weakly Supervised Cellular Profiling in the Subtyping of Malignant Mesothelioma Images
Faculty:
- Mark Eastwood

EP07.03-006. Feasibility of TTFields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Real-World Data
Faculty:
- Rupesh Kotecha

EP07.03-007. Clinicopathological Analyses for Predicting Recurrence After Complete Resection of Thymoma
Faculty:
- Takahiro Suzuki

EP08.01-001. Update Analysis of Sintilimab With Two Cycles Chemotherapy for Untreated Advanced Squamous Non-small-Cell Lung Cancer
Faculty:
- Huijuan Wang

EP08.01-002. Real-World Survival Outcomes of Patients with High PD-L1 Advanced NSCLC Who Received Chemo-Immunotherapy vs Immunotherapy
Faculty:
- Junipearl Cheng

EP08.01-003. Efficacy of Immune Checkpoint Inhibitors in Pulmonary Sarcomatoid Carcinoma, A Multicenter Retrospective Study
Faculty:
- Zhimin Zeng

EP08.01-004. Pattern of Subsequent Treatment and Outcomes in Relapsed PD-L1 high NSCLC Pre-treated with Pembrolizumab
Faculty:
- Anifat Elegbede

EP08.01-005. A Multicenter Prospective Observational Study of Atezolizumab in Unresectable Advanced or Metastatic NSCLC in Japan: J-TAIL
Faculty:
- Akito Hata

EP08.01-006. Using Real World data to build effective predictive machine learining models for NSCLC patients treated with immune-based therapy
Faculty:
- Alessandro De Toma

EP08.01-007. Real-World Outcomes of Patients with Advanced Lung Adenocarcinoma Treated with First-Line Chemo-Immunotherapy in Italy
Faculty:
- Alessandro Leonetti

EP08.01-008. Immune Checkpoint Inhibitors in Oncogenic Driven Non-small Cell Lung Cancer
Faculty:
- Ana Fonseca

EP08.01-009. TRBV Haplotype Profile Was Related to Immune-Induced Adverse Events in Chinese Patients With Advanced NSCLC
Faculty:
- Xiaomin Niu

EP08.01-010. Troponin Elevation and the Risk of Myocarditis among NSCLC Patients Treated with Immune Checkpoint Inhibitors
Faculty:
- Barliz Waissengrin

EP08.01-011. Diabetes Mellitus (DM) is Associated with Poor Outcome in Pembrolizumab-treated Non-Small Cell Lung Cancer (NSCLC) Patients
Faculty:
- Barliz Waissengrin

EP08.01-012. First-line Chemo-Immunotherapy in Advanced Non-Small Cell Lung Cancer with 0-49% PD-L1: A Real-world Experience
Faculty:
- Beatrice Benetti

EP08.01-013. Ramucirumab plus Atezolizumab in Patients with Stage IV NSCLC Previously Treated with Immune Checkpoint Blockade
Faculty:
- Brett Howard Herzog

EP08.01-014. Tislelizumab versus Docetaxel in Previously Treated Advanced Non-Small Cell Lung Cancer: Final Analysis of RATIONALE-303
Faculty:
- Caicun Zhou

EP08.01-015. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Anti-oxMIF Antibody ON203 in Malignant Solid Tumors
Faculty:
- Christine Landlinger-Schubert

EP08.01-016. A Review Of Real-World Treatment Outcomes Of mNSCLC Patients Following Progression On Or After Platinum-Based Chemotherapy
Faculty:
- Cloe Ying Chee Koh

EP08.01-017. Evaluation of Blood Tumor Mutation Burden for Efficacy of Second- Line Atezolizumab Treatment in Non-small Cell Lung Cancer
Faculty:
- Cheol-Kyu Park

EP08.01-018. Patterns of Failure in Metastatic NSCLC Treated with First Line Pembrolizumab and Impact of Local Therapy in Patients with Oligoprogression
Faculty:
- Cole Friedes

EP08.01-019. Modifiable biomarkers of response to immune checkpoint inhibitor treatment in non-small cell lung cancer
Faculty:
- Daniel Spakowicz

EP08.01-020. Phase 2 Platform Trial of Anti-TIGIT GSK'859A/EOS-448 + Anti-PD-1 Dostarlimab in Non-small Cell Lung Cancer (NSCLC)
Faculty:
- David Spigel

EP08.01-021. Phase 2 Study Evaluating Inupadenant in Combination with Chemotherapy in Adults with NSCLC who Progressed on Immunotherapy
Faculty:
- Shouryadeep Srivastava,

EP08.01-022. Treatment Outcomes of Second-Line Immune Modulators in Steroid Refractory/Resistant Immune Related Adverse Events
Faculty:
- Yasar Ahmed

EP08.01-023. Factors Associated with Survival and Refusal of Physician Recommended Immunotherapy in Metastatic Non Small Cell Lung Cancer
Faculty:
- Iktej Singh Jabbal

EP08.01-024. Multicenter Real Life Clinical Outcomes of PDL-1 Tested Patients with Non Small Cell Lung Cancer (NSCLC) in Turkey
Faculty:
- Ozan Yazici

EP08.01-025. PD-L1 Tumor Tissue Expression and Its Relation with Clinico-pathological Profile in Advanced NSCLC
Faculty:
- Sindhu Kilaru

EP08.01-026. Influence of Brain Metastases on Survival of KRASG12C Mutated Stage IV Immune Checkpoint Inhibitor Treated Non-Small Cell Lung Cancer Patients
Faculty:
- Esther M Swart

EP08.01-027. Durvalumab (D) ± Tremelimumab (T) + Chemotherapy (CT) in 1L Metastatic NSCLC: Outcomes by Tumour PD-L1 Expression in POSEIDON
Faculty:
- Edward B. Garon

EP08.01-028. Overestimation with Cox HR - Cox-TEL-Adjusted Associations of PD-L1 Expression with Immune Checkpoint Inhibitor Survival Benefit in Lung Cancer
Faculty:
- Emily Pei-Ying Lin

EP08.01-029. NIVIPI-BRAIN, A Phase II Study of Nivolumab plus Ipilimumab Combined with Chemotherapy for Patients with NSCLC and Synchronous Brain Metastases
Faculty:
- Ernest Nadal

EP08.01-030. Nivolumab+Ipilimumab Vs Platinum-Based CT+Nivolumab In Advanced Lung Squamous-Cell Carcinoma: The Randomized SQUINT Trial
Faculty:
- Federico Cappuzzo

EP08.01-031. Blood Gene Expression Changes in Metastatic Lung Cancer under second-line Immunotherapy according to Clinical Response
Faculty:
- Fabienne Dorothea Lusky

EP08.01-032. Sintilimab in Combination with Anlotinib in NSCLC Patients with Uncommon EGFR Mutations: A Phase II, Single-arm, Prospective Study
Faculty:
- Yun Fan

EP08.01-033. ML40471: Preliminary Analysis of Atezolizumab in Previously Treated Patients With Locally Advanced or Metastatic NSCLC
Faculty:
- Yun Fan

EP08.01-034. Association of Sarcopenia with Survival in Advanced NSCLC Patients Receiving Concurrent Immunotherapy and Chemotherapy
Faculty:
- Fabian Johannes Bolte

EP08.01-035. Personalized ctDNA Detection to Monitor Outcome and Predict Immunotherapy Benefit in Locally Advanced and Metastatic NSCLC
Faculty:
- Guanghui Gao

EP08.01-036. Low-dose EGFR-TKIs Directly Induce Maturation and Functional Activity of Human Dendritic Cells in an EGFR-independent manner
Faculty:
- Hiroyuki Inoue

EP08.01-037. Association of Baseline NLR and BMI with Clinical Outcomes in NSCLC Patients Treated with Immunotherapy Alone Versus Chemo-Immunotherapy
Faculty:
- Hita Moudgalya

EP08.01-038. Clinical Predictors of Treatment Efficacy in Patients with Lung Adenocarcinoma Receiving Immune Checkpoint Inhibitors
Faculty:
- Fang Hu

EP08.01-039. Impact of Pulmonary Function Indexes on Immunotherapy Efficacy in Lung Adenocarcinoma Patients and the Potential Prognostic Factors
Faculty:
- Fang Hu

EP08.01-040. Peripheral Blood Cells as Predictors for Efficacy of Immunotherapy in Patients with Advanced Non-small Cell Lung Cancer
Faculty:
- Jacobo Rogado

EP08.01-041. Impact of Gender on Response to Immune Checkpoint Inhibitors in Patients with Non-small Cell Lung Cancer
Faculty:
- Jae Cheol Lee

EP08.01-042. NEPTUNE China Cohort: First-Line Durvalumab + Tremelimumab versus Chemotherapy in Chinese Patients with Metastatic NSCLC
Faculty:
- Ying Cheng

EP08.01-043. Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced Non-small Cell Lung Cancer (NSCLC)
Faculty:
- Joao Alessi

EP08.01-044. A Phase 2 Multi-Cohort Study of Tiragolumab, Atezolizumab and Bevacizumab in Advanced Non-Squamous Non-Small Cell Lung Cancer
Faculty:
- Joshua Reuss

EP08.01-045. The Impact of Current Smoking Status at Initiation of Immune Checkpoint Inhibitor Therapy on Tumor Mutation Burden and Survival
Faculty:
- Julie T. Wu

EP08.01-046. Examination of Long-Term Administration of Pembrolizumab in Patients with Non-small Cell Lung Cancer at Our Institution
Faculty:
- Kazuhito Nii

EP08.01-047. Chemo-immunotherapy is Associated With Better Survival Than Chemotherapy Alone In Stage IV Non-small Cell Lung Cancer
Faculty:
- Krishna Hitendra Patel

EP08.01-048. Spanish Immunotherapy Registry of Cardiovascular Toxicity (SIR-CVT): Preliminary Analysis of the Lung Cancer Cohort
Faculty:
- Laura Gutiérrez Sainz

EP08.01-049. Unscheduled Hospitalizations in Patients With Thoracic Tumors in the Era of Immunotherapy
Faculty:
- Laura Gutiérrez Sainz

EP08.01-050. Survival Outcome of Metastatic Pulmonary Sarcomatoid Carcinoma Treated with Immunotherapy: An Analysis of National Cancer Database (NCDB)
Faculty:
- Lei Deng

EP08.01-051. Clinical Characterization and Outcomes of Non Small Cell Lung Cancer with HER2 Alterations in the Era of Immunotherapy
Faculty:
- Shenduo Li

EP08.01-052. Toripalimab in Combination with CIK Cells in Patients with Advanced NSCLC: An Exploratory Study
Faculty:
- Xuxinyi Ling

EP08.01-053. PD-1 Inhibitors Plus Chemotherapy in Patients with Brain Metastasis and EGFR/ALK-positive Non-small Cell Lung Cancer after EGFR/ALK-TKIs
Faculty:
- Yutao Liu

EP08.01-054. ICIs combined with Single-agent Chemotherapy in Two or More Lines Treatment for Advanced Non-Small Cell Lung Cancer
Faculty:
- Yutao Liu

EP08.01-055. Utilization of Tumor Mutational Profiling to Identify the Immunotherapy Response in Non-small Cell Lung Cancer
Faculty:
- Wenbin Li

EP08.01-056. Pemetrexed-Based Chemotherapy Plus ICIs or Bevacizumab as First-Line Strategy for Patients with Lung Adenocarcinoma in Real-World Setting
Faculty:
- Xin Li

EP08.01-057. Pembrolizumab Maintenance in Patients with Metastatic Squamous Non-Small Cell Lung Cancer (sNSCLC) - AIO-TRK-0115/PRIMUS
Faculty:
- Martin Reck

EP08.01-058. Access to Immunotherapy in Control Arms of Pivotal First Line Immunotherapy Trials in Metastatic Non-Small Cell Lung Cancer
Faculty:
- Maham Bakhtyar

EP08.01-059. Safety, Tolerability and Clinical Activity of Selinexor in Combination with Pembrolizumab in Metastatic Non-small Cell Lung Cancer
Faculty:
- Mehmet Altan

EP08.01-060. Long term Survival Outcomes in NSCLC Patients with Targeted Therapy and Immunotherapy: An IASLC Analysis of ASCO CancerLinQ Discovery Data
Faculty:
- Madhusmita Behera

EP08.01-061. A Pilot Study of Avelumab and SABR in Non-Responding and Progressing NSCLC Patients Previously Treated with a Checkpoint Inhibitor
Faculty:
- Megan Eileen Daly

EP08.01-062. Body Mass Index, Immune Related Adverse Events, and Survival in Patients with Metastatic Non-small Cell Lung Cancer Treated with Immunotherapy
Faculty:
- Mingjia Li

EP08.01-063. Chemoimmunotherapy versus Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer with a PD-L1 Score of 50-100%
Faculty:
- Mohsin Shah

EP08.01-064. Serum NY-ESO-1 and XAGE1 Antibodies Predict and Monitor Clinical Responses to Immune Checkpoint Therapy for NSCLC
Faculty:
- Mikio Oka

EP08.01-065. Prevalence of Non-driver Mutations and Characterization of Patients with Advanced or Metastatic Non-small Cell Lung Cancer
Faculty:
- Mariano Provencio

EP08.01-066. Assessing Immunotherapy in Real Life: Have We Transferred the Increase in Overall Survival in Stage IV NSCLC from Trials to Clinical Practice?
Faculty:
- Mariano Provencio

EP08.01-067. Rechallenging with PD-1 Inhibitors: Incidence and Management of Immune-Related Adverse Events in Metastatic NSCLC
Faculty:
- Tuan Hoang

EP08.01-068. Going for the Ligand After a Stint With the Receptor: Can Switching Target From PD-1 to PD-L1 (Or Vice-Versa) Be Beneficial?
Faculty:
- Nida Khan

EP08.01-069. A Retrospective Study of Immune Checkpoints Rechallenge/ Retreatment in Metastatic NSCLC Progressing after Previous ICIs
Faculty:
- Nuria Neisy Mederos Alfonso

EP08.01-070. Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC
Faculty:
- Jun Zhao

EP08.01-071. Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Non-Squamous NSCLC
Faculty:
- Jun Zhao

EP08.01-072. Clinical Value of Patras Immunotherapy Score (PIOS) Formula in Patients With Advanced NSCLC Treated With Immunotherapy/Chemotherapy
Faculty:
- Petros Christopoulos

EP08.01-073. AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab plus Tislelizumab in Patients with Metastatic NSCLC
Faculty:
- Rajiv Kumar

EP08.01-074. 'Long Responders' Compared to 'Non-Responders' to a First Line Immune Checkpoint Inhibitor in Incurable Non-Small Cell Lung Cancer
Faculty:
- Rebekah Rittberg

EP08.01-075. Combination of Baseline Disease and Smoking Pack-Years Can Guide The 1st-line Treatment Decision in Advanced NSCLC with High PD-L1 Expression
Faculty:
- Ren Yuan

EP08.01-076. KEYNOTE B36: A Pilot Study of First-line Tumor Treating Fields (150 kHz) Plus Pembrolizumab for Advanced or Metastatic Non-small Cell Lung Cancer
Faculty:
- Rupesh Kotecha

EP08.01-077. Predicting Response to Checkpoint Inhibitors Using Complex Molecular Characteristics and Immunoprofiling in Patients With NSCLC
Faculty:
- Simona Borilova

EP08.01-078. Clinical Outcomes in Metastatic Non-small Cell Lung Cancer Harboring BRAF Mutations Treated With Immune Checkpoint Inhibitors
Faculty:
- Susana Cedres

EP08.01-080. Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced NSCLC in Patients aged ≥ 70
Faculty:
- Bo Shen

EP08.01-081. A Phase I Dose-Escalation Study of HBM4003, an anti-CTLA-4 Heavy Chain Only Monoclonal Antibody, in Combination with Pembrolizumab
Faculty:
- Shun Lu

EP08.01-082. Therapeutic Resistance and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients: A Prospective Study
Faculty:
- Shun Lu

EP08.01-083. Real-World PD-(L)1 Inhibitor Treatment Pattern and Outcomes in Advanced Non-Small Cell Lung Cancer in Sweden
Faculty:
- Simon Ekman

EP08.01-084. Non-Invasive Detection of Predictive Biomarkers for PD-1 Inhibitor Treated Non-Small Cell Lung Cancer Patients
Faculty:
- Simone Stensgaard

EP08.01-085. Sintilimab versus Pembrolizumab as Monotherapy or in Combination with Chemotherapy for Treatment Naïve Metastatic Non-small Cell Lung Cancer
Faculty:
- Si-Yang Maggie Liu

EP08.01-086. Pooled Mutant KRAS-Targeted Peptide Vaccine with Nivolumab and Ipilimumab in Advanced KRAS Mutated Non-Small Cell Lung Cancer
Faculty:
- Samuel Rosner

EP08.01-087. First-Line Pembrolizumab-Combination Therapy for Advanced Squamous NSCLC: Real-World Outcomes at US Oncology Practices
Faculty:
- Stephen V. Liu

EP08.01-088. Direct Acting Antivirals (DAA) and Immune Checkpoint Inhibitors (ICIs) Therapy in Patients with Lung Cancer and Hepatitis C
Faculty:
- Marco Tagliamento

EP08.01-089. Efficacy and Safety of Immune Checkpoint Inhibitors in Treating Brain Metastases in Patients With Non-small Cell Lung Cancer
Faculty:
- Fei Teng

EP08.01-090. Association of Gender and Outcomes in Patients With Advanced NSCLC Treated With Immunotherapy Alone or in Combination With Chemotherapy Upfront
Faculty:
- Teresa Gorria

EP08.01-091. Association of dNLR Score with Outcomes in Patients with Advanced NSCLC Under Immunotherapy Alone +/- Chemotherapy Upfront
Faculty:
- Teresa Gorria

EP08.01-093. ICI in Combination With Chemotherapy or Anti-angiogenic Agents as Second-Line Orbeyondtreatment for Advanced Non-small Cell Lung Cancer
Faculty:
- Lin Wu

EP08.01-094. A Phase II Study of Camrelizumab combined with Apatinib and Albumin Paclitaxel in Advanced Non-squamous NSCLC (CAPAP-lung)
Faculty:
- Lin Wu

EP08.01-095. Efficacy and Safety of Combining Endostar with Camrelizumab plus Chemotherapy in Advanced NSCLC Patients: A Multi-Center Retrospective Study
Faculty:
- Lin Wu

EP08.01-096. Lung Immune Prognostic Index is Prognostic in Patients Treated with PD-1 Inhibitor Combined with Chemotherapy for Non-small Cell Lung Cancer
Faculty:
- Anning Xiong

EP08.01-097. Landscape and Dynamic Changes of Peripheral Immune Cells in Non-small Cell Lung Cancer Patients with First-line Immunotherapy
Faculty:
- Xiangling Chu

EP08.01-098. Evaluating Risk Factors for Pneumonitis in Stage III NSCLC Patients Receiving Durvalumab after Definitive Chemoradiation
Faculty:
- xiaokui Mo

EP08.01-099. Activity of aPD1-MSLN-CART Cells against Metastatic Lung Cancer in a Phase 1 Trial
Faculty:
- Xiaorong Dong

EP08.01-100. Unlocking Primary Resistance to Checkpoint Inhibitors in Non-small Cell Lung Cancer by Metagenomic and Metabolomic
Faculty:
- Xiaorong Dong

EP08.01-101. Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Asian Patients with Advanced NSCLC
Faculty:
- Yiqing Huang

EP08.01-102. Anlotinib Combined with PD-1 Inhibitors May Benefit Advanced Non-small Cell Lung Cancer Patients After Failure of EGFR-TKI Therapy
Faculty:
- Lian Yu

EP08.01-103. Combination of Anlotinib and PD-1/PD-L1 Inhibitors as Second-line and Subsequent Therapy in Advanced Small-cell Lung Cancer
Faculty:
- Lian Yu

EP08.01-104. Baseline Tumor Size and Survival Outcomes among Patients with Advanced NSCLC treated with First-Line Immunotherapy
Faculty:
- Yuji Uehara

EP08.01-105. Efficacy of First-Line Immune Checkpoint Inhibitors in Patients with Advanced NSCLC harboring KRAS, MET, FGFR, RET, BRAF, and HER2 Alterations
Faculty:
- Yuji Uehara

EP08.01-106. PD-1/PD-L1 Inhibitors Increase Myocardial Infarction in Osimertinib-Treated Patients with Non-Small Cell Lung Cancer
Faculty:
- Lucheng Zhu

EP08.01-107. The Increase of Blood Intratumor Heterogeneity Is Associated with Unfavorable Outcomes of ICIs Plus Chemotherapy in NSCLC
Faculty:
- Juan Zhou

EP08.01-108. Real-Life Costs and Benefit of First-Line Pembrolizumab for Advanced NSCLC - A Propensity-Score Matched Case-Control Study
Faculty:
- Vanessa Rambousek

EP08.01-109. TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC
Faculty:
- Martin Forster

EP08.01-110. Trial in Progress: A Phase 2 Multicenter Study (IOV-LUN-202) of Autologous Tumor-infiltrating Lymphocyte (TIL) Cell Therapy (LN-145) in mNSCLC
Faculty:
- Jason Alan Chesney

EP08.02-001. Concurrent Aumolertinib and Cerebral Radiotherapy as First-Line Treatment for EGFR Mutated Non-small Cell Lung Cancer with Brain Metastases
Faculty:
- Ying Wang

EP08.02-002. Aumolertinib in the Treatment of Activated EGFR Mutation Advanced NSCLC Patients with Interstitial Pneumonia
Faculty:
- Jie Tan

EP08.02-003. Aumolertinib Plus Chemotherapy as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation andctDNA Cleared Analysis
Faculty:
- YanWei Li

EP08.02-004. Aumolertinib in Treatment-Naïve EGFR-mutant NSCLC Patients With Brain Metastases: Primary Efficacy and Safety Data from the ARTISTRY
Faculty:
- Huijuan Wang

EP08.02-005. A Prospective Non-randomized Observational Study on Efficacy and Its Relative Factors of Pemetrexed Combined With EGFR-TKIs in NSCLC
Faculty:
- Huijuan Wang

EP08.02-006. Data from Real World to Evaluate the Efficacy of Almonertinib in EGFR-mutant NSCLC Patients
Faculty:
- Huijuan Wang

EP08.02-007. Disease Burden and Clinical Outcomes of Advanced ROS1 Positive NSCLC with Different Fusion Partners
Faculty:
- Zihua Zou

EP08.02-008. Tumor Invasiveness and Clinical Outcomes between Metastatic ROS-1 and ALK Positive NSCLC
Faculty:
- Zihua Zou

EP08.02-009. Progression Pattern, Resistance Mechanism and Subsequent Therapy for ALK Positive NSCLC in the Era of Second-Generation ALK-TKIs
Faculty:
- Zihua Zou

EP08.02-010. Low-Dose Dacomitinib as First-Line Therapy for Driver-Positive Advanced Non-small Cell Lung Cancer: A Multicenter Real-World Study in China
Faculty:
- Liang Gong

EP08.02-011. Design of a Phase I Trial (TOTEM) to Test Repotrectinib in Combination with Osimertinib in Advanced, Metastatic EGFR-Mutant NSCLC
Faculty:
- Andrés Aguilar

EP08.02-012. Real-world Analysis of the Efficacy and Safety of lorlatinib in Patients with ALK-Positive Non-small Cell Lung Cancer in Korea
Faculty:
- Beung-chul AHN

EP08.02-013. Prognostic Utility of the ALI (Advanced Lung Index) in Crizotinib-Treated ALK and ROS1Fusion-Positive NSCLC
Faculty:
- Amanda Gibson

EP08.02-014. Impact of East Asian Ancestry on Response to First-Line Osimertinib: A Real-World Canadian Cohort
Faculty:
- Amanda Gibson

EP08.02-015. The Utility of Liquid Biopsies for Management of Stage IV Non-small Cell Lung Cancer (NSCLC) in an Academic Community Medical Center
Faculty:
- Alisha Paro Maity

EP08.02-016. Frontline and Post-Osimertinib Therapy for EGFR-mutant Advanced NSCLC: Treatment Patterns, Outcomes, Healthcare Use and Costs
Faculty:
- Benjamin Besse

EP08.02-017. Time on Treatment for Patients Treated With Anti-EGFR Tyrosine Kinase Therapy for Metastatic NSCLC: Real-World Experience Data
Faculty:
- Lior Apter

EP08.02-018. Phase 1/2 Study of BLU-451, a Small Molecule Inhibitor of EGFR, in EGFR Exon 20 Insertion-Mutant Incurable Advanced Cancers
Faculty:
- Alexander Spira

EP08.02-019. Phase 1/2 Study of BLU-701, a Highly Selective EGFR Inhibitor, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
Faculty:
- Alexander Spira

EP08.02-020. Preclinical Activity of NVL-655 in a Patient-Derived NSCLC Model with Lorlatinib-Resistant ALK G1202R/T1151M Mutation
Faculty:
- Anupong Tangpeerachaikul

EP08.02-021. A Phase II Trial of Upfront Aumolertinib (HS-10296) plus Radiotherapy for EGFR Mutated Non-small-cell Lung Cancer Patients with Brain Metastases
Faculty:
- Yi Tang

EP08.02-022. Investigating Partners in Crime: Osimertinib Resistance Mechanisms in Non-small Cell Lung Cancer Using Focused CRISPR Screen
Faculty:
- Bengisu Uluata Dayanc

EP08.02-023. Differentiation Syndrome in a Patient with Non-Small-Cell Lung Cancer Harboring IDH2 Mutation Treated with Enasidenib.
Faculty:
- Bhoomika Sukhadia

EP08.02-024. Research Efforts in Systemic Therapy of Lung Cancer With Brain Metastasis From 2015-21: A clinicaltrial.gov Registry Analysis
Faculty:
- Bindu Krishnappa Venugopal

EP08.02-025. Lazertinib as a Frontline Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer: Results from the Phase I/II Trial
Faculty:
- Byoung Chul Cho

EP08.02-026. Real-world Efficacy of EGFR-TKI in Advanced NSCLC and Clinical Predictors of Outcome in Maharaj Nakorn Chiangmai Hospital in Thailand.
Faculty:
- Chaiyut Charoentum

EP08.02-027. T790M Detection Rate After First-Line Treatment with Bevacizumab Plus 1st or 2nd Generation EGFR-TKI in Advanced NSCLC
Faculty:
- Chao-Chi Ho

EP08.02-028. Germline HRR Mutations in Metastatic NSCLC and Impact on Progression-Free Survival: A Single-Center Retrospective Study
Faculty:
- Chetan Vakkalagadda

EP08.02-029. Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations: Effect of Prior Treatment
Faculty:
- James Chih-Hsin Yang

EP08.02-030. Tusamitamab Ravtansine in Patients with NSQ NSCLC and Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA
Faculty:
- Christine Soufflet

EP08.02-031. NRF2 Pathway Signature Predicts KEAP1/NFE2L2 Mutations and Reveals Alternative Pathway-Activating Mutations in NSCLC
Faculty:
- Christoph Arolt

EP08.02-032. High Efficiency Multiplex Detection of Molecular Alterations in Supernatants of Pleural Effusion and Cerebrospinal Fluid
Faculty:
- Clara Mayo de las Casas

EP08.02-033. Anlotinib in Elderly Patients With Advanced Non-squamous NSCLC Who Had Not Received Systemic Chemotherapy: A Single-Arm, Phase II Study
Faculty:
- da zhao

EP08.02-034. OCELOT - Osimertinib then Chemotherapy in EGFR+ Lung Cancer with Osi Third-line Rechallenge and Osimertinib for Uncommon EGFRm in 1L
Faculty:
- Daniel Breadner

EP08.02-035. Clinical Utility of Liquid Biopsy After Progression to First and Second-Generation TKIs in Advanced EGFR Mutant NSCLC Patients
Faculty:
- David Heredia

EP08.02-036. Selpercatinib Striking Response in a Case of Cerebral and Auditory Canal Metastasis of RET Fusion-Positive Non-Small-Cell Lung Cancer
Faculty:
- Diana Moreira Sousa

EP08.02-037. Small Cell Transformation in a Patient with RET Fusion Positive Lung Adenocarcinoma on Pralsetinib
Faculty:
- Anastasios Dimou

EP08.02-038. Study of First-Line Aumolertinib Plus Bevacizumab and Pemetrexed Treated NSCLC with EGFR Mutation and Brain Metastasis
Faculty:
- Shuai Fu

EP08.02-039. An Effective Treatment for EGFR-mutated Lung Adenocarcinoma with Symptomatic Leptomeningeal Metastases Using Aumolertinib
Faculty:
- Xinyong Zhang

EP08.02-040. Dacomitinib Induced Febrile Neutropenia: a Rare Serious Adverse Event
Faculty:
- Debapriya Mondal

EP08.02-041. NVL-520, a Highly Selective ROS1 Inhibitor, in Patients with Advanced ROS1-Positive Solid Tumors: The Phase 1/2 ARROS-1 Study
Faculty:
- Alexander Drilon

EP08.02-042. EGFR-TKI +/- Antiangiogenics for EGFR-mutated Advanced NSCLC
Faculty:
- Laercio Lopes DaSilva

EP08.02-043. The Current State of Biomarker Testing in Lung Cancer as Seen by Health Care Providers
Faculty:
- Daniel A. Saez

EP08.02-044. Adding Alectinib Rescues Progression on Osimertinib Due to Acquired ALK p.R1275Q Variant in EGFR p.L858R-mutated NSCLC
Faculty:
- Edyta Maria Urbanska

EP08.02-045. Phase 1/2 Study of BLU-945 in Patients With Common Activating EGFR-Mutant Non-Small Cell Lung Cancer
Faculty:
- Elaine Shum

EP08.02-046. Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO)
Faculty:
- Elio Gregory Pizzutilo

EP08.02-047. The Impact of CGP on the Decision-making Process in ALK+ aNSCLC After Failure of 2nd/3rd-Generation ALK TKIs
Faculty:
- Elizabeth Dudnik

EP08.02-048. Crizotinib in ROS1+NSCLC: Long-term OS Analysis in Patients with Brain Metastases Included in the Phase II METROS Trial
Faculty:
- Federico Cappuzzo

EP08.02-049. A Phase I Trial of the HER2 Exon 20 Inhibitor, BI 1810631, In Patients With Advanced Solid Tumors With HER2 Aberrations
Faculty:
- Frans Opdam

EP08.02-050. A Retrospective Study of Aumolertinib in Combination with Bevacizumab for EGFR-mutated NSCLC with the Presence of Leptomeningeal Metastasis
Faculty:
- shencun Fang

EP08.02-051. High-dose Aumolertinib as First-line Treatment in Patients With Brain Metastases Associated With EGFR Mutated NSCLC
Faculty:
- Yun Fan

EP08.02-052. Safety and Efficacy of Dabrafenib Plus Trametinib in Chinese Patients With BRAF V600E- Mutation Positive Metastatic NSCLC
Faculty:
- Yun Fan

EP08.02-053. Non-small Cell Lung Cancer withMETExon14 Skipping Mutation: Literature Review of Real-World Evidence Data
Faculty:
- Fernanda Estevinho

EP08.02-054. Efficacy and Safety of TKI Dose Reduction - Can Less Mean More?
Faculty:
- Fernando Pereira da Silva

EP08.02-055. Targeting Lung Adenocarcinoma Cells with a Novel Disulfide Reductase Inhibitor
Faculty:
- Fraser Johnson

EP08.02-056. Coexisting MET Exon 14 Skipping Mutation and MET Amplification in a Patient with Complete Response to MET Inhibitors
Faculty:
- Flávia Amaral Duarte

EP08.02-057. Mechanism of Resistance to Second-Line Aumolertinib and Therapeutic Regime after Resistance
Faculty:
- Lingxin Feng

EP08.02-058. A Case Series of Patients With Kras KRAS G12C Mutation Treated With Sotorasib - Croatian Experience
Faculty:
- Fran Seiwerth

EP08.02-059. EGFR Tyrosine Kinase Inhibitors and Combination Strategies in First-line Treatment of Advanced NSCLC: A Network Meta-analysis
Faculty:
- Gilberto de Castro

EP08.02-060. How Do Oncologists Treat Patients With EGFR Exon-20 Mutant NSCLC Outside of Clinical Trials? Updated Analysis From the European EXOTIC Registry
Faculty:
- Giannis Mountzios

EP08.02-061. Treatment Sequences in ALK-rearranged Non-small Cell Lung Cancer; What Happens in the Real World?
Faculty:
- Grace Chazan

EP08.02-062. Evaluation of In Silico Tools to Determine Potential Actionability of Missense Variants with Experimental Therapies for NSCLC
Faculty:
- Lena Chae

EP08.02-063. SANOVO: A Phase 3 Study of Savolitinib or Placebo in Combination with Osimertinib in Patients with EGFR-mutant and MET Overexpressed NSCLC
Faculty:
- Qing Zhou

EP08.02-064. ASTRIS China: A Real-world Study of Osimertinib in Patients with EGFR T790M Positive Non-small-cell Lung Cancer (NSCLC)
Faculty:
- Qing Zhou

EP08.02-065. Response to Systemic Anti-Cancer Therapy in Uncommon EGFR Mutations
Faculty:
- Hazel M O'Sullivan

EP08.02-066. Real-World Data on the Side Effects of Alectinib, Brigatinib and Lorlatinib
Faculty:
- Debra Montague

EP08.02-067. Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR Mutated Non-small Cell Lung Cancer with Brain Metastases
Faculty:
- Meijuan Huang

EP08.02-068. ALK-Dependent Resistance Mechanism to Ensartinib Differs Between the ALK Fusion Subtypes Variant 1 (V1) and Variant 3 (V3)
Faculty:
- Jie Huang

EP08.02-069. A Retrospective Study of Aumolertinib Monotherapy or Combination Therapy Treated EGFR-mutated NSCLC Patients with Leptomeningeal Metastases
Faculty:
- siyuan Huang

EP08.02-070. High Incidence of Peridiagnosis Thromboembolic Events In Patients with BRAF Mutant Lung Cancer
Faculty:
- Inmaculada Aparicio Salcedo

EP08.02-071. Brain Metastases in EGFR-mutant NSCLC: Outcome of Osimertinib +/- Radiation Therapy in a Real-World Canadian Cohort
Faculty:
- Ishjot Litt

EP08.02-072. The Predictive Value of Longitudinal Monitoring of Mutated EGFR in Plasma of Advanced NSCLC Patients on First-Line EGFR-TKIs
Faculty:
- Joanna Chorostowska-Wynimko

EP08.02-074. Impact of Germline BRCA1/2 Alterations on EGFR Mutant Advanced Non-small Cell Lung Cancer Outcomes
Faculty:
- Jyoti D. Patel

EP08.02-075. Maintained Complete Response for 8+ Years with Erlotinib Alone in Advanced Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion
Faculty:
- Jens Benn Sørensen

EP08.02-076. Efficacy and Safety Evaluations of Anlotinib in Patients with Advanced Non-small Cell Lung Cancer Treated with Bevacizumab
Faculty:
- Fenge Jiang

EP08.02-077. Two Phase III Trials of Aumolertinib Plus Chemotherapy for NSCLC with EGFR and Concomitant non-EGFR Driver Genes /Tumor Suppressor Genes
Faculty:
- Jie Wang

EP08.02-078. Myeloprotection with Trilaciclib in Chinese Patients with Extensive-Stage Small Cell Lung Cancer Receiving Standard Chemotherapy (TRACES)
Faculty:
- Ying Cheng

EP08.02-079. The Use of Lung Adenocarcinoma Patient-Derived Xenografts and Organoids to Study GDP-KRAS G12C Inhibitor Resistance
Faculty:
- Joshua Rosen

EP08.02-080. EGFR Testing Practices, Treatment Choice and Clinical Outcomes in Advanced NSCLC in a Real-World Setting
Faculty:
- Janakiraman Subramanian

EP08.02-081. Cabozantinib Plus Atezolizumab in First or Second-Line Advanced NSCLC and Previously-Treated EGFR Mutant Advanced NSCLC
Faculty:
- Joel W. Neal

EP08.02-082. Treatment Patterns and Outcomes of First-line Osimertinib-treated Advanced EGFR Mutated NSCLC Patients: A Real-world Study
Faculty:
- Jae Yun Lee

EP08.02-083. Real World Treatment and Outcomes in EGFR-mutated Advanced Non-small Cell Lung Cancer Patients: A Nationwide Cohort for 1,932 Thai Patients
Faculty:
- Kakanan Tienchai

EP08.02-084. Evaluation of Tumor Heterogeneity (TH) as a Prognostic Biomarker in Osimertinib treated Non-Small Cell Lung Cancer Patients
Faculty:
- Karthikeyan Murugesan

EP08.02-085. In vitro Activity and Potential Resistance Mutations Against BI-4020, a 4th-generation EGFR-TKI
Faculty:
- Kenichi Suda

EP08.02-086. Randomized Double-blind Placebo-controlled trial of Nicotinamide and EGFR-TKIs for EGFR-mutated Lung Adenocarcinoma
Faculty:
- Young-Chul Kim

EP08.02-087. A 28-Years Old Pregnant Woman Diagnosed as ALK-Rearrangement Lung Adenocarcinoma With Multiple Brain Metastasis - Case Report
Faculty:
- Simona Laštíkova

EP08.02-088. Mutational Status of KRAS, STK11 and CDKN2A Genes as Predictors of Response to Antiangiogenic Agents in Non-small Cell Lung Cancer Patients
Faculty:
- Laura Gutiérrez Sainz

EP08.02-089. Toxicity of Sequential Tyrosine Kinase Inhibitors After Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer
Faculty:
- Lauren Jones

EP08.02-090. Sotorasib Drug-Drug Interactions: Essential Guidance Requested by Physicians Worldwide
Faculty:
- Leila-Sophie Otten

EP08.02-091. Disease Monitoring of EGFR-mutated NSCLC Patients Treated with TKIs via EGFR Status in Circulating ctDNA
Faculty:
- Yan Li

EP08.02-092. Coexistence of a Novel NBAS-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient With LM and Response to Ensartinib
Faculty:
- Na Li

EP08.02-093. Loss of Tumor Endothelial QKI Expression Results in Pronounced Reductions in Metastasis and Remodeling of the Tumor Microenvironment
Faculty:
- lincy edatt

EP08.02-094. Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma (ARISE): A Multicenter, Open-Label, Single-Arm Trial
Faculty:
- Gen Lin

EP08.02-095. Successful Treatment of EGFR Exon 19 Deletion with TP53 and ERBB2 20ins Mutation in Stage IVB NSCLC Patient with Aumolertinib
Faculty:
- Chunling Liu

EP08.02-096. Different Epidermal Growth Factor Receptor Inhibitor Generations Plus Antiangiogenic for EGFR-Mutated NSCLC: A Meta-Analysis
Faculty:
- Leen Al-Kraimeen

EP08.02-097. Prevalence, Clinical Characteristics and Survival of Patients With Brain Metastases and KRAS Mutation Lung Cancer in Argentina
Faculty:
- Luis Basbus

EP08.02-098. Phase 2 EVOKE-02 Study of Sacituzumab Govitecan and Pembrolizumab±Platinum in First-Line Metastatic NSCLC
Faculty:
- Martin Reck

EP08.02-099. Liquid Biopsies as a Tool for Monitoring Patients with Metastatic ALK-positive NSCLC
Faculty:
- Maiken Parm Ulhoi

EP08.02-100. Combination of Bevacizumab and Continuation of EGFR-TKIs in NSCLC Patients beyond Gradual Progression
Faculty:
- Ziyi Xu

EP08.02-101. Real-world Data from KRAS-mutant Advanced NSCLC: the ATLAS Multicenter Cohort Study
Faculty:
- Maristella Bungaro

EP08.02-102. Feasibility and Clinical Utility of ctDNA for Detection of Sensitizing and Resistance EGFR Mutations in Patients with Non-small Cell Lung Cancer
Faculty:
- Marta Garcia de Herreros

EP08.02-103. Lorlatinib for ALK+ NSCLC Patients Pretreated with Second-Generation ALK Inhibitors: Canadian Real-World Experience
Faculty:
- Martin Rupp

EP08.02-104. Osimertinib in Untreated EGFR-Mutant Non-small Cell Lung Cancers: Overall Survival and Budget Impact Analysis in Real-World
Faculty:
- Martina Lorenzi

EP08.02-105. KRAS p.G12 Mutated Advanced Non-Small Cell Lung Cancer. Characteristics and Outcomes from a Danish Nationwide Observational Study
Faculty:
- Matilde Tejlbo Frost

EP08.02-106. KEAP1/NFE2L2 Transcriptomic Signature Predicts Survival in Advanced Stage NSCLC Patients Without Actionable Driver Mutations
Faculty:
- Matthias Scheffler

EP08.02-107. Molecular Biomarker Testing and Initiation of Targeted Therapy in Minority Patients with Stage IV Non-small Cell Lung Cancer
Faculty:
- Matthew Villanueva, PharmD

EP08.02-108. Osimertinib Long-Term Tolerability in Patients with EGFRm NSCLC Enrolled in the AURA Program or FLAURA Study
Faculty:
- Marina Chiara Garassino

EP08.02-109. A Drug-Drug Interaction Study of Mobocertinib and Midazolam in Patients With Advanced Non-Small Cell Lung Cancer
Faculty:
- Michael J. Hanley

EP08.02-110. Plasma-based Molecular Profiling to Guide Treatment Decisions in Patients with Advanced NSCLC and Limited Tissue Biopsy
Faculty:
- Miguel Garcia Pardo

EP08.02-111. RMC-4630, a SHP2 Inhibitor, in Combination with Sotorasib for Advanced KRASG12C NSCLC After Failure of Prior Standard Therapies: A Phase 2 Trial
Faculty:
- Melissa L Johnson

EP08.02-112. Precision Treatment of Non-small Cell Lung Cancer Has a Profound Impact on Outcomes in a Canadian Province
Faculty:
- Michelle Liane Dean

EP08.02-113. Clinico-genomic Characteristics of Patients with Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
Faculty:
- Masanobu Okahisa

EP08.02-114. Comprehensive Analysis of ROS1 Aberrations without Rearrangements in Non-small cell Lung Cancer Patients
Faculty:
- Moritz Glaser

EP08.02-115. A Retrospective, Multicenter, Observational Study to Evaluate Outcomes With Lorlatinib After Alectinib in ALK+ NSCLC in Japan
Faculty:
- Motohiro Tamiya

EP08.02-116. Design of a Phase 1 Study of AMG 193, an MTA-Cooperative PRMT5 Inhibitor, in Patients with Advanced MTAP-Null Solid Tumors
Faculty:
- Miguel Villalona Calero

EP08.02-117. Online CME Improves Clinicians' Ability to Identify and Manage Patients with NSCLC and EGFR Exon 20 Insertion Mutations
Faculty:
- Michelle Arielle Worst

EP08.02-118. TRUST-II: A Global Phase II Study for Taletrectinib inROS1fusion Positive Lung Cancer and Other Solid Tumors
Faculty:
- Misako Nagasaka

EP08.02-119. RNA Sequencing to Characterize Pathways in EGFR-mutated Non-Small Cell Lung Cancer
Faculty:
- Nicole K Yun

EP08.02-120. MET Alterations at Presentation in NSCLC Patients Harboring EGFR Mutations and ALK, RET and ROS1 fusions
Faculty:
- Núria Jordana

EP08.02-121. The Landscape of Anti-neoplastic Drugs for Malignant Pleural Effusion in Non-small Cell Lung Cancer: A Systematic Review of Clinical Trials
Faculty:
- Obada Ehab Ababneh

EP08.02-122. Real-world Experience with Capmatinib in MET Exon 14-mutated Non-small Cell Lung Cancer (RECAP)
Faculty:
- Oliver Illini

EP08.02-123. First Line Osimertinib in Lung Cancer Patients with Postoperative Recurrence
Faculty:
- Atsushi Osoegawa

EP08.02-124. Lorlatinib Treatment Related Adverse Events: Single Centre Real-World Experience in ALK and ROS1-driven NSCLC
Faculty:
- Parvin Begum

EP08.02-125. Tumor Suppressor Gene Alterations Identified at Disease Progression Impact Outcomes in Patients with EGFR-mutant Lung Cancer
Faculty:
- Paul Stockhammer

EP08.02-126. The MOMENT Disease Registry of Patients with Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping
Faculty:
- Petros Christopoulos

EP08.02-127. Resistance Mechanisms to Osimertinib in Advanced EGFR-mutated NSCLC: A Single Institution Prospective Cohort Study
Faculty:
- Bin-Chi Liao

EP08.02-128. Long Term Efficacy of SNK01 Plus Pembrolizumab for NSCLC: Expanded Observation from a Phase I/II A Randomized Controlled Trial
Faculty:
- Hyungjun Park

EP08.02-129. Closing the Gaps with Blood-Based Next Generation Sequencing
Faculty:
- Pratik Vijay Shah

EP08.02-130. Tegavivint Exhibits Antitumor Activity and Modulates Macrophage Phenotype in the Non-small Cell Lung Cancer Tumor Microenvironment
Faculty:
- Raghav Chandra

EP08.02-131. Alectinib after Crizotinib Failure in Patients with Advanced ALK-Positive NSCLC: Results from the Spanish Early Access Program
Faculty:
- Reyes Bernabé-Caro

EP08.02-132. Fatal Interstitial lung disease induced by Osimertinib: a case report
Faculty:
- Ricardo José Cordeiro

EP08.02-133. Sequential Afatinib to Osimertinib in EGFR-mutant NSCLC: A Prospective Observational Study, Gio-Tag Japan Interim Report
Faculty:
- Ryo Morita

EP08.02-134. Real-world Efficacy of Dacomitinib in Patients with Previously EGFR-TKI Treated Non-small Cell Lung Cancer
Faculty:
- Chien-Yeh Chi

EP08.02-135. Anti-EGF Antibodies Significantly Improve the Activity of MET and KRAS Inhibitors in Preclinical Models of Non-small Cell Lung Cancer (NSCLC)
Faculty:
- Silvia Garcia-Roman

EP08.02-136. Final Analysis of a Phase II Study: Anlotinib Plus Docetaxel in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer
Faculty:
- Juan Shen

EP08.02-137. Prospective Study of Aumolertinib in NSCLC Patients with EGFR Sensitive Mutations Who Are Intolerant to Osimertinib Treatment
Faculty:
- Shun Lu

EP08.02-138. SAFFRON: Ph3 Savolitinib + Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression/Amplification Post-Osimertinib
Faculty:
- Shun Lu

EP08.02-139. A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs
Faculty:
- Shun Lu

EP08.02-140. MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC Post-Osimertinib
Faculty:
- Myung-Ju Ahn

EP08.02-141. Our' EGFR population - experience in a secondary center
Faculty:
- Sofia Campos Silva

EP08.02-142. Effects of Afatinib on the Treatment and Prognosis of Brain Metastasis in Advanced EGFR Mutation (+) NSCLC
Faculty:
- Sung Yong Lee

EP08.02-143. Shortening of the Turn around time (TAT) in the Examination of Rapid On-Site cytologic Evaluation (ROSE) at transbronchial biopsy.
Faculty:
- Yoshihiro Taguchi

EP08.02-144. The Impact of CNS Recurrence on Post-recurrence Survival in Patients with EGFR-mutation-positive Non-small-cell Lung Cancer
Faculty:
- Tatsuro Okamoto

EP08.02-145. An Efficacy Analysis of Advanced Non Small Cell Lung Cancer With MET Exon 14 Skipping in the Real World
Faculty:
- Fei Teng

EP08.02-146. Proposal of Foretinib as Second-Line TKI after Capmatinib/Tepotinib Treatment Failure in NSCLC with MET Exon 14 Mutation
Faculty:
- Toshio Fujino

EP08.02-147. Clinical Outcomes in Patients with or without Cell Cycle Gene Alterations in EGFR mutated Non-Small Cell Lung Cancer
Faculty:
- Turja Chakrabarti

EP08.02-148. Extended Follow-up of Efficacy and Safety of Larotrectinib in Patients With TRK Fusion Lung Cancer
Faculty:
- Victor Moreno

EP08.02-149. Spanish Multicenter Retrospective Study of Real-Life Experience of Advanced NSCLC with EGFR Exon 20 Insertions Treated With Amivantamab
Faculty:
- Víctor Albarrán-Artahona

EP08.02-150. Molecular Heterogeneity of Compound Epidermal Growth Factor Receptor (EGFR) Mutations in Lung Adenocarcinoma (LAC)
Faculty:
- Ramesh Bulusu

EP08.02-151. A Real World Evidence of Lorlatinib for Taiwanese with advanced ALK Positive Non-Small Cell Lung Cancer
Faculty:
- Wade Fang

EP08.02-152. Long-Term Survival With Anlotinib in a Patient With Advanced Undifferentiated Large-Cell Lung Cancer and Rare Tonsillar Metastasis
Faculty:
- Zhaoxia Wang

EP08.02-153. The Efficacy and Safety of EGFR-TKIs plus Anlotinib in Maintenance Therapy for Oligoprogressive Advanced or Metastatic EGFR Mutant NSCLC
Faculty:
- Zhaoxia Wang

EP08.02-154. Aumolertinib Plus Anlotinib as 1st-Line Treatment for EGFR Mutant Non-Small Cell Lung Cancer: A Phase II Trial
Faculty:
- Hualin Chen

EP08.02-155. The Difference in Clinical Outcomes Between Osimertinib and EGFR-TKI plus Anti-angiogenic Agent in EGFR-mutant NSCLC Patients
Faculty:
- Yen Hsiang Huang

EP08.02-156. Real-World Treatment Patterns and Impact of Comorbidity Burden on Treatment Duration for Patients with ALK+ NSCLC in the US
Faculty:
- Yin Wan

EP08.02-157. Acquired EGFR Exon 19 Deletion Is a Resistance Mechanism to BRAF/MRK Inhibition in BRAF V600Emutant NSCLC
Faculty:
- Fang Wu

EP08.02-158. Final Analyses of ALTER-L018: A Randomized Phase II Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-line Therapy for EGFR-negative NSCLC
Faculty:
- Lin Wu

EP08.02-159. Post Hoc Analyses of Dacomitinib-Associated Skin Disorders and Efficacy in the ARCHER 1050 Study
Faculty:
- Lin Wu

EP08.02-160. A Pooled Efficacy and Safety Analysis of Anlotinib Plus Docetaxel in Advanced NSCLC Previously Treated with Immunotherapy
Faculty:
- Lin Wu

EP08.02-161. An Exploratory Study on Biomarkers Related to Primary Resistance Of EGFR-TKIs Therapy in Lung Cancer
Faculty:
- Lin Wu

EP08.02-162. Tepotinib with an EGFR-Tyrosine Kinase Inhibitor (TKI) in Patients with EGFR-mutant MET-amplified NSCLC: A Case Series
Faculty:
- Xiuning Le

EP08.02-163. Real-World Case Series on Efficacy and Safety of Amivantamab for EGFR-mutant Non-small Cell Lung Cancer
Faculty:
- Xiuning Le

EP08.02-164. The Effect of Metformin on Survival Outcomes of Advanced EGFR-mutant NSCLC Patients Treated with EGFR TKIs in Thailand
Faculty:
- Siriwimon Saichaemchan

EP08.02-166. Brain Metastases in Patients with ALKrearranged or ROS1-fusion Non-small-Cell Lung Cancers in China
Faculty:
- Shaoyu Yang

EP08.02-167. Diverse Effects of Radiotherapy for Osimertinib Acquired Resistance Non-small Cell Lung Cancer: Gene Matters
Faculty:
- Yasi Xu

EP08.02-168. Efficacy, Safety and Treatment Courses for Patients with ALK Oncogene Positive NSCLC; Retrospective Data in Single Institute
Faculty:
- Yuki Akazawa

EP08.02-169. Research of Aumolertinib Combined with Bevacizumab for Advanced NSCLC Lung Cancer with EGFR Sensitive Mutation
Faculty:
- Dian Sheng Zhong

EP08.02-171. PRO-CTCAE Analysis of Mobocertinib in EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)
Faculty:
- Rosario Garcia

EP08.02-172. Effect of EGFR Inhibition on Bone Health in NSCLC Patients without Skeletal Metastasis
Faculty:
- Marcella Mandruzzato

EP08.02-173. Treatment Patterns and Outcomes Among Patients With EGFR-mutant Advanced NSCLC in the Frontline and Post-Osimertinib Settings
Faculty:
- Joshua Sabari

EP08.02-174. RET Fusions as Primary Oncogenic Drivers and Secondary Acquired Resistance to EGFR TKI in a Large Cohort of Non-Small-Cell Lung Cancers
Faculty:
- Chunyue Wang

EP08.03-001. A Clinical Study on the Safety and Efficacy of Aumolertinib Combined with SBRT in the EGFR-mutant NSCLC with Brain Parenchymal Oligometastases
Faculty:
- Chunyu He

EP08.03-002. Local Ablative Therapy in Oligoprogressive NSCLC - Results from a Tertiary Cancer Center of India
Faculty:
- Anil Tibdewal

EP08.03-003. Surgery for Primary Tumor is Associated with Prolonged Overall Survival in Patients with Oligometastatic NSCLC
Faculty:
- Jose Francisco Corona-Cruz

EP08.03-004. Outcomes of Oligometastatic Non-Small Cell Lung Cancer Patients Undergoing Surgical Resection: A Single Center Experience
Faculty:
- Fulden Gorguner

EP08.03-005. HALT - Targeted Therapy with or without Dose-Intensified Radiotherapy in Oligo-Progressive Disease in Oncogene Addicted Lung Tumours
Faculty:
- Fiona McDonald

EP08.03-006. Survival After Radical Treatment of Oligometastatic Non-small Cell Lung Cancer: A Multicenter Analysis
Faculty:
- Isabelle Opitz

EP08.03-007. Spontaneous Regression in Metastatic Non-small Cell Lung Cancer: A Case Report
Faculty:
- Maria La Mantia

EP08.03-008. Whether Immunotherapy Should Be Maintained or Not After Acquired Resistance in Advanced NSCLC
Faculty:
- Shun Lu

EP08.04-001. Weekly versus 3-Weekly Regimens of Carboplatin and Paclitaxel in Metastatic NSCLC: A Real-World Data
Faculty:
- Barliz Waissengrin

EP08.04-002. Australian Vinorelbine Use in Advanced Lung cancer (The AVAL Study)
Faculty:
- Ben Markman

EP08.04-003. A Simple Clinical Prediction Score to Determine Response to First Line Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients
Faculty:
- Chawalit Chayangsu

EP08.04-004. Impact of Comorbidity Scores on Overall Survival in Advanced Non-Small Cell Lung Cancer Patients -A Real-World Experience from Eastern India
Faculty:
- Srikanth Goud Mamidi

EP08.04-005. Phase II Study of Ramucirumab and Docetaxel for NSCLC Patients with Malignant Pleural Effusion
Faculty:
- Shinnosuke Takemoto

EP08.04-006. Risk Factors of Chemotherapy-Induced Severe Neutropenia in Elderly Lung Cancer: Data From a Regional Hospital in Thailand
Faculty:
- Sunee Neesanun

EP08.05-001. Evaluation of Pneumonitis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Receiving Osimertinib and Thoracic Radiation
Faculty:
- David Y. Mak

EP08.05-002. Sequencing of T cell Receptor Revealed Radiotherapeutic Efficacy and Prognosis in Non-small Cell Lung Cancer Patients with Brain Metastasis
Faculty:
- Xiaorong Dong

EP08.05-003. Evaluation of Dose Changes in Different Periods after 125I Seed Implantation in Lung Cancer
Faculty:
- Haihua Yang

EP08.05-004. The Optimal Intervention Timing of Hypofractionated Stereotactic Radiotherapy for EGFR Mutated NSCLC Patients With Limited Brain Metastases
Faculty:
- Lin Zhou

EP09.01-001. International Collaboration for Thoracic Oncology Education
Faculty:
- Beth Sandy

EP09.01-002. Patient with Immune-associated Dermatomyositis Caused byAdvanced NSCLC Treated with ICIs
Faculty:
- Yuanyong Wang

EP10.01-001. Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Lung Cancer: Dose-Response Effect and Toxicity
Faculty:
- Kaicheng Pan

EP10.01-002. The Effect of Group Rehabilitation Training in the Ward on the Psychological Status and Quality of Life of Lung Cancer Patients
Faculty:
- Li Li

EP10.01-003. Non-Small Cell Lung Cancer Treatment Preferences Among EGFR Mutation Patients and Physicians in Japan
Faculty:
- Akira Inoue

EP10.01-004. Perspectives of Patients with Metastatic Lung Cancer on Symptom Screening and Patient-Reported Symptom Trajectory Data
Faculty:
- Amir H. Safavi

EP10.01-005. Australian Lung Cancer Survivors Experiences of Novel Treatments, Healthcare, and Ongoing Physical and Psychological Needs
Faculty:
- Bea Brown

EP10.01-006. Differences In Toxicity Among Platinum-Based Combinations As Reported By Non-Small Cell Lung Cancer (NSCLC) Patients
Faculty:
- Christie Lagogianni

EP10.01-007. Real World Data Comparing Lung Cancer Side-Effects Between Past/Current Smokers And Never Smokers
Faculty:
- Christie Lagogianni

EP10.01-008. Examining Social Determinants of Health Among Newly Diagnosed Lung Cancer Patients Contacted for Early Specialist Palliative Care Consultation
Faculty:
- Desiree Hao

EP10.01-009. The Impact of the COVID-19 Pandemic on Palliative Care for Cancer: A Preliminary Cross-Country Survey of Clinical Oncologists
Faculty:
- Yu Wang

EP10.01-010. Real-world Study of the Incidence and Risk Factors of Venous Thromboembolism in Chinese Lung Cancer (RIVAL)
Faculty:
- Zhen Wang

EP10.01-011. Prognostic Impact of Body Composition Phenotypes in Non-small Cell Lung Cancer Patients Receiving First-Line Pembrolizumab
Faculty:
- Ilaria Trestini

EP10.01-012. Geriatric Assessment in Patients Undergoing Lung Cancer Surgery and Their Family Caregivers
Faculty:
- Jae Yul Kim

EP10.01-013. Erector Spinae Plane Block for Post-thoracotomy Analgesia; Comparison with Intercostal Block; Preliminary Results
Faculty:
- Kubra Alphan Kavak

EP10.01-014. A Multidisciplinary Team to Manage Patients with Lung Cancer and Opioid Use Disorder
Faculty:
- Lawrence Feldman

EP10.01-015. The Role of CT-Scan as a Body Composition Tool in Oncogene-Addicted Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients.
Faculty:
- Maristella Bungaro

EP10.01-016. Cachexia's Impact on Immunotherapy Dose Reduction, Treatment Discontinuation, and Survival: a Systematic Review
Faculty:
- Richard J. E. Skipworth

EP10.01-017. Use of Lalaby in Lung Cancer Patients to Trace Performance from Phone Sensors and Reported Outcomes Involving Quality of Life
Faculty:
- Teresa Soria-Comes

EP10.01-018. Thromboprophylaxis for Lung Cancer Patients: Results From ACT4CAT Trial
Faculty:
- Nikolaos G Tsoukalas

EP10.01-019. Rowing Against Cancer: From a Support Project to a Research Program. Perspectives and Challenges of Rowing in Metastatic Lung Cancer Patients
Faculty:
- Veronica Franchina

EP10.01-020. Nutritionassessment for With Common Cancer Patients in a Cancer Hospital of China
Faculty:
- Mengting Chen

EP11.01-002. Malignant Pleural Effusion Cell Blocks Are Reliable Resources for PD-L1 Analysis in Advanced Lung Adenocarcinomas
Faculty:
- Aruna Nambirajan

EP11.01-003. Advanced Non Small Cell Lung Cancer With EGFR Exon 20 Insertion Gene Mutation
Faculty:
- Nguyen Son Lam

EP11.01-004. An Effective Two-step Reflex Test for 10 Biomarkers Analysis in Non-small Cell Lung Cancer
Faculty:
- Giacomo Pelizzari

EP11.01-005. Ultra-Fast Gene Fusion Assessment as a Reflex Testing in Daily Clinical Practice for Advanced Non-small Cell Lung Cancer Patients
Faculty:
- Paul Hofman

EP11.01-006. Setting Up an Ultra-Fast Next-Generation Sequencing Approach as a Reflex Testing at Diagnosis in Non-squamous Non-small Cell Lung Cancer
Faculty:
- Paul Hofman

EP11.01-007. Tracking ROS1 Fusions in NSCLC - Mirage or Truth When Screening the Desert
Faculty:
- Johanna Mattsson

EP11.01-008. Discrepancy in MET Exon 14 Skipping Mutation Measurement Between ArcherMET and Oncomine Dx Target Test System
Faculty:
- Kanako Shinada

EP11.01-010. A Prospective Validation Study of Lung Cancer Gene Panel Testing Using Cytological Specimens
Faculty:
- Kei Morikawa

EP11.01-011. Clinical Application of Liquid Biopsy for Assessing Early EGFR Mutation Detection in Non-Small Cell Lung Carcinoma
Faculty:
- Amber Rathor

EP11.01-012. Genomic Landscape of Liquid Biopsy in Advanced Lung Cancer Patients, an Indian Experience
Faculty:
- Shivani Sharma

EP11.01-013. Genomic Landscape of Pulmonary Sarcomatoid Carcinoma
Faculty:
- Hyun Jung Kwon

EP11.01-014. Optimizing Targetable Gene Screening by Sequential Multi-platform Detection Applied to Driver-negative mNSCLC Patients Detected by DNA-NGS
Faculty:
- Yaxi Wang

EP11.02-001. Natural Language Processing to Abstract Preneoplastic and Incidental Pulmonary Lesions from Pathology Reports
Faculty:
- Jessica Petricca

EP11.02-002. A Comparative Study of PD-L1 Scoring: Humans versus AI
Faculty:
- Luka Brcic

EP11.03-001. Loss of SUSD2 Expression in Lung Adenocarcinoma Correlates with Solid Pattern, Higher Histological Grading and Higher Ki-67 Cycling Index
Faculty:
- Hangjun Wang

EP11.03-002. Prognostic Significance of YAP1 and Its Association with Neuroendocrine Markers in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNEC)
Faculty:
- Xujie Sun

EP11.03-003. Adenocarcinoma Grade Correlates with PD-L1 and TP53, but not EGFR/KRAS Status and Diagnostic Yield: Analysis of 346 Cases
Faculty:
- Yu Zhi Zhang

EP11.03-004. Identification of Filigree Pattern Increases Diagnostic Accuracy of Micropapillary Pattern on Frozen Section for Lung Adenocarcinoma
Faculty:
- Shengnan Zhao

EP11.04-001. Cytokeratin 5-Positive Pulmonary Adenocarcinoma: A Study with Resected Specimens
Faculty:
- Akihiko Yoshizawa

EP11.04-002. The Histopathological Reasons for Better Survival of Patients with Lepidic Pattern Dominant Adenocarcinoma
Faculty:
- Ismail Sarbay

EP12.01-001. What Do Patients Want - a European Study Into ALK-Positive Patients Perspectives
Faculty:
- Jamie Gibbard

EP13.01-001. The Burden of Incidental Extra-thoracic Positron Emission Tomography-CT (PET-CT) Findings in Thoracic Malignancies
Faculty:
- Dana Li

EP13.01-002. Radiomic Signature on CT Images: A Noninvasive Biomarker for Pretreatment Discrimination of EGFR Mutations in NSCLC Patients
Faculty:
- Yusuf Kahya

EP13.01-003. Diagnostic Yield of Radial Probe Endobronchial Ultrasonography without Fluoroscopic guidance in Peripheral Pulmonary Lesions
Faculty:
- Joonhee Han

EP13.01-004. Accuracy of Clinical Stage in Resectable Non-small Cell Lung Cancer (NSCLC)
Faculty:
- Hye Ran Gwon

EP13.01-005. Role of Artificial Intelligence on Chest Radiographs for Detecting Resectable Early Lung Cancer
Faculty:
- Eunhye Lee

EP13.01-006. Safety of Image Guided Research Biopsies in Patients with Thoracic Malignancies
Faculty:
- Jia Luo

EP13.01-007. Differentiation between heterogeneous GGNs and part solid nodules using histogram on thin-section CT
Faculty:
- Hirofumi Koike

EP13.01-008. Needle Aspiration versus Forceps Biopsy Using Electromagnetic Navigation Bronchoscopy: CONFIDENT-ENB Trial Design
Faculty:
- Yeon Wook Kim

EP13.01-009. A Modified T Categorization for Pathological Stage I Lung Adenocarcinoma with Lepidic Component in Chinese Population
Faculty:
- Shenghui Li

EP13.01-010. Effect of Perioperative Respiratory Muscle Training with Gamification for Lung Cancer
Faculty:
- Masao Saito

EP13.01-011. Combining Automated Malignancy Risk Estimation with Lung Nodule Detection May Reduce Physician Effort and Increase Diagnostic Accuracy
Faculty:
- Michael E Calhoun

EP13.01-012. Exploring Factors Affecting Variability in Lung Cancer Outcomes Across Southeastern Ontario, Canada
Faculty:
- Shahad AlGhamdi

EP13.01-013. Determination of the Timing of Bevacizumab Administration in Osimertinib and Bevacizumab Combination Therapy
Faculty:
- Fei Teng

EP13.01-014. Evaluation of Malignancy and Survival in Patients Operated With a Preliminary Diagnosis of Interstitial Lung Disease
Faculty:
- Tiffany Melissa Ergin

EP13.01-015. Correlation Between CT Signs and Ki67 Expression in Non-small Cell Lung Cancer
Faculty:
- Yuanyong Wang

EP13.01-016. Are Follow-up Tests Useful in NSCLC? Experience of a Tertiary Hospital
Faculty:
- Yago Garitaonaindía Díaz

EP13.01-017. Assessing Variance Between Radiology versus Multidisciplinary Clinic Recommendations in the Pulmonary Nodule and Lung Screening Clinic
Faculty:
- Inga T. Lennes

EP14.01-001. SCLC Transformation from ALK-rearranged Lung Adenocarcinoma after Alectinib Resistance and Response to Atezolizumab: Case Report
Faculty:
- Guohao Xia

EP14.01-002. Efficacy and Safety of Tiselizumab Combined with Anlotinib and 2-cycle Irinotecan as Second-line Treatment of Small Cell Lung Cancer
Faculty:
- Xian Chen

EP14.01-003. Parotid Metastases from Primary Lung Cancer: Case Series and Systematic Review on the Clinical Features
Faculty:
- Rulan Wang

EP14.01-005. Weekly Sequential ACOCEV Chemotherapy (ADR, CTX, CBDCA, VP16, VCR) for Elderly - Poor PS SCLC Patients: An Observational Study
Faculty:
- Antonio Santo

EP14.01-006. CeLEBrATE: Phase II trial of CarbopLatin, Etoposide, Bevacizumab and Atezolizumab in Patients with exTEnsive-Stage SCLC-GOIRC-01-2019
Faculty:
- Giuseppe Lamberti

EP14.01-007. Next-Generation Sequencing to Dynamically Detect Mechanisms of Resistance to ALK Inhibitors in ALK-positive SCLC Patient: A Case Report
Faculty:
- Renhong Guo

EP14.01-008. Checkpoint Inhibitors Prevent New Onset of Brain Metastases in Relapsed Extensive Disease Small-Cell Lung Cancer
Faculty:
- Jan Alexander Stratmann

EP14.01-009. A Comparative Study of Histological Predictors of Outcome in Patients with Lung Typical and Atypical Carcinoids
Faculty:
- Joana Rei

EP14.01-010. CAN: A Phase II Trial of Combination of Niraparib and Anlotinib in Patients with Recurrent Small Cell Lung Cancer
Faculty:
- Ying Cheng

EP14.01-011. Carcinoid Tumor of the Lung with Osteomimicry. Case Report
Faculty:
- Lovorka Batelja Vuletic

EP14.01-012. A Case Report of Lung Large Cell Neuroendocrine Carcinoma with Carcinoid Morphology
Faculty:
- Lovorka Batelja Vuletic

EP14.01-013. First-Line Chemotherapy vs Chemoimmunotherapy in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung, a Retrospective Study
Faculty:
- Lingbin Meng

EP14.01-014. Risk Factors for Brain Metastasis in Patients with Small Cell Lung Cancer: A Systematic Review and Meta-analysis
Faculty:
- Lizza Hendriks

EP14.01-015. IMforte: A Phase III Study of Lurbinectedin and Atezolizumab Versus Atezolizumab as Maintenance Therapy in ES-SCLC
Faculty:
- Luis Paz-Ares

EP14.01-016. Anlotinib Plus Toripalimab as Maintenance Treatment in Extensive-Stage Small Cell Lung Cancer: a Single-Arm Phase II Study
Faculty:
- Dongqing Lv

EP14.01-018. Small Cell Lung Carcinoma in Morocco
Faculty:
- Ouassima Erefai

EP14.01-019. Identifying Circulating DNA Methylation Patterns in Small Cell Lung Cancer Patients
Faculty:
- Sami Ul Haq

EP14.01-020. Trial in Progress: [177Lu]Lu-DOTA-TATE Combination Therapy in Treatment-Naïve Extensive Stage Small Cell Lung Cancer
Faculty:
- Stephen V. Liu

EP14.01-021. Anlotinib Plus Irinotecan or Docetaxel in Small-Cell Lung Cancer (SCLC) Relapsed within Six Months: a Single-Arm Phase II Study
Faculty:
- Bing Xia

EP14.01-022. Immune Thrombocytopenia in a Patient with Large Cell Neuroendocrine Carcinoma Under Dual Immune Checkpoint Inhibition
Faculty:
- Ioannis Gkiozos

EP14.01-023. A Randomized Phase II Study of Irinotecan Plus Cisplatin With or Without Simvastatin in Ever-Smoking Small Cell Lung Cancer
Faculty:
- Youngjoo Lee

EP14.01-024. Transformation of SCLC to Lung Squamous Cell Carcinoma after First-Line Chemotherapy and Response to Sintilimab: A Case Report
Faculty:
- Zhisheng Liu

EP14.01-025. Anlotinib Plus Standard Chemotherapy as First-line Treatment in Extensive-Stage Small Cell Lung Cancer Patients
Faculty:
- Wei Zhang

EP14.02-001. Could the Oxidative Stress Be Used as a Marker for Neuroendocrine Lung Tumors?
Faculty:
- Luigi Gaetano Andriolo

EP14.02-002. Cisplatin in Combination with Entinostat exerts Synergistic Antineoplastic Activity in Small Cell Lung Cancer
Faculty:
- Anna Schwendenwein

EP14.02-003. Clinical Significance of MYC Family Members in Surgically Resected Limited-Stage Small Cell Lung Cancer: A Multicenter Study
Faculty:
- Christian Lang

EP14.02-004. Barasertib Inhibits the Growth of SCLC Cell Lines and Transformed SCLC Patient Derived Model In Vitro and In Viv
Faculty:
- Jin Soo Kim

EP14.02-005. Therapeutic Targeting Mevalonate-Geranylgeranyl Diphosphate Pathway with Statins Overcomes Chemotherapy-resistance in SCLC
Faculty:
- Chenchen Guo

EP14.02-006. Subtype-specific Hypersensitivity to Oxidative Phosphorylation Inhibition in Small Cell Lung Cancer
Faculty:
- Kristiina Boettiger

EP14.03-001. DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive Stage Small Cell Lung Cancer
Faculty:
- Aditya Juloori

EP14.03-002. Low-Dose Radiotherapy Plus Sugemalimab in Second-Line Treatment for Advanced-Stage Small-Cell Lung Cancer: Initial Results of a Phase I Study
Faculty:
- Youling Gong

EP14.03-003. Phase I Study of Palliative Radiotherapy with Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer
Faculty:
- Neal Sean Mccall

EP14.03-004. Neuro-cognitive Effect of HS-PCI in LS-SCLC
Faculty:
- Suryakanta Acharya

EP14.03-005. Role of Radiotherapy Fraction in Limited-Stage SCLC: a Meta-Analysis of 8585 Reconstructed Individual Patient Data
Faculty:
- Jingjing Zhao

EP14.04-001. Treatment and Outcomes of Patients with Limited-Stage Small-cell Lung Cancer in the Canadian SCLC Database (CASCADE)
Faculty:
- Sara Mieko Moore

EP14.04-002. The Impact of Response on Survival in Extensive-Stage Small-Cell Lung Cancer in the CASPIAN Study
Faculty:
- Sukhvinder Johal

EP14.05-001. Chemoimmunotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer and ECOG Performance Status of 2 or 3
Faculty:
- Muskan Agarwal

EP14.05-002. Impact of Body Mass Index on Survival in Patients with Small Cell Lung Cancer
Faculty:
- Alejandro Rios-Hoyo

EP14.05-003. Recent Stage Shifts and Changes in the Treatment of Stage I Small Cell Lung Cancer in the United States
Faculty:
- Chinmay Satish Haridas

EP14.05-004. Temozolomide and Atezolizumab as Second Line Treatment for Extensive Stage Small Cell Lung Cancer: A Randomized, Multi-Cohort Phase 2 Trial
Faculty:
- Dwight H Owen

EP14.05-005. Survival of Small Cell Lung Cancer in Relation to Chemotherapy Dose Intensity
Faculty:
- Elisa María Fernández Pérez

EP14.05-006. The Impact of Adjuvant Chemotherapy on Survival of Stage I Lung Large Cell Neuroendocrine Carcinoma: A Meta-Analysis of Comparative Studies
Faculty:
- Philip A Haddad

EP14.05-007. A Study of the Best Reduction in Target Lesion Size and Treatment Duration in the Durvalumab plus Platinum-Etoposide Regimen for ES-SCLC
Faculty:
- Kageaki Watanabe

EP14.05-008. Development of a Prognostic Model for High-Grade Neuroendocrine Carcinoma of the Lung Using Next-Generation Sequencing
Faculty:
- Hye Sook Kim

EP14.05-009. LUMINANCE: A Phase IIIb Study of Durvalumab + Platinum-Etoposide for First-Line Treatment of Extensive-Stage SCLC (ES-SCLC)
Faculty:
- Niels Reinmuth

EP14.05-010. Real-World Eligibility for Clinical Trials in Extensive Stage Small Cell Lung Cancer Patients
Faculty:
- Navdeep Dehar

EP14.05-011. Real-World Impact of Platinum Sensitivity and Disease Stage on Survival Among Medicare Patients with Small Cell Lung Cancer
Faculty:
- Paul Cockrum

EP14.05-012. Comparing Costs for Medicare FFS Patients Treated with Etoposide or Irinotecan for Extensive Stage Small Cell Lung Cancer
Faculty:
- Paul Cockrum

EP14.05-013. Real-World Resource Use and Costs by Stage and Platinum Sensitivity among Medicare Patients with Small Cell Lung Cancer
Faculty:
- Paul Cockrum

EP14.05-014. Trends in Population Survival Among Adults Diagnosed with Small Cell Lung Cancer in the U.S. from 2013-2021
Faculty:
- Paul Cockrum

EP14.05-015. Quantifying Recent Trends in Real-World Treatment Patterns Among Adults Diagnosed with Small Cell Lung Cancer in the U.S. from 2013-2021
Faculty:
- Paul Cockrum

EP14.05-016. Patterns of Care for Small Cell Lung Cancer in Victoria Australia. A Prospective Population-Based Observational Study
Faculty:
- Robert Stirling

EP14.05-017. Real World Eligibility of Immune Checkpoint Inhibitors with Platinum-Doublet in Extensive Stage Small Cell Lung Cancer
Faculty:
- Rebekah Rittberg

EP14.05-018. Major Lung Resection for Carcinoid Tumor; Does It Affect Quality of Life?
Faculty:
- Riad Abdeljalil

EP14.05-019. Contemporary Real-World Adverse Events Associated with Small Cell Lung Cancer Diagnosed in a U.S. Population from 2013-2021
Faculty:
- Robert A Ramirez

EP14.05-020. Population-based Outcomes for Patients with Extensive-Stage Small-cell Lung Cancer from the Canadian SCLC Database (CASCADE)
Faculty:
- Sara Mieko Moore

EP14.05-021. Promising Long-Term Survival after Surgical Resection of Early Stage Small Cell Lung Cancer in a Modern Single-Center Cohort
Faculty:
- Sora Ely

EP14.05-022. The Drug Induced Interstitial Lung Disease in Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer
Faculty:
- Rei Takamiya

EP14.05-023. Characterization of Real-World Use of Lurbinectedin in Adult Small Cell Lung Cancer Patients in the United States
Faculty:
- Xue Wang

EP15.01-001. Ask, Advise, Help (AAH) Smoking Cessation Brief Advice Delivery in Patients with Diagnosed Lung Cancer: A Retrospective Audit
Faculty:
- John Lau

EP15.01-002. Lowering Rates of Smoking after Cancer Diagnosis: Use Social Networks
Faculty:
- Melissa Neumann

EP16.01-001. Transforming Growth Factor-inhibits Interferon-mediated Immune Resistance in Lung Cancer
Faculty:
- Ye Fan

EP16.01-002. T Cell Receptor Diversity among Non-Small Cell Lung Cancer Patients Treated with Pembrolizumab Alone or in Combination with Chemotherapy
Faculty:
- Afaf Abed

EP16.01-003. The Dynamic Immune Signature of Patients with Advanced Non-small Cell Lung Cancer in Prediction of Infection After Receiving Immunotherapy
Faculty:
- Chia-I Shen

EP16.01-004. Pleural Mesotheliomas Related with Geographical Asbestos Exposure Show Higher PD-L1 Expression
Faculty:
- Yusuf Kahya

EP16.01-005. Cilia-related mRNA Profile Predicts Clinical Response to PD-1 Blockade in Lung Adenocarcinoma
Faculty:
- Guanghui Gao

EP16.01-006. CD47 Inhibition Impairs the Growth of Orthotopic, Immune Competent Lung Tumour Models
Faculty:
- Kelsie Thu

EP16.01-007. Molecular Characterization by Next-Generation Sequencing (NGS) of Patients with Non-Small Cell Lung Cancer (NSCLC) Treated with Immunotherapy
Faculty:
- Laura Gutiérrez Sainz

EP16.01-008. The Effect of Cytochrome P450 Family 4 Subfamily B Member 1 (CYP4B1) on Lung Adenocarcinoma (LUAD) Immune Microenvironment
Faculty:
- Leen Al-Kraimeen

EP16.01-010. A Machine-Learning Based Survival Prediction for Lung Adenocarcinma by Analyzing Infiltrated Lymphocytes Profiles with CIBERSORT
Faculty:
- Tong Lu

EP16.01-011. PD-L1 Expression on Cytological Imprints and Circulating Tumor Cells versus Standardized Immunohistochemistry in NSCLC
Faculty:
- Martin Reck

EP16.01-012. Immunophenotyping of Lung Adenocarcinoma in situ Based on CD8-positive T Cell Infiltration
Faculty:
- Yu Ma

EP16.01-013. The Diagnostic Accuracy of Tumor Mutational Burden in Advanced NSCLC: An Individual Patient Data Meta-Analysis
Faculty:
- Maria La Mantia

EP16.01-014. Characterisation of Circulating Immune Cells in a Cohort of Non-small Cell Lung Cancer Patients Treated with Immunotherapy
Faculty:
- Marta Gascón- Ruiz

EP16.01-015. Introducing "BiomeOne" a Microbiome-based bBiomarker to Predict Immune Checkpoint Inhibitor Response in NSCLC 1patients
Faculty:
- Maximilian Johannes Hochmair

EP16.01-016. Tumor Treating Fields (TTFields) Application Promotes a Pro-inflammatory Phenotype in Macrophages
Faculty:
- Moshe Giladi

EP16.01-017. T-cell Repertoire Heterogeneity and Homogeneity in Synonymous Multiple Primary Lung Cancers
Faculty:
- Naixin Liang

EP16.01-018. SAKK 16/14 -Peripheral Immune Cell Populations Inresponse to Neoadjuvant Durvalumab in Patients with Stage IIIA(N2) NSCLC
Faculty:
- Sacha I Rothschild

EP16.01-019. The Role of the Pregnancy Associated Protein Glycodelin and Its Influence on the Immune System in Non-small-Cell Lung Cancer
Faculty:
- Sarah Richtmann

EP16.01-020. Predictive Effect of Spatial Protein Signature in Advanced NSCLC Receiving Immunotherapy with a Bispecific Antibody
Faculty:
- Xinyu Song

EP16.01-021. Less Immune Cell Infiltration and Worse Prognosis for NSCLC Patients with XPO1 Copy Number Alterations
Faculty:
- Xuanzong Li

EP16.01-022. A Signature of B Cells-Related Gene Pairs Predicts Oncologic Outcomes and Response to Immunotherapy in NSCLC Patients
Faculty:
- Xuanzong Li

EP16.01-023. Comprehensive Analysis of a Dendritic Cell Marker Genes Signature to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma
Faculty:
- Yuan Li

EP16.01-024. Differential Efficacy of Combined GITR Co-stimulation with PD-1 Blockade in Preclinical Non-small Cell Lung Cancer Models
Faculty:
- Sheng Yan

EP16.01-025. Immune Evolution of Metastases & Underlying Molecular Mechanisms in Non-small Cell Lung Cancer
Faculty:
- Wen-Fang Tang

EP16.01-027. MIF ImprovesImmune Microenvironmentof Lewis Lung Cancer Brain Metastases after Radiotherapy ViaReducing M2 Macrophages
Faculty:
- Xiaorong Dong

EP16.01-028. Immunomodulatory Effects of Cryoablation Combined With Immune Checkpoint Inhibitors in a Murine Lung Cancer Model
Faculty:
- Yoshikane Yamauchi

EP16.01-029. Inter-tumor Heterogeneity of PD-L1 Expression in Non-small Cell Lung Cancer
Faculty:
- Yuichi Saito

EP16.01-030. Peripheral T-Cell Receptor Repertoire Profiling in Non-small Cell Lung Cancer Using an Amplicon-Based Sequencing Assay
Faculty:
- Zi Yi Wan

EP16.01-031. Association Between Programmed Death Ligand-1 (PD-L1) Expression and Clinicopathological Features in Non-small Cell Lung Cancer (NSCLC)
Faculty:
- Sena Valcárcel González

EP16.01-032. Guiding Monotherapy with Docetaxel or Atezolizumab via the Tumour Mutation Index in Non-small Cell Lung Cancer Patients
Faculty:
- Baohui Han

EP16.01-033. Characterisation of T Cell Receptor Repertoire in Non-small Cell Lung Cancer Patients Treated With Immunotherapy
Faculty:
- Andrea Goñi

EP16.02-001. Integration of Primer Exchange Reaction and DNAzyme for Electrochemical Detection of PD-L1-Expressing Exosomes in Lung Cancer
Faculty:
- Bing Bo

EP16.02-002. Circulating Tumor DNA (ctDNA) Changes in Patients With Lung Cancer from a Real-World Prospective Clinico-Genomic (PCG) Study
Faculty:
- Anne Chiang

EP16.02-003. Real World Experience and Feasibility of Tissue Informed CGP and ctDNA Testing in a Cohort of NSCLC Patients
Faculty:
- Georges Azzi

EP16.02-004. Clinical Significance and Genomic Characteristics of CD56+ Circulating Tumor Cells in Small Cell Lung Carcinoma
Faculty:
- Charles Ricordel

EP16.02-005. Liquid Biopsy Detects Genomic Drivers in Non-small Cell Lung Cancer without EGFR Mutations by Single-plex Testing: WJOG13620L
Faculty:
- Daisuke Hazama

EP16.02-006. Evaluation of Carcinoembryonic Antigen (CEA) as Predictive Marker in Patients with Metastatic Non-small Cell Lung Cancer
Faculty:
- Debapriya Mondal

EP16.02-007. Detection of Clinically Relevant Fusions and Exon Skipping Alterations in Non Small Cell Lung Cancer Patients Liquid Biopsies
Faculty:
- Estela Sánchez-Herrero

EP16.02-008. Cerebrospinal Fluid as a Liquid Biopsy for Molecular Characterization of Brain Metastases in Patients With Non-small Cell Lung Cancer
Faculty:
- Georgios Tsakonas

EP16.02-009. Psychobiological Stress Responses to a Lung Cancer Diagnosis
Faculty:
- Hronn Hardardottir

EP16.02-010. Predictive Value of Serum Reactive Oxygen Species Modulator 1 for Surgically Resected Lung Adenocarcinoma
Faculty:
- Seung Hyeun Lee

EP16.02-011. Liquid Biopsies in the Setting of Early-Stage Lung Cancer for the Detection of Actionable Mutations
Faculty:
- Joana Espiga de Macedo

EP16.02-012. cfDNA Analysis Implementation in Early Stage Lung Cancer
Faculty:
- Joana Espiga de Macedo

EP16.02-013. Retrospective Analysis of BRCA1/2 Alterations in Advanced NSCLC Using An Amplicon-based NGS Liquid Biopsy Assay
Faculty:
- Jonathan Poh

EP16.02-014. A Comparative Analysis of Gene Alteration Detected With NGS in Tumor Tissue and Peripheral Blood in Lung Cancer
Faculty:
- Laura Gutiérrez Sainz

EP16.02-015. Phenotyping Malignant Pleural Effusions with Mass Cytometry: Evidence of EMT and MET States in Late-Stage NSCLC
Faculty:
- Loukia Georgiou Karacosta

EP16.02-016. Exploration of Factors Affecting the Performance of MRD Tumor-Informed Assay in Chinese Lung Cancer Patients
Faculty:
- Guomin Lin

EP16.02-017. Predictive Value of Peripheral Blood Immune Cell Profiling in EGFR-T790M Mutant Lung Adenocarcinoma
Faculty:
- Yutao Liu

EP16.02-018. Liquid Biopsies First to Make Treatment Decisions in Patients With Metastatic Non-small Cell Lung Cancer (NSCLC)
Faculty:
- Luis Raez

EP16.02-019. Metabolic Changes in Sputum and Exhaled Breath Condensate of Non-small Cell Lung Cancer Patients after Surgical Resection
Faculty:
- Naseer Ahmed

EP16.02-020. Lung Cancer Cell Dynamics Significantly Depended on Blood Cell Circuit, Biochemical Factors, Hemostasis System, Cancer Characteristics
Faculty:
- Oleg Kshivets

EP16.02-021. The Expression of CEACAMs and Serum CEA Levels as Biomarkers of Postoperative Cancer Recurrence in Non-small Cell Lung Cancer
Faculty:
- Bubse Na

EP16.02-022. Circulating Tumor DNA Minimal Residual Disease Assay Predicts Outcome in Lung Cancer Patients Who Had Curative Treatments
Faculty:
- Youjih Oh

EP16.02-023. Extracellular Vesicles Long RNA Sequencing as Diagnostic Biomarkers for Lung Adenocarcinoma Patients with Tumor Size Smaller than 2cm
Faculty:
- Fangfei Qian

EP16.02-024. Plasma ctDNA Organ-Specific Genomic Patterns and Origination Analysis in Advanced Non-Small Cell Lung Cancer
Faculty:
- Rui Fu

EP16.02-025. SerumTumor Markers as a Surrogate forRadiographicAssessment of Non-Small Cell Lung Cancer
Faculty:
- Scott W Strum

EP16.02-026. Dynamic Change of Indoleamine 2,3-dioxygenase Activity Predicts Survival in Radiotherapy- Received Unresectable Stage III NSCLC
Faculty:
- Linfang Wu

EP16.02-027. Targeted Methylation Analysis of Circulating Cell-Free DNA to Predict Outcomes in Clinical Stage I NSCLC Patients
Faculty:
- Yohan Bossé

EP16.02-028. Schwann Cell Exosomes Promote Lung Cancer Progression via miRNA-21-5P Cargo
Faculty:
- Yan Zhou

EP16.02-029. Plasma-Based Next Generation Sequencing for Molecular Characterization of Lung Adenocarcinoma: A Multicentric Cohort From Argentina
Faculty:
- Martina Paz Spotti

EP16.03-001. High Frequency of KRAS Mutation, Uncommon EGFR Mutation and TMB-H in Xuanwei Female Patients With Lung Adenocarcinoma
Faculty:
- Heng Li

EP16.03-002. Mechanisms of Resistance to First-line Osimertinib in Hispanic Patients with EGFR mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP∫)
Faculty:
- Andres F Cardona

EP16.03-003. Systematic Population-based Identification of NTRK Fusion Genes Among Hispanic Patients with Non-Small Cell Lung Cancer (NSCLC)
Faculty:
- Andres F Cardona

EP16.03-004. Targeting SHP2 Reverts Oncogenic Mediated Resistance to KRAS-G12C Inhibition
Faculty:
- Alicia Isabell Tüns

EP16.03-005. Australian Non-Small Cell Lung Cancer (NSCLC) Biomarker Testing Practices - A Survey of Medical Oncologists and Pathologists
Faculty:
- Ben Markman

EP16.03-006. Genetic Characteristics of EGFR Concurrent Variants with RB1 and TP53 in NCSLC Patients
Faculty:
- Hui Chen

EP16.03-007. Comprehensive Analysis of m6A-Related Gene Mutation Characteristics and Prognosis in Lung Adenocarcinoma
Faculty:
- Jing-Hua Chen

EP16.03-008. The Landscape of NFE2L2 Alteration in Chinese Lung Cancer Patients
Faculty:
- Xuejun Dou

EP16.03-009. Patterns of KEAP1 Genomic Co-alterations in Advanced Non-small Cell Lung Cancer Identified by Plasma-Based Genyotyping
Faculty:
- Dwight H Owen

EP16.03-010. Molecular and Clinical Characterization of Lung Adenocarcinoma With Respect to Patient Age at Diagnosis
Faculty:
- Elsa Arbajian

EP16.03-011. The European Program for ROutine Testing of Patients with Advanced Lung Cancer (EPROPA) 1 Year Activity
Faculty:
- Francesco Passiglia

EP16.03-012. Novel Human-derived EML4-ALK Fusion cell lines identify ribonucleotide reductase RRM2 as a Target of Activated ALK in NSCLC
Faculty:
- Ganesh Umapathy

EP16.03-013. Psychological Distress and Beta-2 Adrenergic Receptor Expression in Non-small Cell Lung Cancer Cells
Faculty:
- Hronn Hardardottir

EP16.03-014. Simultaneous Detection of FGFR Gene Aberrations in Squamous Non-small Cell Lung Cancer Using Targeted DNA- and RNA-based NGS
Faculty:
- Joanna Chorostowska-Wynimko

EP16.03-015. Centrosome Amplification Is a Prognostic Indicator and Potential Therapeutic Vulnerability in Non-small Cell Lung Cancer
Faculty:
- Kelsie Thu

EP16.03-016. Targetable Alterations in Non-Small Cell Lung Cancer According to Age and Sex
Faculty:
- ErinMarie O. Kimbrough

EP16.03-017. Spatial Heterogeneity of Tumor Microenvironment of Lung Adenocarcinoma Associated With Genomic Alterations
Faculty:
- Kwon Joong Na

EP16.03-018. Molecular Features of Subtypes Classified Based on Predominance and Components in Chinese Patients with Lung Adenocarcinoma
Faculty:
- Guomin Lin

EP16.03-019. Landscape of EGFR Extracellular Domain Mutations in Advanced Non Small Cell Lung Carcinoma
Faculty:
- Lesli A Kiedrowski

EP16.03-020. High Tumor Mutational Burden by Whole-Genome Sequencing in Resected NSCLC in Never Smokers is Associated with Worse Prognosis
Faculty:
- Louis-Jacques Ruel

EP16.03-021. Developing of EGFR resistant mutations to Tyrosine Kinase Inhibitors (TKI) in Non-Small Cell Lung Cancer (NSCLC)
Faculty:
- Luis Raez

EP16.03-022. Endobronchial Ultrasound Guided Transbronchial Needle Aspiration Sampling Is Sufficient for Lung Cancer Molecular Profiling
Faculty:
- Luis Raez

EP16.03-023. KRAS Alterations, Clinicopathological Features and Co-occurring Drivers Associated with Prognosis in Advanced NSCLC Patients
Faculty:
- Maritza Ramos-Ramirez

EP16.03-024. Cellworks Singula™ Therapy Response Index (TRI) Identifies Superior OS Outcomes for NSCLC Patients: myCare-203A
Faculty:
- Mark Klein

EP16.03-025. Immunogenomics of Clinical Resistance to KRAS G12C Inhibition
Faculty:
- Mark Woodcock

EP16.03-026. Metastasis Sites and Genomic Alterations in Advanced Non Small Cell Lung Cancer: A Retrospective Study
Faculty:
- Juan Manuel Martínez-Valenciano

EP16.03-027. Routine Molecular Testing Using the TSO500+ NGS Panel in a Cohort of Patients with NSCLC
Faculty:
- Miguel Mosteiro Lamas

EP16.03-028. Cancer Cells May be Re-sensitized to Tumor Treating Fields (TTFields) Through Inhibition of the PI3K/AKT/mTOR Pathway
Faculty:
- Moshe Giladi

EP16.03-029. SLIT2 Expression in NSCLC With Long-Term Response to Pemetrexed
Faculty:
- Eiji Nakajim

EP16.03-031. Transcriptomic Heterogeneity in Non-Small Cell Lung Cancer Harboring Different EGFR Exon 19 Del/Delins Variants
Faculty:
- Shun Lu

EP16.03-032. Structure-Based Classification of Chinese Patients with Non-Canonical EGFR-Mutant Non-Small Cell Lung Cancer
Faculty:
- Shun Lu

EP16.03-033. Transcriptomic Heterogeneity in Non-Small Cell Lung Cancer with Four Structure-Based EGFR-Mutation Subgroups
Faculty:
- Shun Lu

EP16.03-034. Differential Prognostic Effect of EGFR Mutation According to Smoking Status and Pathologic Stage in Non-mucinous Lung Adenocarcinoma
Faculty:
- Sukki Cho

EP16.03-035. Driver Mutations on Metastatic NSCLC - Experience in a Secondary Center
Faculty:
- Sofia Campos Silva

EP16.03-036. Clinical and Genomic Features of HER2 exon 20 Insertion Mutations in East Asian NSCLC
Faculty:
- Stephanie Pei Li Saw

EP16.03-037. Poor Prognosis of Patients with EGFR Mutations Left behind by Selective Detection in NSCLC
Faculty:
- Taisuke Matsubara

EP16.03-038. Single-cell Analyses Reveal Tumor Microenvironment Differences between EGFR 19del and L858R mutations in Lung Adenocarcinoma
Faculty:
- Tao Wang

EP16.03-039. Characterizing SHPRH as a Novel Tumor Suppressor Gene in Lung Adenocarcinoma
Faculty:
- Tianna Shindi Sihota

EP16.03-040. Biomarkersatlas.com: the Italian NSCLC Precision Medicine Knowledge Data Base
Faculty:
- Umberto Malapelle

EP16.03-041. Single Cell RNA Sequencing Reveals Phenotypic Predispositions to Developing Lung Cancer in Never-Smokers
Faculty:
- Venessa Chin

EP16.03-042. BET Inhibitors Stimulate NK Cytotoxic Activity in NSCLC through Attenuation of YAP/TAZ and SMAD3 Transcriptional Programs
Faculty:
- Valentina Sancisi

EP16.03-043. Comprehensive Genomic Profiling of Tumor Mutational Burden-high in Chinese Lung Cancer Patients
Faculty:
- Wei Li

EP16.03-044. Genomic Evidence Depicting Clonal Evolution of Lung Adenosquamous Carcinoma
Faculty:
- Yuchen Han

EP16.03-045. The Effect of Vascular Endothelial Growth Factor Gene Polymorphisms in the Clinical Outcome of Patients with Lung Cancer
Faculty:
- Younes El Founini

EP16.03-046. Tumor Grade Associated Genomic Mutations in Chinese Patients with Lung Cancer
Faculty:
- Min Zheng

EP16.03-047. Genomic Landscape of Squamous Cell Carcinoma Lung in an Indian Cohort
Faculty:
- Ullas Batra

EP16.04-001. The Role of Stromal PDGFR-activation in NSCLC
Faculty:
- Amanda Lindberg

EP16.04-002. Combining Patient-Derived Xenografts and Barcoding Technology to Evaluate Response to Targeted Therapies in ALK+NSCLC
Faculty:
- Anne Petzold

EP16.04-003. High Dimensional Spatial Profiling of the NSCLC Tumour Microenvironment
Faculty:
- Arutha Kulasinghe

EP16.04-004. Impact of Gender on Cellular Response to Cigarette Smoke Extract
Faculty:
- Anne-Marie Baird

EP16.04-005. Investigating the Side Effects of Docetaxel on Rat Lung and Heart
Faculty:
- Berna Komurcuoglu

EP16.04-006. A Novel Orthotopic Xenograft Mouse Model to Study Lung Cancer-Associated Fibroblasts and Lymphangiogenesis
Faculty:
- Caoyang Chen

EP16.04-007. ALDH2 Downregulation, Aberrant DNA Methylation, and Loss of Stemness Pathways as an Enhanced Biomarker in Lung Adenocarcinoma
Faculty:
- Thi-Oanh Tran

EP16.04-008. Cytotoxic Effects of Carnosic Acid Are Mediated by Induction of Autophagy and Activation of Sestrin-2/LKB1/AMPK Signalling in H1299 NSCLC Cells
Faculty:
- Eric Jordan O'Neill

EP16.04-009. The Proliferative Effect of 27-Hydroxycholesterol as a Selective Estrogen Receptor Modulator on Pathology of NSCLC
Faculty:
- Ikki Takada

EP16.04-010. Histological and Genetic Parental Tumor Characteristics are Conserved in Patient-derived Non-small Cell Lung Cancer Organoids
Faculty:
- Isabelle Opitz

EP16.04-011. Sex Hormone Signalling in Lung Adenocarcinoma Limits Tumour Virulence
Faculty:
- John Le Quesne

EP16.04-012. Retrospective Analysis of Non-Small Cell Lung Cancer with Mucinous Histology Subtype
Faculty:
- Katherine Garcia

EP16.04-013. Spatial Multi-Omics Landscape of Radiologically Preinvasive/Invasive Lesion in Part-Solid Lung Adenocarcinoma
Faculty:
- Kwon Joong Na

EP16.04-014. NTRK in Lung Cancer Patients with History of Hodgkin's Lymphoma
Faculty:
- Mariola Blanco Clemente

EP16.04-015. Chemotherapy Upregulates Programmed Cell Death Ligand 1 Expression in Non-Small Cell Lung Cancer Cell Lines and Patient-Derived Organoid Models
Faculty:
- Maryam Khalil

EP16.04-016. Overexpression of CEACAM6 Activates Src-FAK Signaling and Inhibits Anoikis, through Homophilic Interactions in Lung Adenocarcinomas
Faculty:
- Eun Young Kim

EP16.04-017. Lineage Switching and Tumor Microenvironment Roles of Tumor Suppressors in Autochthonous Lung Cancer Models
Faculty:
- Nisitha Sengottuvel

EP16.04-018. DNA Mismatch Repair in Lung Adenocarcinoma in Morocco
Faculty:
- Ouassima Erefai

EP16.04-019. Impact of Chemotherapy on Tridimensional Multicellular Non-small Cell Lung Cancer Spheroids With Microenvironment Cells
Faculty:
- Pauline Hulo

EP16.04-020. Dysregulation of 14-3-3 Signaling Adapters in Lung Adenocarcinoma, New Insights Into the Impact on Cancer Cell Biology
Faculty:
- Rhys Hamon

EP16.04-021. Chromatin Remodeling Drives Lung Pre-malignancy and is a Target for Prevention
Faculty:
- Steven Belinsky

EP16.04-022. Prognosis of Epithelial-Mesenchymal Transition-Related lncRNA Profile in LUSC Patients
Faculty:
- Shanshan Xiao

EP16.04-024. HMGB1-mediated Autophagy Promotes Gefitinib Resistance in Human Non-small Cell Lung Cancer
Faculty:
- Zhaoxia Wang

EP16.04-025. Statins Suppress SOAT1 Expression & Reduce Cholesterol Esterification in Statin-sensitive Lung Cancer Cells
Faculty:
- Katsuhiko Warita

EP16.04-026. Effectiveness of Atorvastatin and SR-12813 Combination in Statin-resistant and Statin-sensitive Lung Cancer Cell Lines
Faculty:
- Tomoko Warita

EP16.04-027. Identification of Optimal Internal Reference Gene to Analyze the Anticancer Effects of Statins in Lung Cancer Cells
Faculty:
- Tomoko Warita

EP16.04-028. PHLPP2 Regulates Ferroptosis Through Nrf2 Pathway to Affected Cell Cycle and Apoptosisin Lung Squamous Cell Carcinoma
Faculty:
- Haihua Yang

EP16.04-029. Downregulation of PHLPP2 Induced by Radiation Promotes GPX4-mediated Ferroptosis Defense and Radioresistance in Lung Cancer
Faculty:
- Haihua Yang

EP16.04-030. Cancer-Associated Fibroblasts Attenuate DNA Damage Repair by Promoting Glycolysis in Non-small Cell Lung Cancer
Faculty:
- Hongfang Zhang

EP16.04-031. Connexin 43 Overexpression Induces Angiogenesis in Vitro Following Phosphorylation at Ser279 in its C Terminus
Faculty:
- Zizi Zhou

EP16.04-032. Indoleamine 2,3-dioxygenase 1 (IDO1) Blood Metabolites May Improve Predictive Accuracy for Radiation Pneumonitis
Faculty:
- Feng-Ming Spring Kong

Summary
Availability: On-Demand
Cost: FREE
Credit Offered:
No Credit Offered
Contains (846)
EP01.01-002. Challenges in the Use of NLST Image Data for Quantitative Algorithm Development
EP01.01-003. DELFI-L101: Development of a Blood Based Assay That Evaluates Cell-Free DNA Fragmentation Patterns to Detect Lung Cancer
EP01.01-004. The Correlation Between Exhaled Volatile Organic Compounds Using Breath Analyzer and Interleukin-23 (IL-23) in Lung Cancer
EP01.01-005. Increased Levels of mRNAs and miRNAs Associated with Imminent and Advanced Lung Cancer
EP01.01-006. Sensitive Detection of Lung Cancer Using a Multiomic Plasma Cell-Free DNA Sequencing Assay
EP01.01-007. Incorporating cfDNA Detection to CT Scan Assessment in Post-Surgical Lung Cancer Patients
EP01.01-009. Common MicroRNAs in Pre-diagnostic Serum Associated with Lung Cancer in Two Cohorts up to Eight Years Before Diagnosis: A HUNT Study
EP01.01-010. Graphene Based Activity Sensors Detect All Stages of Lung Cancer Using an Evolutionary Machine Learning Algorithm Approach
EP01.01-011. Utility of Arm-level cfDNA Fragment Size Distribution in the Early Detection of Lung Cancer and Pan Cancer
EP01.01-002. Clinical and Molecular Features of Chinese Early-stage Multiple Primary Lung Cancer Patients
EP01.02-001. Citizens’ Perspective on Combination Screening for Lung Cancer, COPD and CVD
EP01.02-002. Awareness of Palestinians about Lung Cancer Symptoms: A National Cross-sectional Study
EP01.02-003. Lung Cancer Screening: A Systematic Review of Knowledge Translation Interventions
EP01.02-004. Education Messages and Strategies About Lung Cancer Screening: A Systematic Review
EP01.02-005. Exploring Individuals’ Views on Invitation to Lung Cancer Screening: Developing a Tailored Approach
EP01.02-006. Excuse Me? Patient Perceptions of Lung Cancer Screening Results
EP01.02-007. It's Not How You Start, It's How You Finish: Patient Motivators to Follow Low-Dose Screening Recommendations
EP01.02-008. Pocket Nodules, An Innovative Patient Education Tool to Explain Lung Nodules
EP01.03-001. Māori Perspectives on a Potential Lung Cancer Screening Programme Aotearoa NZ: An Indigenous People’s Perspective.
EP01.03-002. Implementation of the International Lung Screen Trial (ILST) in Catalonia: A Cost Analysis study
EP01.03-003. AI Detection of Emphysema in an Ultra-Low Dose CT Lung Cancer Screening Program
EP01.03-004. Should We Screen for Lung Cancer? A 10-Country Analysis Identifying Key Decision-Making Factors
EP01.03-005. Current status of High-risk Smokers Participating in Population-based National Lung Cancer Screening Program in Korea
EP01.03-006. Potential Drivers of Lung Cancer Screening Participation in Australia: A Qualitative Study to Inform Future Implementation
EP01.03-007. Lung Cancer Screening Use Among Screening-Eligible Adults With Disability in the United States: Evidence From Population-Based Data
EP01.03-008. Lung Cancer Screening Patients Experiences and Satisfaction: Quantitative and Qualitative Findings From a Survey Study
EP01.03-009. Cost-effectiveness of Lung Cancer Screening in New Zealand Varies by Ethnicity
EP01.03-010. China Lung Cancer Screening Study (CLUS) Version 2.0: Study Design and Baseline Screening Results
EP01.03-011. Clinical Features and Surgical Outcomes of Young Patients with Ground Glass Opacity Featured Lung Adenocarcinoma
EP01.03-012. Acceptability and Feasibility of Lung Cancer Screening in Australia: The View of Key Stakeholders
EP01.03-013. A Pilot Study of Lung Cancer Screening with Low Dose CT in Georgia (One Centre Experience and Preliminary Data).
EP01.04-001. A Programmatic Approach to Improve Efficiency in Lung Cancer Screening
EP01.04-002. The Impact of Enforcing a Structure in Lung Cancer Screening Strategy on the Effectiveness and Efficiency of the Screening Program
EP01.04-003. Effectiveness of Cloud-based Computer Aided Quality Control System in Korean National Lung Cancer Screening
EP01.04-004. Overcoming the Barriers to Lung Cancer Screening using a Systemwide Approach
EP01.04-005. Quantitative Characteristics in Global CT Lung Cancer Screening Populations Using the ELIC Distributed Database and Computation Environment
EP01.04-006. Clinical Scores, Biomarkers and It Tools in Lung Cancer Screening - Can an Integrated Approach Overcome Current Challenges?
EP01.05-001. Radiomics to Increase the Effectiveness of Lung Cancer Screening Programs. Radiolung Preliminary Results
EP01.05-002. Role of the Lung Cancer Screening MDT in the Manchester Lung Health Check Programme
EP01.05-003. Changes of Repeated Lung Cancer Screening Results and Affected Factors; Analysis of Korean National Lung Cancer Screening Program
EP01.05-004. Trial in Progress: An Observational Study for Management of Lung Nodules across Latin America (DOuBLED Study)
EP01.05-005. The Accuracy of Baseline Low-dose CT Lung Cancer Screening: A Systematic Review and Meta-analysis
EP01.05-006. Influenza Season Influence on Incidence and Outcome of Nodules in the NELSON Trial
EP01.05-007. Radiomics Based Machine Learning Model for Sub-cm Lung Nodule Malignancy Diagnosis in the PanCan Screening Study
EP01.05-008. Pre-Trial Validation of a Risk Prediction Model for Pulmonary Nodules Trained on a Nested Case-Control Study with No External Cohort
EP01.05-009. Simulation-Based Sample Size Estimation for an Early Detection of Lung Cancer Clinical Utility Trial in Indeterminate Pulmonary Nodules
EP01.05-010. Using a Pattern Submodel Approach to Predict Lung Cancer in High-Risk Lung Nodule Clinics
EP01.05-011. Radiologic Features of Nodules Attached to the Mediastinal or Diaphragmatic Pleura
EP01.06-001. Lung Cancer after First Primary Breast Cancer: Risk Factors and Results of Treatment
EP01.06-002. Impact of Immediate AI Enabled Patient Triage to Chest CT on the Lung Cancer Pathway: LungIMPACT
EP01.06-003. Female Asian Nonsmoker Screening Study (FANSS): Exploring Lung Cancer Screening in a High Risk Population
EP01.06-004. Eliciting Quantitative Smoking History by the Use of Natural Language Processing
EP01.06-005. Assessment of Cardiovascular Risk in the Non Screening Radically Treated Lung Cancer Cohort
EP01.06-006. Impact of Low Dose CT Screening on Cause of Death in Different Socio-Economic Groups
EP01.06-007. The Impact of Modified Screening Eligibility Criteria on Race and Sex Disparities in Lung Cancer Screening
EP01.06-008. Low Dose CT Screening in Asian Female-Never-Smokers is as Efficacious as in Asian Male-Ever-Smokers. A Systemic Review and Meta-Analysis
EP01.06-009. Frequency of Lung Adenocarcinoma in Patients With Growing Nonsolid and Part-Solid Nodules With Solid Component ≤5 mm
EP01.07-001. Surveillance with FDG PET/CT after Completion of Therapy for NSCLC: A Status Update on Inclusion in the SUPE_R Trial
EP01.07-002. Objectives and Design of the ACR Lung Cancer Screening CT Incidental Findings - Quick Reference Guide
EP01.07-003. Accuracy of Cytological Diagnosis for Malignant Nodule in Participants With Nonsolid Nodules and Part-Solid Nodules With Solid Component≤5 mm
EP01.07-004. FDG-PET-CT for Staging Screen Detected Lung Cancer
EP01.07-005. Combined Diffusion-Weighted Imaging and Dynamic Contrast-Enhanced MRI for Diagnosing Indeterminate Pulmonary Nodules
EP01.07-006. Incidence and Resource Burden for the Management of CT Detected Ground Glass Opacities at a Tertiary Lung Cancer Service in the UK
EP02.01-001. Plasma Cell-Free DNA as a Point-of-Care Wellbeing Biomarker for Early-Stage Non-Small Cell Lung Cancer Patients
EP02.01-002. Development of Circulating and Tissue Biomarkers Predicting Immune Phenotype and Response to Immunotherapy in NSCLC.
EP02.01-003. Predictive Role of Novel Grading System on Adjuvant Chemotherapy in Early Resected Lung Adenocarcinoma Based on EGFR Mutation Status
EP02.01-004. Application of a Genomic Assay for Risk Stratification of Resected NSCLC in a Community Cancer Center Setting, a Pilot Study
EP02.01-005. The Efficacy of Platinum-Based Chemotherapy as Adjuvant Therapy in EGFR Mutant Lung Adenocarcinoma
EP02.01-006. Advances in the Treatment of Postoperative Recurrence of Non-Small Cell Lung Cancer and Their Real-World Impact on Survival
EP02.01-007. Clinicopathologic and Prognostic Features of Early Resected Lung Adenocarcinoma Characterized With Uncommon EGFR Mutation
EP02.01-008. Clinicopathological Features of Rare but Targetable Mutations in Surgically Resected Lung Carcinomas
EP02.01-009. PD-L1 Expression in Biopsies and Surgical Specimens of Lung Cancer: Impact of Biopsy Methods and Neoadjuvant Therapy
EP02.01-010. Preoperative PET-SUVmax and Volume Based PET Metrics of the Tumor Fail to Predict Nodal Upstaging in Early-Stage Lung Cancer
EP02.01-011. Immune-related Histologic Phenotype in Pretreatment Tumor Biopsy Predicts Efficacy of Neoadjuvant Anti-PD-1 Treatment in Squamous Lung Cancer
EP02.01-012. PD-L1 Expression Predicts Prognosis in Completely Resected NSCLC Patients with an EGFR Mutation
EP02.01-013. Real World Treatment Patterns, Prevalence and Outcomes in Patients with KRAS Mutated Non Small Cell Lung Cancer in Southwestern Ontario
EP02.01-014. Prognostic Classification of Early-Stage Lung Cancer Using Preoperative Prealbumin and D-dimer Levels
EP02.01-015. Computer-Aided Volumetry by Multidetector Computed Tomography is Efficient for Prognostic Prediction of Early-Stage Solid Lung Cancers
EP02.01-016. Molecular Alterations and Clinical Prognostic Factors in Resectable Non-Small Lung Cancer
EP02.01-017. The Role of Adjuvant Chemotherapy for Stage II/III Lung Adenocarcinoma Based on Epidermal Growth Factor Receptor Mutation Status
EP02.01-018. EGFR Mutations Promote Lung Adenocarcinoma From Adenocarcinoma in Situ to Minimally Invasive Carcinoma to Invasive Adenocarcinoma
EP02.02-001. Genome-wide Analysis and Dynamic Changes of Human Non-small Cell Lung Carcinoma Cells After Radiation
EP02.02-002. Increased Utilization of Stereotactic Body Radiotherapy Has Decreased Treatment Disparities for Early-Stage NSCLC
EP02.02-003. Mean Lung Dose Correlates with Volume of Radiation-Induced Lung Injury in Patients Treated with SABR for Lung Cancer
EP02.02-004. Clinical Outcomes Following Photon-Based and Proton-Based Stereotactic Body Radiation Therapy for Early Stage Lung Cancer
EP02.02-005. Changes in PFT Parameters and Correlation with Symptomatic Pulmonary Toxicity Following SBRT For Early Stage Lung Cancer
EP02.02-006. Differing Doses: The Effects of Radiation Dose Calculation Algorithms on Local Control in Early-Stage Lung Cancer
EP02.02-007. Correlation between Biological Equivalent Dose and Radiological Changes after Lung Stereotactic Ablative Radiation Therapy
EP02.02-008. Transbronchial Microwave Ablation of Lung Nodules - Good Safety Profile and Promising Mid-Term Results
EP02.02-009. Stereotactic Body Radiotherapy for Primary and Metastatic Lung Cancer, Cyberknife-M6 Experience
EP02.02-010. Histology Impacts Time-to-Treatment on Lung SBRT Outcomes
EP02.03-001. The Role of Completion Lobectomy Following Sublobar Resection in Patients with T1 Non-Small Cell Lung Cancer
EP02.03-002. Impact of Society and National Guidelines on Patient Selection for Lung Cancer Surgery in the UK from 2008 to 2013
EP02.03-003. Survival of Patients with Interstitial Lung Disease Who Undergoing Lung Cancer Surgery: A Propensity Score Matching Study
EP02.03-004. Association Between Sarcopenia and Outcomes of Lung Cancer Surgery in Old-Age Patients: Interim Analysis of Prospective Cohort Study
EP02.03-005. Perioperative Factors That Predict or Are Associated With Prolonged Air Leaks After Robotic-Assisted Pulmonary Lobectomy
EP02.03-006. Oncological Outcome And Surgical Instruments in VATS Lobectomy For Early Stage Lung Cancer
EP02.03-007. Seeds of Gold. Triple Contrast Marking in Hybrid Operative Room for All-in One Diagnostic and Therapeutic Precision Surgery
EP02.03-008. Combined Robotic Assisted Thoracic Surgery (CRATS)
EP02.03-009. Real-world Disease-Free Survival as a Predictor of Overall Survival in Resected Early-Stage Non-Small Cell Lung Cancer
EP02.03-010. Intrapulmonary and Hilar Lymph Node Dissection Performed by the Surgical Team: Impact on Pathological Stage of NSCLC
EP02.03-011. Timeliness of Surgery for Early-Stage Lung Cancer: Perspectives from Surgeons and Patients
EP02.03-012. Peri-operative and Oncologic Outcomes after Robotic-Assisted Segmentectomy at a NCI-designated Cancer Center
EP02.03-013. Should Visceral Pleural Invasion Be Prognostic Factor in Early-Stage Lung Adenocarcinoma With Tumor Size 3cm or Less?
EP02.03-014. Pulmonary Segmentectomy via Minimally Invasive Open Surgery: An Analysis From a Japanese High-Volume Hospital
EP02.03-015. Fully Robotic Arm Robot Assisted Lung Surgery Exploration
EP02.03-016. Dynamics of Recurrence After Curative Resection of Non-small Cell Lung Cancer
EP02.03-017. Novel Intraoperative CT-Guided Marking Using O-Arm in Video-Assisted Thoracoscopic Surgery
EP02.03-019. T3 Non Small Cell Lung Cancer with Satellite Nodules: A Multicentric Analysis.
EP02.03-020. Patient Outcomes Following Salvage Lung Cancer Surgery Post Definitive Chemotherapy or Radiation
EP02.03-021. Uncertain Resection for Localized cN0M0 Non Small Cell-Lung Cancer: The Crucial Prognosis of Suboptimal Lymph Node Assessment
EP02.03-022. Evolution of Lung Cancer Resection Quality: A Prospective Staggered Implementation Quality Improvement Study
EP02.03-023. Decreasing Time to Definitive Therapy with MIDAS: Minimally Invasive Diagnosis and Surgery
EP02.03-024. Clinical and Prognostic Impact of Pleural Adhesions during Lung Cancer Surgery
EP02.03-025. Long-Term Oncological Outcomes and Risk Factors of Recurrence After Segmentectomy for Primary Lung Cancer
EP02.03-026. Is Ratio of Surgical Margin to Nodule Size a Prognostic Factor in Stage 1 Adenocarcinoma?
EP02.03-027. After Surgery Factors Affecting Relapse in Early Stage Non Small Cell Lung Cancer
EP02.03-028. Pathologic Risk Factors for Recurrence in Early Stage Invasive Lung Adenocarcinoma with Tumor Spread through Air Spaces
EP02.03-029. Prognostic Factors in Curative Intent Stage I lung Adenocarcinoma: Hospital's Cancer Registry Based Analysis
EP02.04-001. Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-Positive NSCLC: ALNEO Phase II Trial (GOIRC-01-2020)
EP02.04-002. Synergy of Local Treatment with Pulsed Electric Fields and Anti-PD1 Checkpoint Blockade
EP02.04-003. A Retrospective Comparison of Survival Outcomes in EGFR-mutated, NSCLC Patients on Osimertinib +/- Brain Metastases
EP02.04-004. Time to Surgery After Neoadjuvant Immunotherapy: Not a Day Too Soon
EP02.04-005. Phase II NAUTIKA1 Study of Targeted Therapies in Stage II-III NSCLC: Preliminary Data of Neoadjuvant Alectinib for ALK+ NSCLC
EP02.04-006. Adjuvant Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Preoperative Chemotherapy
EP02.04-007. Phase 2 Trial of Neoadjuvant KRASG12C Directed Therapy with Adagrasib (MRTX849) With or Without Nivolumab in Resectable NSCLC (Neo-KAN)
EP02.04-008. Efficacy and Safety of Neoadjuvant Chemoimmunotherapy in Resectable Non-small Cell Lung Cancer (NSCLC): a systematic review and meta-analysis
EP02.04-009. Real World Survival Outcome Analysis of Adjuvant Therapies in Non-EGFR, Non-ALK Early Stage Resected NSCLC
EP02.04-010. Clinical Outcomes After Neoadjuvant Tislelizumab plus Chemotherapy in Resectable Stage IIIA-B NSCLC: A Retrospective Study
EP03.01-001. Is Airflow Limitation a CausalFactor for Lung Squamous Cell Carcinoma? Evidence from Mendelian Randomization Analysis
EP03.01-002. Co-occurring Mutations, Smoking Status and Prognosis of Early-stage Resected NSCLCs with EGFR Mutations
EP03.01-003. Clinical Features and Molecular Profile of Advanced Non-small Cell Lung Cancer in Latin America: LATINO Lung (LACOG 0116)
EP03.01-004. Impact of Covid-19 Pandemic in Lung Cancer Patients in Albania
EP03.01-005. Clinicopathological Features of ROS1-rearranged Adenocarcinomas: A Single Institutional Experience Spanning Four Years From India
EP03.01-006. Familial Aggregation in Non-small Cell Lung Cancer - An Observational Study
EP03.01-007. Comprehensive Genomic Profile of Advanced Lung Cancer in a Region With the Worst Human Development Index in Brazil
EP03.01-008. Shift in Lung Cancer Stage at Diagnosis during the COVID-19 Pandemic in New York City
EP03.01-009. BrainMets-Cross-Sectional Study To Identify The Presence Of Brain Metastasis At Diagnosis Of Advanced NSCLC EGFRm in Portuguese Patients
EP03.01-010. Clinicopathological Characteristics of Non-Small Cell Lung Cancer patients in the United Arab Emirates and Correlation with Their Outcomes
EP03.01-011. Prevalence of KRASMutations in Treatment-naïve Non-small Cell Lung Cancer Patients in Hong Kong
EP03.01-012. Characterization of Lung Cancer in Patients With High Familial Aggregation of Cancer: Preliminary Data From the SCAN Study
EP03.01-013. Improving the Risk Estimation for Second Primary Lung Cancer after Lung Cancer by Taking Histologic Subtype into Account
EP03.01-014. Results From the BEWELL Study: Black Raspberry Nectar for the Prevention of Lung Cancer (NCT04267874)
EP03.01-015. Disease-Free Survival and Clinical Characteristics in Early-Stage NSCLC Patients From a Danish Cohort
EP03.01-016. The Canadian Small Cell Lung Cancer Database (CASCADE): Results from a Multi-Institutional Real-World Evidence Collaboration
EP03.01-017. Epidemiology of Lung Cancer in Northern Serbia During the Past Ten Years
EP04.01-001. Prevalence And Outcomes of EGFR Exon 20 Insertion Mutation In NSCLC: Princess Margaret Cancer Center Experience
EP04.01-002. Costs of Locoregional and Metastatic Recurrences in Patients with Resectable Stage II-III NSCLC in Spain
EP04.01-003. Is It Time for a New Paradigm in Care of Young Cancer Patients? A Retrospective Study
EP04.01-004. Interim Feedback on Pilot Public Facing Website for Cancer Clinical Trial Patient-Reported Symptom Data: Project Patient Voice
EP04.01-005. Lung Cancer Diagnosis Following Emergency Admission: Diagnostic and Therapeutic Pathways and Outcomes Within an Italian Cancer Center
EP04.01-006. A Systematic Review (SR) of Cost-effectiveness Analysis (CEA) of ALK Inhibitors (iALK) in Advance Non-small Cell Lung Cancer (NSCLC)
EP04.01-007. Impact of Precision Medicine Methods on First-Line Therapies in Metastatic Non-Small Cell Lung Cancer
EP04.01-008. Factors Impacting Time from Biopsy to Initiation of Treatment for Advanced NSCLC at an Academic Hospital and Affiliate Hospitals
EP04.01-009. Performance Indicators of Lung Cancer MDT at a Regional Center: Disagreements Between Trust and NLCA Data
EP04.01-010. Addressing Barriers to Lung Cancer Care for Diverse Populations through Patient Navigation: The University of Miami Experience
EP04.01-011. Diagnostic Approach and Treatment of Lung Cancer Patients in Portugal: Portuguese Lung Cancer Study Group Survey
EP04.01-012. Sex and Age-Related Guideline-Adherence Disparities in Non-Small-Cell Lung Cancer Treatment Patterns: Real-World Data
EP04.01-013. Frailty Index Predicts Treatment Outcomes in Older Adults with Lung Cancer
EP04.01-014. Adherence to Treatment Recommendations From Multidisciplinary Tumor Boards
EP04.01-015. Lung Cancer after Solid Organ Transplantation - A Claims Data Analysis
EP04.01-017. Cost-Effectiveness of Atezolizumab for Adjuvant Treatment of Patients with Stage II-IIIA PD-L1+ Non-small Cell Lung Cancer
EP04.01-018. Medical Oncology and Radiation Oncology Consultation in Non-small Cell Lung Cancer (NSCLC). A Population-Based Study Using Administrative Data
EP04.01-019. Into the Wild: Assessing Acute Care for Lung Cancer Patients, A Cohort Study to Improve Cancer Care at Emergency Department
EP04.01-020. Impact of Next-Generation Sequencing on Treatment Choice Among Patients with Metastatic NSCLC from the CHUM University Center
EP04.01-021. Cancer Clinical Quality Registries: A Systematic Review of the Utilisation and Effectiveness of Knowledge Translation Interventions
EP04.01-022. Real-world Evidence of Durvalumab for Stage III NSCLC: Survival Outcomes and Patterns of Care Post-progression
EP04.01-023. Development of an Australia and New Zealand Lung Cancer Clinical Quality Registry (ANZLCR)
EP04.01-024. Influence of Lung Diagnostic Assessment Program on Health Resource Utilization in Lung Cancer in Southeastern Ontario, Canada
EP04.01-025. Implementation of Electronic Patient Reported Outcomes in Routine Cancer Care
EP04.01-026. Cone-Beam CT Guided Navigation Bronchoscopy: a Cost-Effective Modality for the Diagnosis of Pulmonary Nodules
EP04.01-027. Pain and Interventions in Stage IV Non-Small Cell Lung Cancer: A Province-Wide Analysis
EP04.01-029. Reduction of ER Visits of Lung Cancer Patients Through Care Interventions in Day-To-Day Clinical Service: Experience of a Thoracic Unit in Mexico
EP04.02-001. Sex as a Potential Independent Prognostic Factor in Non-Small Cell Lung Cancer Survival
EP04.02-003. Improving Supportive Care for Patients with Thoracic Cancer
EP04.02-004. The Patient Impact of Liquid Biopsy - Health-Related Quality of Life in Patients Undergoing Liquid Biopsy for Advanced Non-Small Cell Lung Cancer
EP04.02-005. First Comprehensive Lung Cancer Long-Term Survivorship Program - Late Toxicities and Overall Survival
EP04.02-006. Burn-Out Syndrome: Neglected Syndrome Among Health Care Professionals Managing Lung Cancer Patients
EP05.01-001. Hispanic Patients with Unresectable Stage III NSCLC under PACIFIC Protocol: Evidence of Interior Outcomes and Health Inequity
EP05.01-002. Real World Treatment Patterns and Outcomes among Unresectable Stage III Non-Small Cell Lung Cancer Patients Initiating Chemoradiotherapy
EP05.01-003. First Real-World Data on Unresectable Stage III NSCLC Patients Treated with Durvalumab after Chemoradiotherapy in Asia Area
EP05.01-004. Induction Chemoimmunotherapy before Definitive Chemoradiotherapy for Large-Volume Unresectable Locally Advanced NSCLC
EP05.01-005. Impact of Antibiotic Use Before Definitive Concurrent Chemoradiation in Patients With Locally Advanced Non Small Cell Lung Cancer
EP05.01-006. Population Kinetic Assessment of Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
EP05.01-007. CONCORDE - A Phase Ib Platform Study of Novel Agents in COmbinatioN with COnventional RaDiothErapy in Non-small Cell Lung Cancer (NSCLC)
EP05.01-008. The Scottish Inflammatory Prognostic Score predicts survival in non-small cell lung cancer treated with chemoradiotherapy
EP05.01-009. A Clinical Outcome Comparison of IMRT and VMAT in Stage II and III NSCLC Irradiated with Radical Intent
EP05.01-010. External Validation of Two Prediction Models for Severe Radiation-induced Lymphopenia during Concurrent Chemoradiotherapy for Lung Cancer
EP05.01-011. Real World Outcomes of Durvalumab after Chemoradiotherapy in unresectable advanced Non-Small Cell Lung Cancer: The Mayo Clinic Experience
EP05.01-012. Avoiding Cardiac Toxicity in Lung Cancer Radiotherapy (ACcoLade) Trial - Initial Results
EP05.01-013. Increased C-reactive Protein after Chemoradiotherapy and Immunotherapy in Locally Advanced Non-small Lung Cancer Indicates Worse Survival
EP05.01-014. Circulating Tumor DNA to Identify Genomic Biomarkers of Radiation Sensitivity in Locally Advanced Non-Small Cell Lung Cancer
EP05.01-015. Validate Radiomics Features and XGBoost Model in Radiation Pneumonitis (RP) Prediction in Patients with Primary Lung Cancer: A MultiCenter Study
EP05.01-016. Radiation Recall Pneumonitis (RRP) Induced by Immune Checkpoint Inhibitors (ICIs) after Thoracic Radiotherapy for Lung Cancer
EP05.01-017. Exploring the Benefits of Adaptive Radiotherapy in NSCLC-patients
EP05.01-018. Chemoradiotherapy Followed by Durvalumab in Unresectable Locally Advanced NSCLC- A Single Institution Experience in Croatia
EP05.01-019. 4D CT Ventilation Image-Guided Lung Functional Avoidance Radiotherapy: A Single-Arm Prospective Pilot Clinical Trial
EP05.01-020. Unanticipated Radiation Re-planning for Stage III Non-small Cell Lung Cancer
EP05.01-021. Radiation Dose to Cardiac Substructures and the Incidence of Cardiac Events in Patients with Stage III NSCLC Receiving CCRT
EP05.01-022. Evaluation of the Management of Stage III NSCLC at Mohamed IV Center for Cancer Treatment Casablanca
EP05.01-023. Feasibility of Functional Lung Avoidance using Ga-68 4D Ventilation Perfusion PET/CT: The HI-FIVE Trial
EP05.01-024. Real-life Management of Stage III NSCLC Patients in Italy: The BE-PACIFIC Observational Study
EP05.01-025. Planned Interim Analysis of a Phase II Trial of Concurrent Durvalumab and Radiation Therapy for Locally Advanced Lung Cancer
EP05.01-026. Carboplatin Dose Calculations for Patients with Lung Cancer: Significant Dose Differences Found Depending on Dosing Equation
EP05.01-027. Uncertain Resection of pN2 NSCLC Patients-survival Analysis of Postoperative Radiotherapy and Driver Gene Mutations
EP05.01-028. Thoracic Radiotherapy of Baseline Severe Pulmonary Dysfunction NSCLC Patients and Predictive Analysis for Acute Radiation Pneumonitis
EP05.01-029. Association between DNA Repair Gene Pathway SNPs and Tumour Response in NSCLC Patients Receiving Radiotherapy: A Meta-Analysis
EP05.01-030. CRISP: First Real-World Evidence of NSCLC Stage I, II and III in Germany - AIO-TRK-0315
EP05.01-031. Lysimachia Capillipes Capilliposide C Enhances the Radiosensitivity of Lung Cancer by Promoting ERRFI1 via Inhibiting Phosphorylation of STAT3
EP05.01-032. The Incidence of Brain Metastasis and Radiation Pneumonitis With Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC
EP05.01-033. Stimulation CT-Based Radiomics Predict Radiation Pneumonitis after Chemoradiotherapy in Locally Advanced NSCLC
EP05.01-036. Role of Nanoparticle Polymeric Micellar Paclitaxel in Reducing Toxicity and Enhancing Efficacy in Non-small Cell Lung Cancer
EP05.02-001. Early Treatment Failure Of Consolidation Durvalumab for Unresectable Stage III NSCLC: A Real-World Canadian Cohort
EP05.02-002. Who Benefits More of Durvalumab after Chemoradiotherapy (CRT) in Real-World Patients with Locally Advanced Non-Small-Cell Lung Cancer (NSCLC)?
EP05.02-003. Durvalumab after Chemoradiotherapy (CRT) in Unresectable Stage III NSCLC. Comparative Study of Two Cohorts in the Real-World Setting
EP05.02-004. Could Fifty Percent Tumor Viability Be a Good Prognostic Factor?
EP05.02-005. Is Immunotherapy Safer Than Radiotherapy in Combination With Chemotherapy in Neoadjuvant Therapy?
EP05.02-007. Impact Of Fibrinogen Levels and mGPS on Survival of Stage III/N2 NSCLC Patients Treated with Neoadjuvant Therapy and Radical Surgery
EP05.02-008. Phase II Trial of Neoadjuvant Icotinib Plus Chemotherapy for Stage II-IIIB EGFR-mutant Non-small-Cell Lung Cancer
EP05.02-009. Aumolertinib Versus Erlotinib/Chemotherapy for Neoadjuvant Treatment of Stage IIIA EGFR-mutant NSCLC (ANSWER)
EP05.02-010. Robotic-Assisted Thoracic Surgery Following Neoadjuvant Chemoimmunotherapy in Patients with Stage III Non-small Cell Lung Cancer
EP05.02-011. Phase II Trial of Neoadjuvant Tislelizumab with Chemotherapy for Resectable Stage IIB-III Non-small Cell Lung Cancer
EP05.02-012. Chemoradiotherapy versus Chemotherapy in Neoadjuvant Settings for Stage III-N2M0 Non-Small Cell Lung Cancer (NSCLC) Patients
EP05.02-013. Immune-Related Adverse Effects and Durvalumab Treatment Patterns in VHA Patients with Unresectable Stage III NSCLC
EP05.02-014. Neoadjuvant Toripalimab Combination in Patients with Stage IIB-IIIB NSCLC: A Single-Arm, Phase 2 Trial (Renaissance Study)
EP05.02-015. Neoadjuvant Prehabilitation Therapy for Locally Advanced Non-small-Cell Lung Cancer: Optimizing Outcomes throughout the Trajectory of Care
EP05.02-016. Aumolertinib after Adjuvant Chemotherapy/Radiotherapy in Stage pIIIA-N2 Non-Small-Cell Lung Cancer with EGFR Mutation
EP05.02-017. Prognostic Factors Following Induction Therapy for N2 Lung Cancer
EP05.02-019. Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: Surgical Outcomes in a Regionalized Pulmonary Oncology Network
EP05.02-020. IL-9Stimulates Anti-tumor Immune Response and Facilitates Checkpoint Blockade in Lung Cancer
EP05.02-021. An Updated Analysis of Toripalimab and Platinum-Doublet Chemotherapy as Neoadjuvant Therapy for Potentially Resectable NSCLC
EP05.02-022. Thoracic Radiotherapy May Increase the Risk of Treatment-induced Pneumonitis after Immune Checkpoint Inhibitors: A Meta-Analysis
EP05.03-001. Impact of Neoadjuvant Chemo/radiotherapy Followed by Surgical Resection on T4N0-1 Non-Small Cell Lung Cancer
EP05.03-002. Pulmonary Artery Reconstruction for Lung Cancer With N1 Vessel Infiltration: Is It Justified?
EP05.03-003. Superior Sulcus (Pancoast) Tumors: A 11-Year Single-Centre Experience
EP05.03-004. Risk Prediction of Multiple-station N2 Metastasis in Patients with Clinical Single-station N2 Non-small Cell Lung Cancer
EP05.03-006. Real-World Treatment Pathways In Stage III Non-Small Cell Lung Cancer in Portugal (PICTuRE): An Interim Analysis Of Surgical Patients
EP05.03-007. Comparison of Surgical Methods in Patients Receiving Neoadjuvant Treatment; Thoracoscopy vs. thoracotomy
EP05.03-008. Surgery after First-Line Alectinib for (Locally) Advanced ALK-rearranged NSCLC: Pathological Response and Peri-Operative Results
EP05.03-009. Prognostic Impact of Tumor Volume Doubling Time for Resected Squamous Cell Carcinoma of the Lung
EP05.03-010. Extended Resection of Non-small Cell Lung Cancer with Superior Vena Cava Involvement: A Systematic Review and Meta-analysis
EP05.03-011. Bilateral Orthotopic Lung Transplantation for a Patient with Advanced Invasive Mucinous Adenocarcinoma
EP05.03-012. Deep Learning-based Classifier to Predict Intensified Locoregional Approach Need in Stage III Non-Small Cell Lung Cancer
EP06.01-001. The Longitudinal Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer at a Canadian Academic Centre: A Retrospective Chart Review
EP06.01-002. Cancer Care in a Time of COVID: Lung Cancer Patient's Experience of Telehealth and Connectedness
EP06.01-003. Impact of COVID-19 on Lung Cancer Patients; The Patients' Perspective
EP06.01-004. Lung Cancer Resection During the Covid-19 Pandemic: A Single Centre Study
EP06.01-005. COVID-19 and Post-COVID Outcomes in Lung Cancer Patients: Experience from an Indian Cancer Center
EP06.01-006. Multidisciplinary Team during the COVID-19 Pandemic: The BE-PACIFIC Italian Observational Study Analysis
EP06.01-007. Fate of Pneumonectomy Patients During Covid-19 Pandemic
EP06.01-008. COVID-Protected Pathways for Image Guided Lunc Cancer Intervention During the COVID-19 Pandemic: A Cohort Study
EP06.01-009. Maintaining Thoracic Services During COVID-19 - A Single Centre Experience
EP06.01-010. Clinical Outcomes after Hypo Fractionated Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer During The Covid-19 Pandemic In Morocco
EP06.01-011. COVID-19 Impact in Thoracic Surgery: a Comparison Between Public and Private Care in a Single-Center Facility
EP06.01-012. Impact of COVID-19 on the Stage of Lung Cancer Diagnosis at the Mohamed VI Center for Cancer Treatment in Morocco
EP06.01-013. Differences of Oncology Treatment for Lung Cancer Patients in Pandemic COVID-19 Year: Our Clinical Experience
EP06.01-014. Lung Resections After COVID: Short-term Outcomes
EP06.01-015. Will Virtual Care Stand the Test of Time; One Site's Perspective on the Continuity of Virtual Care Post-Pandemic
EP06.01-016. Nationwide Activity of Lung Cancer Surgery Before and During the COVID-19 Pandemic
EP06.01-017. Clinical Impact of SARS-CoV2 Pandemic in the Diagnosis of Early-Stage Thoracic Tumours
EP07.01-001. Molecular Profiling Predicts Outcomes in Patients With Resected Malignant Pleural Mesothelioma
EP07.01-002. Surgery in Stage I-III Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER)- Medicare Analysis 1995-2015
EP07.01-003. Metadata-Oriented Data Engineering Approach for Integration of Medical Data: A Pilot Study
EP07.01-004. Long Survivor Epithelioid Pleural Mesotheliomas Are Characterized by Tertiary Lymphoid Structures: An Update to the MATCH Study
EP07.01-005. Second Primary Cancers in a Population-Based Mesothelioma Registry
EP07.01-006. Clinicopathologic Determinants of Survival in Thoracic NUT Carcinoma (TNUT): Analysis of a Pooled Database
EP07.01-007. Is Extended Resection for Tracheo Bronchial Adenoid Cystic Carcinoma Warranted?
EP07.01-008. Perturbation of Warburg Effect by Dichloroacetate and Niclosamide in Malignant Pleural Mesothelioma in Vitro and in Vivo
EP07.01-009. Solitary Fibrous Tumors of the Pleura, Clinical and Surgical Dilemma. Single-Center Experience
EP07.01-010. Results of Multimodal Treatment in Patients with Malignant Pleural Mesothelioma Undergoing Pleurectomy/Decortication
EP07.01-011. Integrating PD-L1 Expression to the CALGB Prognostic Scoring System in Malignant Pleural Mesothelioma
EP07.01-012. Ipilimumab and Nivolumab in Pretreated Patients with Malignant Pleural Mesothelioma
EP07.01-013. Physical Function, Symptom Burden, and Quality of Life in Patients with Malignant Pleural Mesothelioma
EP07.01-014. Mesothelioma-Associated Fibroblasts Enhance Mesothelioma Aggressiveness and Modulate Drug Response
EP07.01-015. Multimodality Imaging for Characterization, Classification, and Staging of Malignant Pleural Mesothelioma, Focusing on MR Imaging
EP07.01-016. Role of Neoadjuvant Chemotherapy in Thymic Tumors
EP07.01-017. Malignant Fibrous Solitary Tumour of the Pleura Is Not All the Same: Evaluation of Risk Stratification Models in a Large Single Centre Series
EP07.01-018. Phase III Randomized Trial on Surgery, Chemo and Pleural Radiation (IMPRINT) for Resectable Pleural Mesothelioma (NRG LU-006)
EP07.01-019. Multiinstitutional Patterns of Use and Compliance with Tumor Treating Fields for Patients with Unresectable Malignant Pleural Mesothelioma
EP07.01-020. Pulmonary MALT Lymphoma: Detailed CT Findings
EP07.01-021. Clinical and Biochemical Profiling of Pleural Mesothelioma Patients Treated With Immunotherapy
EP07.01-022. Analysis of Second Surgery for Recurrence in Malignant Pleural Mesothelioma (MPM) Patients (P)
EP07.01-023. Family History of Cancer in a Series of Malignant Pleural Mesothelioma (MPM) Patients (P)
EP07.01-024. Preclinical Investigation of Immune Checkpoint Blockade and Anti-Angiogenic Therapy in Malignant Pleural Mesothelioma
EP07.01-025. Survival Advantage of Pulmonary Metastasectomy in Advanced Melanoma Patients: A Population-Based Study
EP07.01-026. Primary Pulmonary Ewing'S Sarcoma: Post Hoc Analysis From Two International Multicenter Prospective Randomized Trials
EP07.02-001. Evaluation of FGF18 as a Contributing Factor in Malignant Pleural Mesothelioma Growth and Its Role as a Potential Biomarker
EP07.02-002. Investigating the Role of MicroRNAs in Cell Growth and Cisplatin-Sensitivity of Malignant Pleural Mesothelioma
EP07.02-003. Characterization of the Extracellular Vesicle-Derived Transcriptome in Malignant Pleural Mesothelioma
EP07.02-004. Endogenous Retrovirus Expression and Type I Interferon Signaling in Human Mesothelioma
EP07.03-001. Comparison of Treatment Outcomes in Neoadjuvant Chemotherapy and Chemo-radiotherapy for Thymoma and Thymic Carcinoma
EP07.03-002. Combined Classifications for Thymoma and Thymic Carcinoma From a 10 years CHUM University Hospital Real-world Experience
EP07.03-003. First Line Combination of Toripalimab and Chemotherapy in Advanced Thymic Carcinoma: A Single-Center, Prospective, Single-Arm, Phase II Trial
EP07.03-004. Efficacy of Thoracic Radiotherapy for Local Progression in Advanced Thymic Carcinoma
EP07.03-005. MesoGraph: Graph Neural Networks for Weakly Supervised Cellular Profiling in the Subtyping of Malignant Mesothelioma Images
EP07.03-006. Feasibility of TTFields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Real-World Data
EP07.03-007. Clinicopathological Analyses for Predicting Recurrence After Complete Resection of Thymoma
EP08.01-001. Update Analysis of Sintilimab With Two Cycles Chemotherapy for Untreated Advanced Squamous Non-small-Cell Lung Cancer
EP08.01-002. Real-World Survival Outcomes of Patients with High PD-L1 Advanced NSCLC Who Received Chemo-Immunotherapy vs Immunotherapy
EP08.01-003. Efficacy of Immune Checkpoint Inhibitors in Pulmonary Sarcomatoid Carcinoma, A Multicenter Retrospective Study
EP08.01-004. Pattern of Subsequent Treatment and Outcomes in Relapsed PD-L1 high NSCLC Pre-treated with Pembrolizumab
EP08.01-005. A Multicenter Prospective Observational Study of Atezolizumab in Unresectable Advanced or Metastatic NSCLC in Japan: J-TAIL
EP08.01-006. Using Real World data to build effective predictive machine learining models for NSCLC patients treated with immune-based therapy
EP08.01-007. Real-World Outcomes of Patients with Advanced Lung Adenocarcinoma Treated with First-Line Chemo-Immunotherapy in Italy
EP08.01-008. Immune Checkpoint Inhibitors in Oncogenic Driven Non-small Cell Lung Cancer
EP08.01-009. TRBV Haplotype Profile Was Related to Immune-Induced Adverse Events in Chinese Patients With Advanced NSCLC
EP08.01-010. Troponin Elevation and the Risk of Myocarditis among NSCLC Patients Treated with Immune Checkpoint Inhibitors
EP08.01-011. Diabetes Mellitus (DM) is Associated with Poor Outcome in Pembrolizumab-treated Non-Small Cell Lung Cancer (NSCLC) Patients
EP08.01-012. First-line Chemo-Immunotherapy in Advanced Non-Small Cell Lung Cancer with 0-49% PD-L1: A Real-world Experience
EP08.01-013. Ramucirumab plus Atezolizumab in Patients with Stage IV NSCLC Previously Treated with Immune Checkpoint Blockade
EP08.01-014. Tislelizumab versus Docetaxel in Previously Treated Advanced Non-Small Cell Lung Cancer: Final Analysis of RATIONALE-303
EP08.01-015. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Anti-oxMIF Antibody ON203 in Malignant Solid Tumors
EP08.01-016. A Review Of Real-World Treatment Outcomes Of mNSCLC Patients Following Progression On Or After Platinum-Based Chemotherapy
EP08.01-017. Evaluation of Blood Tumor Mutation Burden for Efficacy of Second- Line Atezolizumab Treatment in Non-small Cell Lung Cancer
EP08.01-018. Patterns of Failure in Metastatic NSCLC Treated with First Line Pembrolizumab and Impact of Local Therapy in Patients with Oligoprogression
EP08.01-019. Modifiable biomarkers of response to immune checkpoint inhibitor treatment in non-small cell lung cancer
EP08.01-020. Phase 2 Platform Trial of Anti-TIGIT GSK'859A/EOS-448 + Anti-PD-1 Dostarlimab in Non-small Cell Lung Cancer (NSCLC)
EP08.01-021. Phase 2 Study Evaluating Inupadenant in Combination with Chemotherapy in Adults with NSCLC who Progressed on Immunotherapy
EP08.01-022. Treatment Outcomes of Second-Line Immune Modulators in Steroid Refractory/Resistant Immune Related Adverse Events
EP08.01-023. Factors Associated with Survival and Refusal of Physician Recommended Immunotherapy in Metastatic Non Small Cell Lung Cancer
EP08.01-024. Multicenter Real Life Clinical Outcomes of PDL-1 Tested Patients with Non Small Cell Lung Cancer (NSCLC) in Turkey
EP08.01-025. PD-L1 Tumor Tissue Expression and Its Relation with Clinico-pathological Profile in Advanced NSCLC
EP08.01-026. Influence of Brain Metastases on Survival of KRASG12C Mutated Stage IV Immune Checkpoint Inhibitor Treated Non-Small Cell Lung Cancer Patients
EP08.01-027. Durvalumab (D) ± Tremelimumab (T) + Chemotherapy (CT) in 1L Metastatic NSCLC: Outcomes by Tumour PD-L1 Expression in POSEIDON
EP08.01-028. Overestimation with Cox HR - Cox-TEL-Adjusted Associations of PD-L1 Expression with Immune Checkpoint Inhibitor Survival Benefit in Lung Cancer
EP08.01-029. NIVIPI-BRAIN, A Phase II Study of Nivolumab plus Ipilimumab Combined with Chemotherapy for Patients with NSCLC and Synchronous Brain Metastases
EP08.01-030. Nivolumab+Ipilimumab Vs Platinum-Based CT+Nivolumab In Advanced Lung Squamous-Cell Carcinoma: The Randomized SQUINT Trial
EP08.01-031. Blood Gene Expression Changes in Metastatic Lung Cancer under second-line Immunotherapy according to Clinical Response
EP08.01-032. Sintilimab in Combination with Anlotinib in NSCLC Patients with Uncommon EGFR Mutations: A Phase II, Single-arm, Prospective Study
EP08.01-033. ML40471: Preliminary Analysis of Atezolizumab in Previously Treated Patients With Locally Advanced or Metastatic NSCLC
EP08.01-034. Association of Sarcopenia with Survival in Advanced NSCLC Patients Receiving Concurrent Immunotherapy and Chemotherapy
EP08.01-035. Personalized ctDNA Detection to Monitor Outcome and Predict Immunotherapy Benefit in Locally Advanced and Metastatic NSCLC
EP08.01-036. Low-dose EGFR-TKIs Directly Induce Maturation and Functional Activity of Human Dendritic Cells in an EGFR-independent manner
EP08.01-037. Association of Baseline NLR and BMI with Clinical Outcomes in NSCLC Patients Treated with Immunotherapy Alone Versus Chemo-Immunotherapy
EP08.01-038. Clinical Predictors of Treatment Efficacy in Patients with Lung Adenocarcinoma Receiving Immune Checkpoint Inhibitors
EP08.01-039. Impact of Pulmonary Function Indexes on Immunotherapy Efficacy in Lung Adenocarcinoma Patients and the Potential Prognostic Factors
EP08.01-040. Peripheral Blood Cells as Predictors for Efficacy of Immunotherapy in Patients with Advanced Non-small Cell Lung Cancer
EP08.01-041. Impact of Gender on Response to Immune Checkpoint Inhibitors in Patients with Non-small Cell Lung Cancer
EP08.01-042. NEPTUNE China Cohort: First-Line Durvalumab + Tremelimumab versus Chemotherapy in Chinese Patients with Metastatic NSCLC
EP08.01-043. Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced Non-small Cell Lung Cancer (NSCLC)
EP08.01-044. A Phase 2 Multi-Cohort Study of Tiragolumab, Atezolizumab and Bevacizumab in Advanced Non-Squamous Non-Small Cell Lung Cancer
EP08.01-045. The Impact of Current Smoking Status at Initiation of Immune Checkpoint Inhibitor Therapy on Tumor Mutation Burden and Survival
EP08.01-046. Examination of Long-Term Administration of Pembrolizumab in Patients with Non-small Cell Lung Cancer at Our Institution
EP08.01-047. Chemo-immunotherapy is Associated With Better Survival Than Chemotherapy Alone In Stage IV Non-small Cell Lung Cancer
EP08.01-048. Spanish Immunotherapy Registry of Cardiovascular Toxicity (SIR-CVT): Preliminary Analysis of the Lung Cancer Cohort
EP08.01-049. Unscheduled Hospitalizations in Patients With Thoracic Tumors in the Era of Immunotherapy
EP08.01-050. Survival Outcome of Metastatic Pulmonary Sarcomatoid Carcinoma Treated with Immunotherapy: An Analysis of National Cancer Database (NCDB)
EP08.01-051. Clinical Characterization and Outcomes of Non Small Cell Lung Cancer with HER2 Alterations in the Era of Immunotherapy
EP08.01-052. Toripalimab in Combination with CIK Cells in Patients with Advanced NSCLC: An Exploratory Study
EP08.01-053. PD-1 Inhibitors Plus Chemotherapy in Patients with Brain Metastasis and EGFR/ALK-positive Non-small Cell Lung Cancer after EGFR/ALK-TKIs
EP08.01-054. ICIs combined with Single-agent Chemotherapy in Two or More Lines Treatment for Advanced Non-Small Cell Lung Cancer
EP08.01-055. Utilization of Tumor Mutational Profiling to Identify the Immunotherapy Response in Non-small Cell Lung Cancer
EP08.01-056. Pemetrexed-Based Chemotherapy Plus ICIs or Bevacizumab as First-Line Strategy for Patients with Lung Adenocarcinoma in Real-World Setting
EP08.01-057. Pembrolizumab Maintenance in Patients with Metastatic Squamous Non-Small Cell Lung Cancer (sNSCLC) - AIO-TRK-0115/PRIMUS
EP08.01-058. Access to Immunotherapy in Control Arms of Pivotal First Line Immunotherapy Trials in Metastatic Non-Small Cell Lung Cancer
EP08.01-059. Safety, Tolerability and Clinical Activity of Selinexor in Combination with Pembrolizumab in Metastatic Non-small Cell Lung Cancer
EP08.01-060. Long term Survival Outcomes in NSCLC Patients with Targeted Therapy and Immunotherapy: An IASLC Analysis of ASCO CancerLinQ Discovery Data
EP08.01-061. A Pilot Study of Avelumab and SABR in Non-Responding and Progressing NSCLC Patients Previously Treated with a Checkpoint Inhibitor
EP08.01-062. Body Mass Index, Immune Related Adverse Events, and Survival in Patients with Metastatic Non-small Cell Lung Cancer Treated with Immunotherapy
EP08.01-063. Chemoimmunotherapy versus Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer with a PD-L1 Score of 50-100%
EP08.01-064. Serum NY-ESO-1 and XAGE1 Antibodies Predict and Monitor Clinical Responses to Immune Checkpoint Therapy for NSCLC
EP08.01-065. Prevalence of Non-driver Mutations and Characterization of Patients with Advanced or Metastatic Non-small Cell Lung Cancer
EP08.01-066. Assessing Immunotherapy in Real Life: Have We Transferred the Increase in Overall Survival in Stage IV NSCLC from Trials to Clinical Practice?
EP08.01-067. Rechallenging with PD-1 Inhibitors: Incidence and Management of Immune-Related Adverse Events in Metastatic NSCLC
EP08.01-068. Going for the Ligand After a Stint With the Receptor: Can Switching Target From PD-1 to PD-L1 (Or Vice-Versa) Be Beneficial?
EP08.01-069. A Retrospective Study of Immune Checkpoints Rechallenge/ Retreatment in Metastatic NSCLC Progressing after Previous ICIs
EP08.01-070. Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC
EP08.01-071. Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Non-Squamous NSCLC
EP08.01-072. Clinical Value of Patras Immunotherapy Score (PIOS) Formula in Patients With Advanced NSCLC Treated With Immunotherapy/Chemotherapy
EP08.01-073. AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab plus Tislelizumab in Patients with Metastatic NSCLC
EP08.01-074. 'Long Responders' Compared to 'Non-Responders' to a First Line Immune Checkpoint Inhibitor in Incurable Non-Small Cell Lung Cancer
EP08.01-075. Combination of Baseline Disease and Smoking Pack-Years Can Guide The 1st-line Treatment Decision in Advanced NSCLC with High PD-L1 Expression
EP08.01-076. KEYNOTE B36: A Pilot Study of First-line Tumor Treating Fields (150 kHz) Plus Pembrolizumab for Advanced or Metastatic Non-small Cell Lung Cancer
EP08.01-077. Predicting Response to Checkpoint Inhibitors Using Complex Molecular Characteristics and Immunoprofiling in Patients With NSCLC
EP08.01-078. Clinical Outcomes in Metastatic Non-small Cell Lung Cancer Harboring BRAF Mutations Treated With Immune Checkpoint Inhibitors
EP08.01-081. A Phase I Dose-Escalation Study of HBM4003, an anti-CTLA-4 Heavy Chain Only Monoclonal Antibody, in Combination with Pembrolizumab
EP08.01-082. Therapeutic Resistance and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients: A Prospective Study
EP08.01-083. Real-World PD-(L)1 Inhibitor Treatment Pattern and Outcomes in Advanced Non-Small Cell Lung Cancer in Sweden
EP08.01-084. Non-Invasive Detection of Predictive Biomarkers for PD-1 Inhibitor Treated Non-Small Cell Lung Cancer Patients
EP08.01-085. Sintilimab versus Pembrolizumab as Monotherapy or in Combination with Chemotherapy for Treatment Naïve Metastatic Non-small Cell Lung Cancer
EP08.01-086. Pooled Mutant KRAS-Targeted Peptide Vaccine with Nivolumab and Ipilimumab in Advanced KRAS Mutated Non-Small Cell Lung Cancer
EP08.01-087. First-Line Pembrolizumab-Combination Therapy for Advanced Squamous NSCLC: Real-World Outcomes at US Oncology Practices
EP08.01-088. Direct Acting Antivirals (DAA) and Immune Checkpoint Inhibitors (ICIs) Therapy in Patients with Lung Cancer and Hepatitis C
EP08.01-089. Efficacy and Safety of Immune Checkpoint Inhibitors in Treating Brain Metastases in Patients With Non-small Cell Lung Cancer
EP08.01-090. Association of Gender and Outcomes in Patients With Advanced NSCLC Treated With Immunotherapy Alone or in Combination With Chemotherapy Upfront
EP08.01-091. Association of dNLR Score with Outcomes in Patients with Advanced NSCLC Under Immunotherapy Alone +/- Chemotherapy Upfront
EP08.01-093. ICI in Combination With Chemotherapy or Anti-angiogenic Agents as Second-Line Orbeyondtreatment for Advanced Non-small Cell Lung Cancer
EP08.01-094. A Phase II Study of Camrelizumab combined with Apatinib and Albumin Paclitaxel in Advanced Non-squamous NSCLC (CAPAP-lung)
EP08.01-095. Efficacy and Safety of Combining Endostar with Camrelizumab plus Chemotherapy in Advanced NSCLC Patients: A Multi-Center Retrospective Study
EP08.01-096. Lung Immune Prognostic Index is Prognostic in Patients Treated with PD-1 Inhibitor Combined with Chemotherapy for Non-small Cell Lung Cancer